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SYNOPSIS
A brief summary of the work to be incorporated in the thesis entitled
"DISCOVERING THE NEW CHEMICAL ENTITIES OF THERAPEUTIC
INTEREST" has been described as under.
[A] STUDIES ON FURAN DERIVATIVES
Furan derivatives have been found to be associated with the interesting
bio log ica l  ac t iv i t ies  such as  ant i in f lammatory,  musc le  re lexants ,
antidepressant, antibacterial, antidiabetic etc. These findings prompted us
to synthesis some furan derivatives possessing better therapeutic value which
have been described as under.
PART - I  : STUDIES ON PYRAZOLINES
Pyrazolines constitute one of the most active class of compounds
possessing diversified biological applications such as anticancer, analgesic,
antiinflammatory, anticonvulsant, antimicrobial and antipyretic. Prompted
by above facts some new pyrazolines have been prepared which have been
described in the following sections.
SECTION - I : Synthesis and therapeutic evaluation of 1-Aryl-
3-[5'-(m,p-dichlorophenyl)-2'-furyl]-2-propene-1-
ones
The chalcones of type (I) have been synthesised by the condensation
of 5-(m,p-dichlorophenyl)-2-furaldehyde with different aromatic ketones.
1






SECTION - II : Synthesis and therapeutic evaluation of 1-
Acetyl-3-aryl-5-[5'-(m,p-dichlorophenyl)-2'-furyl]-
pyrazolines
Pyrazolines of type (II) have been synthesised by the condensation of
the chalcones of type (I) with hydrazine hydrate in glacial acetic acid.
SECTION - III : Synthesis and therapeutic evaluation of 5-[5'-
(m,p-dichlorophenyl)-2'-furyl]-3-aryl-1-phenyl
pyrazolines
Pyrazolines of type (III) have been synthesised by the condensation of
the chalcones of type (I) with phenyl hydrazine.
PART - II  : STUDIES ON CYANOPYRIDINES
Pyridine nucleus plays an important role in medicine, agriculture and
industrial chemistry. Cyanopyridine possess antibacterial, antifungal,
antidiabetic, anticholesterimic and antihypertensive activity. They have been
also used as dyes for cotton and polyster fabrics. These findings prompted
us to synthesise some new cyanopyridine derivatives possessing better
therapeutic value which have been described as under.















SECTION - I : Synthesis and therapeutic evaluation of 2-Amino-
3-cyano-6-aryl-4-[5'-(m,p-dichlorophenyl)-2'-furyl]-
pyridines
Cyanopyridines of type (IV) have been synthesised by the reaction of
type (I) with malononitrile and ammonium acetate.
PART - III  : STUDIES ON 2-AMINOPYRIMIDINES
It has been reported that pyrimidine derivatives are associated with
various biological activities like antifungal, antitubercular, antibacterial and
herbicidal. These valid observations contemplated us to synthesise amino
pyrimidine derivatives which have been described as under.
SECTION - I : Synthesis and therapeutic evaluation of 6-Aryl-
4-[5'-(m,p-dichlorophenyl)-2'-furyl]-2-amino-
pyrimidines
Aminopyrimidines of type (V) have been synthesised by the reaction








Type (IV) R = Aryl









PART - IV  : STUDIES ON THIOSEMICARBAZONES
These derivatives have been extensively studied because of their broad
spectrum of biological activities and variety of industrial applications. They
are used as insecticides, rodenticides, antitubercular and antimicrobial
agents. It was considered of interest to synthesise some thiosemicarbazones
as under.
SECTION - I : Synthesis and therapeutic evaluation of 3-[5'-
(m,p-dichlorophenyl)-2'-furyl]-1-aryl-2-propene-
1-thiosemicarbazones
Thiosemicarbazones of type (VI) have been synthesised by the
condensation of chalcones of type (I) with thiosemicarbazide in alcohol.
PART - V : STUDIES ON CYCLOHEXENONES
Cyclohexenone derivatives play a vital role owing to their wide range
of biological activities such as anticancer, antibacterial and antifungal. In
view of these facts, it was contemplated to synthesise cyclohexenones which
have been described as under.










Type (VI) R = Aryl
4
Cyclohexenones of  type (VI I )  have been synthes ised by the
condensation of chalcones of type (I) with ethylacetoacetate in presence of
anhydrous K2CO3.
PART - VI  : STUDIES ON INDAZOLES
Various indazole derivatives exhibit interesting biological activities such
as anticancer, anti-inflammatory, anticonvulsant and antipyretic. With a view
to getting better therapeutic agent and to evalute its pharmacological profile,
different types of indazoles have been synthesised, which have been
described as under.
SECTION - I : Synthesis and therapeutic evaluation of 6-Aryl-
4 - [5 ' - (m,p-dichlorophenyl ) -2 ' - fury l ]3 -oxo-
3,3a,4,5-tetrahydro-2H-indazoles
The indazole derivatives of type (VIII) have been synthesised by the
condensation of cyclohexenone derivatives of type (VII) with hydrazine
hydrate.














Type (VIII) R = Aryl
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PART - VII  : STUDIES ON BARBITONES
The emerging role of barbitones in pharmaceutical chemistry as well
as in biochemistry stimulated tremendous interest in the synthesis of
barbitones with therapeutic potential. With this in view and in continuation
of our research work on new chemical entities of therapeutic interest, we
report herein barbitones.
SECTION - I : Synthesis and therapeutic evaluation of 1-Aryl-3-
[5'-(m,p-dichlorophenyl)-2'-furyl]-2-propenylidene
barbituric acids
Barbitones of type (IX) have been synthesised by the condensation of
chalcones of type (I) with barbituric acid in glacial acetic acid.
PART - VIII  : STUDIES ON 5-OXO-IMIDAZOLINES
5-Oxo-imidazoline derivatives have been reported to be active as
anticonvulsant, potent CNS depressant, antiinflammatory, anticancer,
hypnotics and as monoaminooxidase (MAO) inhibitor. In view of the above
findings, some new 5-oxo-imidazoline derivatives have been synthesised
which have been described as under.
SECTION - I : Synthesis and therapeutic evaluation of 1-Aryl-
2 - p h e n y l - 4 - [ 5 ' - ( m , p - d i c h l o r o p h e n y l ) - 2 ' -
furylidene]-5-oxo-imidazolines











The compounds of type (X) have been synthesised by the condensation
of 4-oxo-2-phenyl-5-[5'-(m, p-dichlorophenyl)-2'-furylidene] oxazole with
different arylamines.
PART - IX  : STUDIES ON THIAZOLIDINONES
The study of thiazolidinones have revealed valuable drugs for the
diseases like cancer, tuberculosis, diabetes and malaria. These valid
observations led us to synthesise some new thiazolidinones in search of
agents having better potency, which have been described as below.
SECTION - I : Synthesis and therapeutic evaluation of 2-
Arylimino-3-aryl-5-[5'-(m,p-dichlorophenyl)-2'-
furylidene]-4-thiazolidinones
Thiazolidinones of type (XI) have been synthesised by the condensation
of 5-(m,p-dichlorophenyl)-2-furaldehyde with different thiazolidinones.



















PART - X : STUDIES ON NITRILES
The nitrile derivatives possess antipyretic, analgesic, antiseptic,
antimalarial, antithyroid, anticonvulsant, antisecretory and antimicrobial
activities.
In order to achieve better therapeutic activity we have synthesised some
new acetonitrile derivatives bearing furan nucleus which is described as
under.
SECTION - I : Synthesis and therapeutic evaluation of α-
Arylamino-[5'-(m,p-dichlorophenyl)-2'-furyl]-
acetonitriles
Nitriles of type (XII) have been synthesised by the condensation of
different aromatic amines with 5-(m,p-dichlorophenyl)-2-furaldehyde by
using potassium cyanide in presence of acetic acid at 0 to 5oC.
The constitution of all the above products have been supported by
elemental analyses and spectral studies like IR, NMR and Mass spectral data.
In vitro study of multiple biological activities:
(1) Selected compounds have been evaluated for their in vitro biological
assay like antitubercular activity towards a strain of Mycobacterium
tuberculosis H37 Rv at a concentration of 6.25 µg/ml using Rifampin
as standard drug, which have been tested at Tuberculosis Antimicrobial







Type (XII) R = Aryl
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(2) All the compounds have been also evaluated for their antibacterial
activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of
40 µg/ml. The biological activity of the synthesised compounds have








Research in the field of pharmaceutical has its most important task in the
development of new and better drugs and their successful introduction into
clinical practice. The word 'drug' is derived from the french word 'drogue' which
means a dry herb. In general way, a drug may be defined as a substance used in
the prevention, diognosis, treatment or cure of disease in man or other animals.
The basis of understanding in the medicinal chemistry lies in an awareness
of the relationships between the chemistry of a particular compound or group
of compounds and their interections with the body, which is known as structure-
activity relationship, and the mechanism by which the compound influences
the biological system, which is known as its mode of action.
We must always continue to search for drugs which exhibit clear advantages
over the already existing respective drugs. Such advantages may be: (1)  A
qualitative or quantitative improvement in activity, (2) a partial or total absence
of undesirable side effects, (3) a lower toxicity, (4) more neutritive value, (5)
improved stability and (6) a decrease in production cost.
Any drug must ideally have a broad spectrum of activity, with a rapid
bactericidal action. Some bacteria produce enzymes that  can inactivate or modify
antibiotics action. Some bacteria produce enzymes that can inactivate or modify
antibiotics, and insusceptibility of a drug to such degradation or modification
could result in its playing an important part in therapy. Likewise, some bacteria
possess an outer membrane that acts as a permeability barrier to the entry of
some, but not all, antibiotics. Drugs that can readily penetrate this barrier might
again be expected to be of possible clinical importance.
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During the period of 1940 to 1960 a large number of important drugs
have been introduced and this period is regarded as "Golden Period" of new
drug discovery. These are some of the specific examples representing new
therapeutics.
NAME OF DRUGS YEAR USAGES





Adrenergic  betablockers 1958 Coronary Vasodilatory
Semi synthetic penicillins 1960 Antibacterial
Trimethoprim 1965 Antimicrobial
Disodium chromoglycoate 1967 Antiallergic
During the past decade, the threat of antimicrobial resistance has become
increasingly real and its global dimensions have been increasingly recognized.
Antimicrobial resistance is defined as a property of bacteria that confers the
capacity to inactivate or exclude antibiotics, or a mechanism that blocks the
inhibitory or killing effects of antibiotics, leading to survival despite exposure to
antimicrobials. Some bacteria become multi-resistant, i.e., resistant to different
groups of antibiotics. Increasing reports of outbreaks of antimicrobial resistant
bacteria, such as hospital outbreaks of vancomycin resistant enterococci,
community outbreaks of antimicrobial resistant. Streptococcus pneumoniae and
human and animal outbreaks of multi-resistant. Salmonella Typhimurium
definitive type 104, have heightened the concerns of the international public -
and animal-health communities, medical and veterinary clinicians and the
general public. Another reason for increased concern is the slowing of research
and development of new antimicrobials due to the cost and time to develop
new drugs as well as a focus by pharmaceutical companies on developing
products for non-infectious disease.
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AIMS AND OBJECTIVES
In the pharmaceutical field, there has always been and will continue to be
a need for new and novel chemical entities with diverse biological activities.
Our efforts are focused on the introduction of chemical diversity in the molecular
frame work in order to synthesizing pharmacologically interesting compounds
of widely different composition.
During the course of research work, several entities have been designed,
generated and characterised using spectral studies. The details are as under.
l To generate several derivatives like chalcones, pyrazolines,  cyanopyridines,
aminopyrimidines, thiosemicarbazones, cyclohexenones, indazoles,
barbitones, imidazolinones, thiazolidinones and nitriles bearing furan
nucleus.
l To check the purity of all compounds using thin layer chromatography.
l To characterise these products for structure elucidation using spectroscopic
techniques like IR, PMR and Mass spectral studies.
l To evaluate these new products for better drug potential against different
strains of bacteria and fungi.
l Selected compounds have been sent to "Tuberculosis Antimicrobial
Acquisition and Co-ordinating facility (TAACF), Southern Research Institute,






Furan derivatives comprise an industrially significant class of heterocyclic
compounds. The furan ring system is found in many naturally occuring
compounds, either as a fully unsaturated structure or in a reduced or partly
reduced form. Typical furan radicals are 2-furyl (I), 2-furfuryl (II), 2-furoyl (III)
and 2-furfurylidene (IV).
Reactivity of the furan nucleus is directly related to the electron density at
particular ring atoms. Canonical forms (Va) through (Vd) represent the overall
electron distribution. Centers of high electron density at the α positions of the
ring are readily supported by the behavior of furans in electrophilic substitution
reactions. Such reactions proceed with great facility at an α position.
Furans which occur in nature in a reduced or otherwise modified form
include pentose sugars such as ribose and deoxyribose, which are components
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Furfural or 2-furaldehyde, the best furan compound, was discovered
accidentally in 1832. The nitrofudam (VII) shows antidepressant activity and
ranitidine (VIII) shows antiulcer activity which possess substituted furan ring.
SYNTHETIC ASPECT
Various methods for the preparation of furan derivatives have been cited
in literature1-5.
1. Diazotized solution of p-aminobenzoic acid with furfural gives 4-[2'-
(formyl)furyl] benzoic acid.6
2. H. Surya Prakash et al.7 have prepared diarylfuran derivatives (IX) from
but - 2-ene-1,4-diones / but-2-yne-1,4-diones using formic acid in the
presence of a catalytic amount of palladium on carbon and in poly ethylene
glycol medium under microwave irradiation (1-5 min.)
THERAPEUTIC EVALUATION
Several furan derivatives reported to possess pharmacological activity





















































































































3. Antiviral & Anti-HIV10
4. Insecticidal11,12









Oomura O. et al.25 have prepared furan derivatives which shows antiulcer
activity. Hulin B.26 has synthesised benzofurans as hypoglycemic and
hypocholesteremic agents. Nishimura Y. and co-workers27 have assessed
furfurylthioacetic acid derivatives as intermediates for pharmaceuticals and
agrochemicals. O'Malley and Hedtmann28 have evaluated furan derivaives as
acetylcholinesterase inhibitors.
Preparation of furan derivatives (X) for inhibition of pneumocystis carinii
pneumonia, giardia lamblia and cryptosporidium parvum have been undertaken










Smith S. et al.30 have synthesised furan derivatives as PAF antagonist.
Matsuno H. et al.31 have demonstrated furan derivatives as insecticides. Toyoo
N. et al.32 have reported amidinonaphthyl furancarboxylate derivatives which
are useful for treatment of arthritis and nephritis. Furan derivatives have been
evaluated as cox-2-inhibitors33.
Benzofuran compounds useful for treatment of post menopausal syndrome
and aortal smooth muscle cell proliferation have been synthesised by Bryant
Henry et al.34 Aminoalkoxybenzylbenzofurans showing estrogenic activity have
been reported35 Matsuo M. et al36 have prepared thiazolylbenzofurans (XI) as
leukotriene and SRS-A inhibitors.
Several co-workers have reported furan derivatives as HIV protease
inhibitors37, 5-HT4 agonists
38, insecticides39, endothelin receptor antagonist40,
β3 adrenaline receptor agonist41, antiinflammatory42, antimicrobial43,44 and
antitumor45,46 agent.
Furan derivatives which possess plant growth regulatory activity have been
reported47. Antitumor activity of furopyrimidines (XII) have been observed by



























Anti-HIV active furan derivatives have been claimed by Battistino L. et
al.49 Preparation of some 3,4-diacyloxyfurans as prodrugs for antioxidants have
been undertaken50. Baker Robert et al.51 have evaluated immunosupressant
activity of furan derivatives. Benzofuro [3,2-b] pyridines have been reported as
mixed ETA/ETB and selective ETB endothelin receptor antagonists.52 Y.
Cheng53 have described furan derivatives which are useful as inhibitors of cox-
2. Preparation of aryl furan derivatives as PDE IV inhibitors have been studied.54
Nguyen et al55 have synthesised furan derivat ives which possess
antibacterial and antifungal activity. Furan derivatives have been demonstrated
which are useful in psychotherapeutics56. Furopyridines and related compounds
have been synthesised as p-38 MAP kinase inhibitors57. Wang Z. et al58 have
prepared furan derivatives as selective oxygenase-2-inhibitors. Furan derivatives
(XIII) has been studied which shows cardiovascular activity59. Furan derivatives
(XIV) having highly selective antagonistic action60 on a muscarine M3 receptor
have been reported.
El Nabawia et al.61 have studied furan derivatives and reported their
antimicrobial activity. Furan derivatives as antiallergic and antiinflammatory
agents have been investigated62. Sui Zhihua and co-workers63 have synthesised
benzofurans as antagonists of gonadotropin releasing hormone. Difuran
derivatives (XV) useful as antifeedant agent have been reported64 Buckleu G.















Hennequin L. et al66 have reported benzofuranyl substituted 3-cyano-
quinolines which are useful in the treatment of solid tumors. Some furan
derivatives have been studied for their antimicrobial activity.67,68 Furan
derivatives possessing antiviral activity have been reported.69 Tulshian D. et al.70
have synthesised furan derivatives as adenosine Aza receptor antagonists. Furan
derivatives have been evaluated as human hormone sensitive lipase inhibitors.71
Thus the impor tant role displayed by furan derivatives for various
therapeutic and pharmaceutical activities prompted us to synthesise some
pyrazol ines,  cyanopyridines,  2-aminopyrimidines,  thiosemicarbazones,
cyclohexenones, indazoles, barbitones, 5-oxo-imidazolines, thiazolidinones, and
nitriles bearing furan nucleus. These studies are described in the following parts.
STUDIES ON FURAN DERIVATIVES
PART - I : STUDIES ON PYRAZOLINES
PART - II : STUDIES ON CYANOPYRIDINES
PART - III : STUDIES ON 2-AMINOPYRIMIDINES
PART - IV : STUDIES ON THIOSEMICARBAZONES
PART - V : STUDIES ON CYCLOHEXENONES
PART - VI : STUDIES ON INDAZOLES
PART - VII : STUDIES ON BARBITONES
PART - VIII : STUDIES ON 5-OXO-IMIDAZOLINES
PART - IX : STUDIES ON THIAZOLIDINONES






















Amongst nitrogen containing five membered heterocycles, pyrazolines
have proved to be the most useful framework for biological activities. Pyrazolines
have attracted attention of medicinal chemists for both with regard to heterocyclic
chemistry and the pharmacological activities associated with them. The
pharmaceutical importance of these compounds lies in the fact that they can be
effect ively ut i l ized as ant ibacter ial ,  ant i fungal,  ant iviral ,  ant iparasi t ic ,
antitubercular and insecticidal agents. In 1967 Jarboe, reviewed the chemistry
of pyrazolines, which have been studied extensively for their biodynamic
behaviour and industrial applications.
As evident from the literature, in recent years a significant portion of
research work in heterocyclic chemistry has been devoted to pyrazolines
containing different aryl groups as substituents.
SYNTHETIC ASPECTS
Different methods for the preparat ion of 2-pyrazol ine derivat ives
documented in literature are as follows.
1. The most common procedure for the synthesis of 2-pyrazolines is the














2. Epoxidation of chalcones gave epoxy ketones which reacted with hydrazine
and phenyl hydrazine to give pyrazolines72.
3. A number of diarylidene cycloalkanones on reaction with hydrazine hydrate
produce pyrazolines73.
4. Dipolar cyclo addition of nitrilimines to dimethyl fumarate, fumaro nitrile
and the N-aryl maleimides yields the corresponding pyrazolines74.
5. Reaction of Et 2-(phenylazo)-3-oxobutanoates with nicotinic acid hydrazide
using glacial acetic acid gives following type of pyrazoline derivatives75.
REACTION MECHANISM






















( i ) proton transfer




















Nucleophilic attack by hydrazine at the β-carbon of the α,β-unsaturayed
carbonyl system forms species (II), in which the -ve charge is mainly accomodated
by the electro negative oxygen atom. Proton transfer from the nitrogen to -ve
oxygen produces an intermediate enol which simultaneously ketonises to
ketoamine (III). Another intermolecular nucleophilic attack by the primary amino
group of ketoamine on its carbonyl carbon followed by proton transfer from
nitrogen to oxygen leads ultimately to carbonyl amine (IV). The later with a
hydroxy group and amino group on the same carbon lose water easily to yield
the pyrazolines.
THERAPEUTIC EVALUATION
From the literature survey, it was revealed that 2-pyrazoline derivatives













N. Richard89 investigated pyrazolines bis phosphonate ester as novel
antiinflammatory and antiar thritic agent. Some new 1,3,5-substituted-2-
pyrazolines (VI) have been described for their antimicrobial activity.90
Pyrazolines... 22
T. Atif and co-workers91 have patented 3-methyl-4'-(substituted phenylazo)-
pyrazol-5-ones as antibacterial agents. R. H. Udupi and A. R. Bhat92 have
reported the synthesis and biological activity of Mannich bases of certain 1,2-
pyrazolines. Pyrazoline derivatives of salicylic acid possessing antimicrobial
properties have been reported93.
T. M. Stavenson et al.94 have investigated N-substituted pyrazoline type
insecticides. T. Katsuhori95 have patented pyrazoline derivatives as herbicides.
Pyrazolines derivatives showing significant antibacterial activity are described96.
CONTRIBUTION FROM OUR LABORATORY
Several pyrazolines bearing thymol moiety were evaluated for their ability
as potent antimicrobial by K. P. Roda.97 Jatin Upadhyay et al.98 have described
the pyrazoline derivatives and their use as antimicrobial agents. H. J. Vikani
and co-workers99 have prepared pyrazoline derivatives from arsanilic acid for
their antimicrobial activity. Parekh et al.100 have synthesised and reported the
antimicrobial activity of pyrazoline derivatives.
Parekh et al.101 have prepared 1-acetyl-5-aryl-3-[3-(3,4-dihydro-2-methyl-
4-one-3-quinazolinyl)-phenyl]-2-pyrazolines which possess antimicrobial activity.
Akhil Bhatt and co-workers102 have reported pyrazoline derivatives showing
antimicrobial activity. Parekh et al.103 have synthesised acetyl pyrazoline







Moreover, some pyrazoline derivatives have been studied for their
antidepressant activity104. Eggenweiler and co-workers105 have reported some
pyrazoline derivatives as inhibitors of cGMP and cAMP phosphodiesterase.
Pyrazoline derivatives of anthranilic acid (VIII) as potent antiinflammatory agents
have been investigated106. Maurer et al.107 have prepared pyrazolines and
reported their pesticidal activity. K. Mogilaiah and Sudhakar108 have prepared
1,8-naphthyridinyl-2-pyrazolines and studied their antibacterial activity.
Looking to the diversified activities exhibited and in continuation of our
work on the synthesis of biologically active compounds, the synthesis and
biological screening of pyrazoline derivatives have been described as under.
SECTION-I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
1-ARYL-3-[5'-(m,p-DICHLOROPHENYL)-2'-FURYL]-2-
PROPENE-1-ONES
SECTION-II : SYNTHESIS  AND THERAPEUTIC EVALUATION OF
1-ACETYL-3-ARYL-5-[5'-(m,p-DICHLOROPHENYL)-
2'-FURYL]-PYRAZOLINES






















SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-ARYL-3-[5'-(m,p-
DICHLOROPHENYL)-2'-FURYL]-2-PROPENE-1-ONES
As a part of our drug discovery program, considerable evidence has been
accumulated to demonstrate the efficiency of chalcones in inducing variety of
therapeutic activities. Our interest in further exploration in such a class of
compounds as antibacterial and antifungal agent led us to synthesise, a series
of chalcones of type (I) by the condensation of 5-(m,p-dichlorophenyl)-2-
furaldehyde with different aromatic ketones.
The constitution of the synthesised products have been characterised using
elemental analyses, IR and 1H nuclear magnetic resonance spectroscopy and
mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.








R = ArylType (I)
REACTION SCHEME




NaNO2      HCl



















IR SPECTRAL STUDY OF 1-(ρ-ANISYL)-3-[5'-(m,p-DICHLOROPHENYL)-2'-FURYL]-
2-PROPENE-1-ONE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2970 2975-2950 444
-CH3 C-H str. (sym.) 2839 2880-2860 "
C-H def. (asym.) 1460 1470-1435 "
C-H def. (sym.) 1398 1390-1370 "
Aromatic C-H str. 3066 3080-3030 445
C=C str. 1508 1520-1480 "
C-H i.p.def. 1022 1070-1000 "
C-H o.o.p. def. 831 835-810 "
Furyl moiety C-O-C str. (sym.) 1255 1275-1200 444
C-O-C str. (asym.) 1022 1075-1020 "
(overlaped)
C-Cl str. 783 800-750 "
Vinyl CH=CH str. 3066 3050-3000 446
(overlaped)








PMR SPECTRAL STUDY OF 1-(p-TOLYL)-3-[5'(m,p-DICHLOROPHENYL)-2'-FURYL]-
2-PROPENE-1-ONE
Internal Standard : TMS; Solvent : DMSOd6 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons in Hz
1 2.41 3H singlet -CH3 -
2 7.20 1H doublet furyl-H J=3.6
3 7.36 1H doublet furyl-H J=3.6
4 7.39 2H doublet Ar-He,e' Jed=8.0
5 7.56 1H doublet Vin-HA J=15.3
6 7.73 1H doublet Ar-Ha Jab=8.5
7 7.78 1H doublet Vin-HB J=15.3
8 7.93 1H double doublet Ar-Hb Jba=8.5
Jbc=2.0
9 8.06 2H doublet Ar-Hd,d' Jde=8.2






























Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)


























































































m/z = 185 m/z = 199
m/z = 226
m/z = 173m/z = 315












Gram positive bacteria : Staphylococcus aureus
Bacillus megaterium
Gram negative bacteria : Proteus vulgaris
Escherichia coli
Fungi : Aspergillus niger
Concentration : 40 µg.
Solvent : Dimethyl formamide
Standard drugs : Ampicillin, Amoxicillin,
Norfloxacin, Penicillin, Greseofulvin
The antimicrobial activity was compared with standard drugs viz. Ampicillin,
Amoxicillin, Norfloxacin, Penicillin and antifungal activity was compared with viz.
Greseofulvin. The zones of inhibition have been measured in mm.
ANTITUBERCULAR ACTIVITY
The antitubercular activity was carried out at Tuberculosis Antimicrobial
Acquisition Co-ordinating Facility (TAACF), U.S.A.
Method : BACTEC 460 Radiometric System
Bacteria : Mycobacterium tuberculosis H37Rv
Concentration : 6.25 µg/ml
Standard drug : Rifampin
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC  EVALUATION OF 1-ARYL-3-[5'-(m,p-
DICHLOROPHENYL)-2'-FURYL]-2-PROPENE-1-ONES
(A) Preparation of 5-(m,p-Dichlorophenyl)-2-furaldehyde
A mixture of 3,4-dichloroaniline (16.2 g, 0.01 M), dil.  HCl (15%, 60 ml)
and water (90 ml) was heated to get a clear solution. The solution was cooled to
0OC  and diazotised with NaNO2 solution (30%, 24 ml). The diazonium salt
solution was filtered and to the filtrate, water (50 ml) and freshly distilled furfural
(11.1 ml, 0.1 M) and aqueous cupric chloride (2.5 g in 10 ml of water) were
added with stirring. The stirring was continued for 4 hrs. and kept overnight.
The separated solid was collected by filtration and washed with cold ethanol,
cr ys ta l l i sed f rom a mixture of  e thanol-DMF. Yie ld 80%, m.p.  270oC.
(C11H6Cl2O2; required : C, 54.81; H, 2.51%; found: C, 54.60; H, 2.33%).
(B) Preparation of 1-(p-Anisyl)-3-[5'-(m,p-dichlorophenyl)-2'-furyl]-2-
propene-1-one
A solution of p-methoxyacetophenone (1.5 g, 0.01 M) in minimum quantity
of ethanol (5 ml) was added to a mixture of 5-(m,p-dichlorophenyl)-2-
furaldehyde (2.41 g, 0.01 M) in ethanol (30 ml) and 40% NaoH was added to
make it alkaline. The reaction mixture was then stirred for 24 hrs. at room
temperature. The product was isolated and crystallised from DMF. Yield 75%
m.p. 210oC. (C20H14Cl2O3; required: C, 64.31 ; H, 3.72%; found: C, 64.11;
H, 3.48%).
Similarly other substituted chalcones were prepared. The physical constants
are recorded in Table No. 1.
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(C) Therapeutic evaluation of 1-Aryl-3-[5'-(m,p-dichlorophenyl)-2'-
furyl]-2-propen 1-ones
All the products have been evaluated for antimicrobial activity and
antitubercular activity as described under.
(a) Antimicrobial activity
It was carried out by cup-plate diffusion method which has been described
as under.
(I) Antibacterial activity
The purified products were screened for their antibacterial activity. The
nutrient agar broth prepared by the usual method, was inoculated aseptically
with 0.5 ml of 24 hrs. old subcultures of B. megaterium, S. aureus, E. coli and
P. vulgaris in separate conical flasks at 40-50oC and mixed well by gently shaking.
About 25 ml  content of the flasks were poured and evenly spreaded in a petridish
(13 cm in diameter) and allowed to set for two hrs. The cups (10 mm in diameter)
were formed by the help of borer in agar medium and filled with 0.04 ml (40
µg) solution of sample in DMF.
The plates were incubated at 37OC for 24 hrs. and the control was also
maintained with 0.04 ml of MDF in a similar manner and the zones of inhibition
of the bacterial growth were measured in millimeter and recorded in Graphical
Chart No. 1.
(II) Antifungal activity
A. niger was employed for testing antifungal activity using cup-plate
method. The culture was maintained on Sabouraud's agar slants. Sterilised
Sabouraud's  agar medium was inoculated with 72 hrs. old 0.5 ml suspension of
fungal spores in a separate flask. About 25 ml of the inoculated medium was
evenly spreaded in a petridish and allowed to set for two hrs. The cups (10 mm
34
in diameter) were punched. The plates were incubated at 30OC for 48 hrs. After
the completion of incubation period, the zones of inhibition of growth in the
form of diameter in mm was measured. Along the test solution in each petridish
one cup was filled up with solvent which acts as control. The zones of inhibition
are recored in Graphical Chart No. 1.
(b) Antitubercular activity
The antitubercular evaluation of the compounds was carried out at
Tuberculosis Antimicrobial Acquisition and Co-ordinating Facility (TAACF),
U.S.A. Primary screening of the compounds for antitubercular activity have been
conducted at 6.25 µg/ml towards Mycobacterium Tuberculosis H37Rv in BACTEC
12B medium using the BACTEC 460 rediometric system. The compounds
demonstrating atleast >90% inhibition in the primary screen have been retested
at lower concentration towards Mycobacterium Tuberculosis H37Rv to determine
the actual minimum inhibitory concentration (MIC) in the BACTEC 460.
The antitubercular activity data have been compared with standard drug























1a C6H5- C19H12Cl2O2 343 212 0.71 68
1b 3-NH2-C6H4- C19H13Cl2NO2 358 144 0.78 71 3.91 3.70
1c 4-NH2-C6H4- C19H13Cl2NO2 358 170 0.68 59 3.91 3.69
1d 4-Br-C6H4- C19H11BrCl2O2 422 200 0.81 63
1e 4-Cl-C6H4- C19H11Cl3O2 377.5 155 0.66 60
1f 4-F-C6H4- C19H11Cl2FO2 361 133 0.48 58
1g 2-OH-C6H4- C19H12Cl2O3 359 165 0.78 68
1h 4-OCH3-C6H4- C20H14Cl2O3 373 210 0.84 75
1i 4-CH3-C6H4- C20H14Cl2O2 357 180 0.71 73
1j 3-NO2-C6H4- C19H11Cl2NO4 388 145 0.65 70 3.61 3.28
1k 4-NO2-C6H4- C19H11Cl2NO4 388 192 0.58 62 3.61 3.33
1l α-C4H3S- C17H10Cl2O2S 349 232 0.42 56










GRAPHICAL CHART NO. 1 :  ANTIMICROBIAL ACTIVITY OF 1-ARYL-3-[5’-(m, p-DICHLOROPHENYL)-2’-FURYL]-






















B. mega 20 14 17 20 15 17 12 13 22 19 11 20 22 24 23 25 0
S. aureus 14 19 12 19 20 12 16 20 13 16 17 11 20 22 19 24 0
E. coli 19 16 13 20 14 16 14 12 19 11 12 18 19 18 20 22 0
P. vulgaris 15 17 12 16 15 14 11 19 14 17 15 15 17 20 21 23 0
A.niger 19 17 18 21 14 14 18 19 13 17 19 13 0 0 0 0 26













SYNTHESIS AND THERAPEUTIC EVALUTION OF 1-ACETYL-3-ARYL-
5-[5'-(m,p-DICHLOROPHENYL)-2'-FURYL]-PYRAZOLINES
Considerable attention has been focussed on the development and synthesis
of pyrazolines of type (II) for obtaining biologically potent molecules which have
been prepared by the condensation of chalcones of type (I) with hydrazine
hydrate in glacial acetic acid.
The constitution of the synthesised products have been characterised using
elemental analyses, IR and 1H nuclear magnetic resonance spectroscopy and
mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of synthesised compounds were compared with standard
drugs.
Moreover, some selected compounds have been evaluated for their in vitro
biological assay towards a strain of mycobacterium tuberculosis H37Rv at
a concentration of 6.25 µg/ml using Rifampin as a standard drug which have



















IR SPECTRAL STUDY OF 1-ACETYL-3-(ρ-ANISYL)-5-[5'-(m,p-DICHLOROPHENYL)-
2'-FURYL]-PYRAZOLINE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2954 2975-2950 444
-CH3 C-H str. (sym.) 2833 2880-2860 "
C-H def. (asym.) 1440 1470-1435 "
C-H def. (sym.) 1363 1390-1370 "
Aromatic C-H str. 3060 3080-3030 445
C=C str. 1515 1520-1480 "
C-H i.p.def. 1039 1070-1000 "
C-H o.o.p. def. 833 835-810 "
Furyl moiety C-O-C str. (sym.) 1249 1275-1200 444
C-O-C str. (asym.) 1039 1075-1020 "
(overlaped)
C-Cl str. 794 800-750 "
Pyrazoline C=O str. 1668 1660-1600 447
C=N str. 1602 1630-1580 "











PMR SPECTRAL STUDY OF 1-ACETYL-3-(p-TOLYL)-5-[5'(m,p-DICHLORO PHENYL)-
2'-FURYL]-PYRAZOLINE
Internal Standard : TMS; Solvent : DMSOd6 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons in Hz
1 2.29 3H singlet Ar-CH3 -
2 2.36 3H singlet CO-CH3 -
3 3.50 1H double doublet -CHA JAB=18
JAX=4.8
4 3.75 1H double doublet -CHB JBA=18
JBX=11.7
5 5.67 1H double doublet -CHX JXA=4.8
JXB=11.7
6 6.46 1H doublet furyl-H J=3.3
7 7.06 1H doublet furyl-H J=3.3
8 7.30 2H doublet Ar-Hd,d' Jed=7.8
9 7.57 1H double doublet Ar-Hb Jba=8.4
Jbc=1.5
10 7.64 1H doublet Ar-Ha Jab=8.4
11 7.72 2H doublet Ar-He,e' Jde=7.8






























Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)






































































































SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-ACETYL-3-ARYL-
5[5'-(m,p-DICHLOROPHENYL)-2'-FURYL]-PYRAZOLINES
(A) Preparation of 5-(m,p-Dichlorophenyl)-2-furaldehyde
Part-I, Section-I(A)
(B) Preparation of 1-(p-Anisyl)-3-[5'-(m,p-dichlorophenyl)-2'-furyl]-2-
propene-1-one
Part-I, Section-I(B)
(C) Preparation of 1-Acetyl-3-(p-anisyl)-5-[5'-(m,p-dichlorophenyl)-2'-
furyl]-pyrazoline.
A mixture of 1-(p-methoxyphenyl)-3-[5'-(m,p-dichlorophenyl)-2'-furyl]-2-
propene-1-one (3.73 g, 0.01M) and hydrazine hydrate (2 ml, 0.04 M) in 30 ml
acetic acid was refluxed for 10 hrs. The solution was poured into crushed ice.
Product was isolated and crystallised from ethanol. Yield 65%, m.p. 192OC.
(C22H18Cl2N2O3; required : C, 61.52 ;  H, 4.20 ; N, 6.53%; found : C, 61.26;
H, 4.04 ; N. 6.25%).
Similarly other substituted pyrazolines were prepared. The physical
constants are recorded in Table No. 2
(D) Therapeutic evaluation of 1-Acetyl-3-aryl-5-[5'-(m,p-dichloro
phenyl)-2'-furyl]-pyrazolines
Antimicrobial testing was carried out as described in Part-I, Section-I(C).
The zone of inhibition of the test solution are recorded in Graphical Chart No.
2.
The antitubercular screening was carried out as described in Part-I,























2a C6H5- C21H16Cl2N2O2 399 188 0.64 59 7.02 6.72
2b 3-NH2-C6H4- C21H17Cl2N3O2 414 202 0.82 63 10.14 9.92
2c 4-NH2-C6H4- C21H17Cl2N3O2 414 208 0.80 72 10.14 9.95
2d 4-Br-C6H4- C21H15BrCl2N2O2 478 258 0.78 69 5.86 5.64
2e 4-Cl-C6H4- C21H15Cl3N2O2 433.5 156 0.61 66 6.46 6.22
2f 4-F-C6H4- C21H15Cl2FN2O2 417 280 0.58 58 6.71 6.50
2g 2-OH-C6H4- C21H16Cl2N2O3 415 241 0.48 71 6.75 6.48
2h 4-OCH3-C6H4- C22H18Cl2N2O3 429 192 0.58 65 6.53 6.25
2i 4-CH3-C6H4- C22H18Cl2N2O2 413 148 0.65 62 6.78 6.62
2j 3-NO2-C6H4- C22H15Cl2N3O4 444 200 0.80 70 9.46 9.30
2k 4-NO2-C6H4- C22H15Cl2N3O4 444 142 0.78 68 9.46 9.18








GRAPHICAL CHART NO. 2 :  ANTIMICROBIAL ACTIVITY OF 1-ACETYL-3-ARYL-5-[5’-(m, p-DICHLOROPHENYL)-
























B. mega 17 14 17 20 21 13 18 12 19 13 16 22 24 23 25 0
S. aureus 20 13 17 12 16 13 16 19 21 14 12 20 22 19 24 0
E. coli 18 15 17 11 19 12 13 20 12 17 14 19 18 20 22 0
P. vulgaris 17 15 12 19 18 13 11 14 19 13 14 17 20 21 23 0
A.niger 13 17 19 18 21 17 15 19 20 17 13 0 0 0 0 26


















-  S a u r a s h t r a Alamar H37Rv >6.25 74 M I C  R i f a m p i n =0.25µ g / m l







-  S a u r a s h t r a Alamar H37Rv >6.25 19 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n




-  S a u r a s h t r a Alamar H37Rv >6.25 17 M I C  R i f a m p i n =0.25µ g / m l





-  S a u r a s h t r a Alamar H37Rv >6.25 11 M I C  R i f a m p i n =0.25µ g / m l





-  S a u r a s h t r a Alamar H37Rv >6.25 6 M I C  R i f a m p i n =0.25µ g / m l







-  S a u r a s h t r a Alamar H37Rv >6.25 6 M I C  R i f a m p i n =0.25µ g / m l







-  S a u r a s h t r a Alamar H37Rv >6.25 4 M I C  R i f a m p i n =0.25µ g / m l





-  S a u rashtra Alamar H37Rv >6.25 1 M I C  R i f a m p i n =0.25µ g / m l





-  S a u r a s h t r a Alamar H37Rv >6.25 0 M I C  R i f a m p i n =0.25µ g / m l







-  S a u r a s h t r a Alamar H37Rv >6.25 0 M I C  R i f a m p i n =0.25µ g / m l







-  S a u r a s h t r a Alamar H37Rv >6.25 0 M I C  R i f a m p i n =0.25µ g / m l
U n i v e r s i t y @ 9 8 %  i n h i b i t i o n
Dr. A. R. Parikh
Saurashtra University
TABLE NO. 2a  : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
TAACF, Southern Research Institute



















SYNTHESIS AND THERAPEUTIC EVALUATION OF 5-[5 ' - (m,p-
DICHLOROPHENYL)-2'-FURYL]-3-ARYL-1-PHENYL PYRAZOLINES
With a view to getting biologically better compounds and considering the
association of various pharmacological activity of furan nucleus, the preparation
of  pyrazolines of type (III) have been undertaken by the condensation of type
(I) with phenyl hydrazine.
The constitution of the synthesised products have been characterised using
elemental analyses, IR and 1H nuclear magnetic resonance spectroscopy and
mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.













R = ArylType (III)
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IR SPECTRAL STUDY OF 5-[5'-(m,p-DICHLOROPHENYL)-2'-FURYL]-3-(p-TOLYL)-
1-PHENYL PYRAZOLINE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2920 2975-2950 444
-CH3 C-H str. (sym.) 2862 2880-2860 "
C-H def. (asym.) 1463 1470-1435 "
C-H def. (sym.) 1380 1390-1370 "
Aromatic C-H str. 3055 3080-3030 445
C=C str. 1496 1520-1480 "
C-H i.p.def. 1028 1070-1000 "
C-H o.o.p. def. 815 835-810 "
Furyl moiety C-O-C str. (sym.) 1267 1275-1200 444
C-O-C str. (asym.) 1068 1075-1020 "
C-Cl str. 781 800-750 "
Pyrazoline C=N str. 1591 1627-1580 447
N-Ph 1496 1507-1495 "
(overlaped)







PMR SPECTRAL STUDY OF 5-[5'(m,p-DICHLOROPHENYL)-2'-FURYL]-3-(p-ANISYL)-
1-PHENYLPYRAZOLINE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons in Hz
1 3.41 1H double doublet -CHA JAB=16.9
JAX=6.7
2 3.73 1H double doublet -CHB JBA=16.9
JBX=11.9
3 3.86 3H singlet -OCH3 -
4 5.35 1H double doublet -CHX JXA=6.8
JXB=12.0
5 6.27 1H doublet furyl-H J=3.4
6 6.55 1H doublet furyl-H J=3.4
7 7.00 2H doublet Ar-He,e' Jed=8.1
8 7.21 5H multiplet Ar-H f,g,h,i,j -
9 7.39 1H doublet Ar-Ha Jab=8.4
10 7.51 1H double doublet Ar-Hb Jba=8.2
Jbc=2.0
11 7.64 2H doublet Ar-Hd,d' Jde=8.2











































































































SYNTHESIS AND THERAPEUTIC EVALUATION OF 5-[5 ' - (m,p-
DICHLOROPHENYL)-2'-FURYL]-3-ARYL-1-PHENYL PYRAZOLINES
(A) Preparation of 5-(m,p-Dichlorophenyl)-2-furaldehyde
Part-I, Section-I (A)
(B) Preparation of 1-(p-Tolyl)-3-[5'-(m,p-dichlorophenyl)-2'-furyl]-2-
propene-1-one
Part-I, Section-I (B)
(C) Preparation of 5-[5'-(m,p-Dichlorophenyl)-2'-furyl]-3-(p-tolyl)-1-
phenyl pyrazoline
A  mixture of 1-(p-methyl)-3-[5'-(m,p-dichlorophenyl)-2'-furyl]-2-propene-
1-one (3.57 g, 0.01 M) and phenyl hydrazine (1.08 g, 0.01 M) in DMF was
refluxed for 10 hrs. The solution was poured into crushed ice. Product was
iso la ted and crys ta l l i sed f rom ethanol -DMF. Yie ld.  68% m.p.  230OC.
(C26H20Cl2N2O; required: C, 69.78; H, 4.49; N,6.26%; found: C, 69.58 ; H,
4.28; N, 6.02%).
Similarly other substituted pyrazolines were prepared. The physical
constants are recorded in Table No. 3
(D) Therapeutic eveluation of 5-[5'-(m,p-Dichlorophenyl)-2'-furyl]-3-
aryl-1-phenyl pyrazolines
Antimicrobial testing was carried out as described in Part-I, Section-I(C).























3a C6H5- C25H18Cl2N2O 433 180 0.68 62 6.46 6.22
3b 3-NH2-C6H4- C25H19Cl2N3O 448 132 0.62 63 9.37 9.05
3c 4-NH2-C6H4- C25H19Cl2N3O 448 162 0.68 68 9.37 9.10
3d 4-Br-C6H4- C25H17BrCl2N2O 512 210 0.78 64 5.47 5.18
3e 4-Cl-C6H4- C25H17Cl3N2O 467.5 148 0.67 70 5.99 5.70
3f 4-F-C6H4- C25H17Cl2FN2O 451 126 0.63 70 6.21 6.04
3g 2-OH-C6H4- C25H18Cl2N2O2 449 262 0.84 67 6.23 6.02
3h 4-OCH3-C6H4- C26H20Cl2N2O2 463 192 0.77 72 6.05 5.72
3i 4-CH3-C6H4- C26H20Cl2N2O 447 230 0.74 68 6.26 6.02
3j 3-NO2-C6H4- C25H17Cl2N3O3 478 256 0.66 66 8.78 8.48
3k 4-NO2-C6H4- C25H17Cl2N3O3 478 198 0.67 64 8.78 8.58
3l α-C4H3S- C23H16Cl2N2OS 439 248 0.72 72 6.38 6.18










GRAPHICAL CHART NO. 3 :  ANTIMICROBIAL ACTIVITY OF 5-[5’-(m, p-DICHLOROPHENYL)-2’-FURYL]-3-ARYL-






















B. mega 19 16 17 15 19 12 11 12 20 17 14 15 22 24 23 25 0
S. aureus 11 18 14 16 14 17 11 13 19 14 12 17 20 22 19 24 0
E. coli 16 15 14 16 13 15 12 13 17 12 15 15 19 18 20 22 0
P. vulgaris 14 16 14 17 11 12 15 14 18 12 13 14 17 20 21 23 0
A.niger 14 19 15 18 14 16 18 14 20 12 19 14 0 0 0 0 26
















Pyridine and its derivatives represent one of the most active class of
compounds possessing a wide spectrum of biological activities in the field of
medicine, agriculture and industrial chemistry. Pyridine-3-carboxamide occurs
as a component of the structure of the important coenzymes NADP+, one of
the B12 complex of vitamins, occurs in red blood corpuscles and participates in
biochemical redox reaction. Pyridoxol (Vitamin B6) (I), occurs in yeast and
wheatgerm is an important food additive.
The availability of 3-cyanopyridine, nicotinamide and nicotinic acid make
possible their use as synthetic intermediates.
Most derivatives are prepared by manipulation of pyridine and its simple
homologues in a manner similar to chemistry of the benzenoid chemistry.
However the simple pyridine compounds are prepared by the cyclisation of
aliphatic raw materials.
SYNTHETIC ASPECTS
Preparation of 3-cyanopyridines have been cited in literature110-114 with
different methods. The well known method is:
1. Samour and co-workers115 have prepared substituted cyanopyridines by











The mechanism for the condensation of chalcones with malononitrile is
shown as under.
This reaction proceeds through conjugated addition of active methylene
compounds to the α,β-unsaturated system. The α,β-unsaturated compound is
known as acceptors and active methylene compound is known as addender.
THERAPEUTIC EVALUATION

































































S. S. Verma et al.125 have synthesised 2-amino-3-cyano-2,6-disubstituted
pyridines and studied their biological activities. The insecticidal activity of
cyanopyridines has been investigated126 I. Teu and co-workers127 have shown
cyanopyridines as agrochemical fungicides. Hussans M. and co-workers128 have
prepared 3-cyanopyridines and reported their pharmacological activity. Various
cyanopyridine derivatives (III) have been documented for their multiple biological
activities.129
Manna F. and co-workers130 have reported the antiinflammatory activity
of 3-cyanopyridines. Some new 3-cyanopyridine derivatives have been found
to show anticancer and anti HIV activity.131  A. R. Parikh et al.132,133 have
prepared some new cyanopyridines and studied their antimicrobial activity.
Pyachenko U. D. and co-workers134 have synthesised some cyanopyridine
derivatives (IV) which are useful in the treatment of retroviral diseases.





















Parekh et al.136 have prepared new cyanopyridines and all products have
been evaluated for their in vitro growth inhibitory activity against different
microbes. Lowinger et al.137 have prepared some new cyanopyridines and
postulated them as vitro & cellular activities.
Moreover,  Haruda H.  e t  a l .138  synthes i sed 2-acy lamino-3,5-
dicyanopyridine derivat ives useful  as calc ium channel opening drugs.
Antimicrobial activity of cyanopyridine derivatives have reported by Mona M.139
Villhauer E. et al.140 have prepared novel cyanopyridines which has been found
to be bioavailable dipeptidyl peptidase inhibitors.
The synthesis of cyanopyridines is of current interest owing to their
enormous occurence in biologically active derivatives. Hence, considerable
attention has been focused on the study of efficient and pharmaceutically
important cyanopyridines bearing furan nucleus, which is described as under.






SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-AMINO-3-
CYANO-6-ARYL-4-[5'-(m,p-DICHLOROPHENYL)-2'-FURYL]-PYRIDINES
Pyridine nucleus plays an important role in medicine, agriculture and
industrial chemistry. To further assess the potential of such a class of compounds,
cyanopyridine derivatives of type (IV) have been synthesised by the condensation
of chalcones of type (I) with malononitrile and ammonium acetate.
The constitution of the synthesised products have been characterised using
elemental analyses, IR and 1H nuclear magnetic resonance spectroscopy and
mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
















R = ArylType (IV)
61
IR SPECTRAL STUDY OF 2-AMINO-3-CYANO-6- (p -TOLYL) -4 - [5 ' - (m,p-
DICHLOROPHENYL)-2'-FURYL]-PYRIDINE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2947 2975-2950 444
-CH3 C-H str. (sym.) 2840 2880-2860 "
C-H def. (asym.) 1446 1470-1435 "
Aromatic C-H str. 3033 3080-3030 445
C=C str. 1535 1520-1480 "
C-H i.p.def. 1043 1070-1000 "
C-H o.o.p. def. 840 835-810 "
Furyl moiety C-O-C str. (sym.) 1232 1275-1200 444
C-O-C str. (asym.) 1026 1075-1020 "
C-Cl str. 756 800-750 "
Pyridine N-H str. (sym.) 3361 3350-3250 "
C= N str. 2210 2240-2120 "
C=N str. 1608 1640-1500 "









PMR SPECTRAL STUDY OF 2 -AMINO-3-CYANO-6- (p -ANISYL) -4 - [5 ' (m,p-
DICHLOROPHENYL)-2'-FURYL]-PYRIDINE
Internal Standard : TMS; Solvent : DMSOd6 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons in Hz
1 3.89 3H singlet -OCH3 -
2 6.95 1H doublet furyl-H J=3.7
3 7.05 2H doublet Ar-He,e' Jed=8.7
4 7.18 1H singlet –CHx -
5 7.40 1H doublet furyl-H J=3.7
6 7.52 1H doublet Ar-Ha Jab=8.6
7 7.57 2H doublet Ar-Hd,d' Jde=9.0
8 7.67 1H double doublet Ar-Hb Jba=8.5
Jbc=1.9































Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
































































































































SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-AMINO-3-
CYANO-6-ARYL-4-[5'-(m,p-DICHLOROPHENYL)-2'-FURYL]-PYRIDINES
(A) Preparation of 5-(m,p-Dichlorophenyl)-2-furaldehyde
Part - I, Section - I (A).
(B) Preparation of 1-(p-Anisyl)-3-[5'-(m,p-dichlorophenyl)-2'-furyl]-2-
propene-1-one
Part - I, Section - I (B)
(C) Preparat ion of  2-Amino-3-cyano-6- (p-anisy l ) -4 - [5 ' - (m,p-
dichlorophenyl)-2'-furyl]-pyridine
A mixture of 1-(p-anisyl)-3-[5'-(m,p-dichlorophenyl)-2'-furyl]-2-propene-1-
one (4.36 g, 0.01 M), malononitrile (0.66 g, 0.01 M) and ammonium acetate
(2.31 g, 0.03 M) in DMF (30 ml) was refluxed for 8 hrs., poured into crushed
ice. The solid  obtained was filtered, washed with water and crystallised from
DMF. Yield 70%, m.p. 195oC. (C23H15Cl2N3O2; required: C, 63.32; H, 3.47;
N, 9.63%; found: C, 63.14; H, 3.30; N, 9.42%).
Similarly other substituted  cyanopyridines were prepared. The physical
constants are recorded in Table No. 4.
(D) Therapeutic evaluation of 2-Amino-3-cyano-6-aryl-4-[5'-(m,p-
dichlorophenyl)-2'-furyl]-pyridines
Antimicrobial testing was carried out as described in Part-I, Section - I
























4a C6H5- C22H13Cl2N3O 406 143 0.55 65 10.34 10.12
4b 3-NH2-C6H4- C22H14Cl2N4O 421 122 0.62 64 13.30 13.05
4c 4-NH2-C6H4- C22H14Cl2N4O 421 165 0.65 70 13.30 13.08
4d 4-Br-C6H4- C22H12BrCl2N3O 485 155 0.54 63 8.66 8.41
4e 4-Cl-C6H4- C22H12Cl3N3O 440.5 225 0.58 69 9.53 9.33
4f 4-F-C6H4- C22H12Cl2FN3O 424 220 0.60 74 9.90 9.68
4g 2-OH-C6H4- C22H13Cl2N3O2 422 128 0.59 65 9.95 9.78
4h 4-OCH3-C6H4- C23H15Cl2N3O2 436 195 0.54 70 9.63 9.42
4i 4-CH3-C6H4- C23H15Cl2N3O 420 130 0.73 63 10.00 9.74
4j 3-NO2-C6H4- C22H12Cl2N4O3 451 185 0.62 69 12.42 12.14
4k 4-NO2-C6H4- C22H12Cl2N4O3 451 130 0.68 74 12.42 12.20
4l α-C4H3S- C20H11Cl2N3OS 412 202 0.54 64 10.19 10.00










GRAPHICAL CHART NO. 4 :  ANTIMICROBIAL ACTIVITY OF 2-AMINO-3-CYANO-6-ARYL-4-[5’-(m, p-DICHLOROPHENYL)-






















B. mega 17 19 15 14 22 12 16 18 20 16 19 13 22 24 23 25 0
S. aureus 18 16 14 13 20 16 18 14 21 12 15 17 20 22 19 24 0
E. coli 17 16 14 15 18 12 17 15 18 13 12 16 19 18 20 22 0
P. vulgaris 16 14 15 18 13 15 13 18 12 12 17 14 17 20 21 23 0
A.niger 16 19 17 17 20 15 18 18 20 15 13 14 0 0 0 0 26
















2-Aminopyrimidine is the most important member of all the diazines as
this ring system occurs widely in living organisms. Pyrimidine and its derivatives
have gained prominence bacause of their potential pharmaceutical values. Many
pyrimidine derivatives play vital role in many physiological action. They are
among those molecules that make life possible as being some of the building
blocks of DNA and RNA.
Pyrimidine is considered to be a resonance hybrid of the charged and
uncharged cannonical structures, its resonance energy has been found to be
less than benzene or pyridine. The naturally occuring pyrimidine derivatives
was first  isolated by Gabrial and Colman in 1870, and its structure was confirmed
in 1953 as 5-β-D-gluco-pyranoside of divicine.
SYNTHETIC ASPECT
2-Aminopyrimidines has been synthesised by different methods, which has
been described in literature141-144.
1. Rasaki145 synthesised 2-aminopyrimidines by the reaction of chalcone
epoxides with guanidine carbonate in xylene.
2. The reaction of chalcone with guanidine hydrochloride  in presence of





3. Abd-El-gali E. Amr147 synthesised 2-aminopyrimidines by the reaction of
chalcones with guanidine hydrochloride in the presence of NaOH.
MECHANISM
The reaction of guanidine hydrochloride with α,β-unsaturated system leads
to the formation of 2-aminopyrimidine.
In the formation of 2-aminopyrimidine derivatives, it involves cycloaddition
process. The reaction proceeds through conjugated addition of guanidine to
the α,β-unsaturated system. Here bond formation take place between N-atom
of guanidine and C-atom of chalcone.
THERAPEUTIC EVALUATION
Large number of drugs possess aminopyrimidine ring system. Well-known
antimalarial agents like trimethoprim (I) and pyrimethamine (II), hypotensive






















































6. Inhibitor of cellular protiferation154
7. Cardiovascular155
8. Antiviral156
9. Tyrosine kinase inhibitor157
10. Antagonists158
Gangjee A. et al.159 Synthesised aminopyrimidines which possess
ant i tumor act iv i ty.  Pan S.160 prepared 2-methyl th io-4-amino-6-(3,5-
diacetylphenylamino) pyrimidines which show anti HIV activity in Hq cell
cultures. Ugarkar B. et al.161  found aminopyrimidines in the inhibition of
cardiovascular and ceribrovascular disorders. Some aminopyrimidines have been
























Breault et al.163 and Uckun et al.164 have prepared some aminopyrimidine
derivatives and screened its anticancer activity. Chamanlal and co-workers165
synthesised aminopyrimidines which possess antihistaminic(H1) activity.
Hewawasam P.  et al.166 prepared 2,4-disubstituted pyrimidine-5-carboxamides
as KCNQ potassium channel modulators.
Bargiotti A. et al.167 prepared aminopyrimidine derivatives for their
therapeutic use as telomerase inhibitors and anticancer agent. Jden and Juan168
synthesised some new aminopyrimidines for the treatment of cytomegalovirus
infections. Tsutsumi H. et al.169 prepared aminopyrimidine (V) as adenosine
receptor antagonists. Some novel aminopyrimidine derivatives (VI) have been
evaluated as dihydrofolate reductase inhibitors.170
Patricia F. et al.171 have prepared 2-tosyliminopyrimidine derivatives as
inhibitors of some leukocyte functions. Some pyrimidine derivatives showing
significant biological activity have been reported.172 Aleem G. et al.173 have
prepared aminopyrimidine derivatives of glutamic acid as potential dual inhibitors
of dihydrofolate reductase and as potential antitumor agents.
Looking to the diversified activities exhibited and in continuation of our
work on the synthesis of biologically active heterocycles, the synthesis and
biological  screening of aminopyrimidine derivatives have been described as
under.



















SYNTHESIS AND THERAPEUTIC EVALUATION OF 6-ARYL-4-[5'-(m,p-
DICHLOROPHENYL)-2'-FURYL]-2-AMINOPYRIMIDINES
Many aminopyrimidine derivatives are reported to possess different
biological activities. In view of these reports, it was considered worthwhile to
synthesise some new 4-[5'-(m,p-dichlorophenyl)-2'-furyl]-2-amino-pyrimidines
of type (V) to study their biological activities. Aminopyrimidine derivatives have
been prepared by the reaction of the chalcones of type (I) with guanidine
hydrochloride in presence of potassium-t-butoxide in t-butanol.
The constitution of the synthesised products have been characterised using
elemental analyses, IR and 1H nuclear magnetic resonance spectroscopy and
mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towared gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.






















IR SPECTRAL STUDY OF 6-(p-TOLYL)-4-[5'-(m,p-DICHLOROPHENYL)-2'-FURYL]-
2-AMINOPYRIMIDINE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2950 2975-2950 444
-CH3 C-H def. (asym.) 1461 1470-1435 "
C-H def. (sym.) 1357 1390-1370 "
Aromatic C-H str. 3037 3080-3030 445
C=C str. 1517 1520-1480 "
C-H i.p.def. 1029 1070-1000 "
C-H o.o.p. def. 833 835-810 "
Furyl moiety C-O-C str. (sym.) 1269 1275-1200 444
C-O-C str. (asym.) 1064 1075-1020 "
C-Cl str. 794 800-750 "
Pyrimidine N-H str. (sym.) 3328 3450-3350 "
C= N str. 1614 1640-1500 "








PMR SPECTRAL STUDY OF 6-(p-ANISYL)-4-[5'(m,p-DICHLOROPHENYL)-2'-FURYL]-
2-AMINOPYRIMIDINE
Internal Standard : TMS; Solvent : DMSOd6 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons in Hz
1 3.90 3H singlet -OCH3 -
2 6.86 1H doublet furyl-H J=3.7
3 7.04 2H doublet Ar-He,e' Jed=9.0
4 7.32 1H doublet furyl-H J=4.5
5 7.43 1H singlet -CHx -
6 7.51 1H doublet Ar-Ha Jab=8.5
7 7.63 1H double doublet Ar-Hb Jba=8.4
Jbc=2.1
8 7.89 1H doublet Ar-Hc Jcb=2.1













































































































SYNTHESIS AND THERAPEUTIC  EVALUATION OF 6-ARYL-4-[5'-(m,p-
DICHLOROPHENYL)-2'-FURYL]-2-AMINOPYRIMIDINES
(A) Preparation of 5-(m,p-Dichlorophenyl)-2-furaldehyde
Part-I, Section I (A)
(B) Preparation of 1-(p-Anisyl)-3-[5'-(m,p-dichlorophenyl)-2'-furyl]-2-
propene-1-one
Part-I, Section I (B)
(C) Preparation of 6-(p-Anisyl)-4-[5'-(m,p-dichlorophenyl)-2'-furyl]-2-
aminopyrimidine
A mixture of 1-(p-anisyl)-3-[5'-(m.p-(dichlorophenyl)-2'-furyl]-2-propene-
1-one (4.12g, 0.01M) and guanidine hydrochloride (1.10g, 0.01M) was refluxed
in potassium-t-butoxide (1.12g, 0.01M) in t-butanol (20 ml) on a water-bath for
4-5 hours. The solvent was evaporated and the residue was neutralized with
20% HCl, the separated solid was filtered out and crystallised from DMF. Yield
60%, m.p. 222oC. (C21H15Cl2N3O2; required: C, 61.18; H, 3.67; N, 10.19%;
found : C, 61.03; H, 3.47; N, 9.90%).
Similarly other substituted aminopyrimidines were prepared. The physical
constants are recorded in Table No. 5.
(D) Therapeutic evalution of 6-Aryl-4-[5'-(m,p-dichlorophenyl)-2'-furyl]-
2-amino pyrimidines
Antimicrobial testing was carried out as described in Part-I, Section-I
























5a C6H5- C20H13Cl2N3O 382 198 0.71 68 10.99 10.75
5b 3-NH2-C6H4- C20H14Cl2N4O 397 190 0.64 65 14.10 13.90
5c 4-NH2-C6H4- C20H14Cl2N4O 397 215 0.67 69 14.10 13.84
5d 4-Br-C6H4- C20H12BrCl2N3O 461 225 0.60 71 9.11 8.84
5e 4-Cl-C6H4- C20H12Cl3N3O 416.5 168 0.54 64 10.08 9.88
5f 4-F-C6H4- C20H12Cl2FN3O 400 212 0.50 62 10.50 10.32
5g 2-OH-C6H4- C20H13Cl2N3O2 398 245 0.65 66 10.55 10.30
5h 4-OCH3-C6H4- C21H15Cl2N3O2 412 222 0.52 60 10.19 9.90
5i 4-CH3-C6H4- C21H15Cl2N3O 396 210 0.65 64 10.60 10.32
5j 3-NO2-C6H4- C20H12Cl2N4O3 427 268 0.72 66 13.11 12.85
5k 4-NO2-C6H4- C20H12Cl2N4O3 427 182 0.58 62 13.11 12.92
5l α-C4H3S- C18H11Cl2N3OS 388 170 0.76 58 10.82 10.60
* TLC Solvent System : 5g, 5h : Acetone : Benzene (2 : 8)































B. mega 17 19 16 21 15 12 16 20 15 17 19 12 22 24 23 25 0
S. aureus 12 15 16 18 20 17 15 21 18 14 15 17 20 22 19 24 0
E. coli 17 13 16 12 18 11 15 16 14 13 12 14 19 18 20 22 0
P. vulgaris 16 16 14 11 13 14 12 19 14 14 15 14 17 20 21 23 0
A.niger 15 16 18 14 19 14 13 20 17 15 14 16 0 0 0 0 26


















Thiosemicarbazone derivatives are of special importance because of their
versat i le biological and pharmacological act ivi t ies.  Thiosemicarbazone
derivatives have found applications in drug development for the treatment of
central nervous system disorders, of bacterial infections, as well as analgesic
and antiallergic agent. They are potent intermediates for the synthesis of
pharmaceutical and bioactive materials.
The clinically active drug methisazone and related compounds have shown
activity against DNA viruses, principally the Orthopoxviruses, both in vitro
and in vivo.
SYNTHETIC ASPECT
Nowadays reaction between thiosemicarbazide with ketones or aldehydes
have attracted a great attention, because of their interesting nature of resulting
compounds for their applications and biological activities.
Different methods are used for the synthesis of thiosemicarbazones which
is described in literature174-177









2. Perumal Y. and co-workers179 have prepared thiosemicarbazones by the
condensation of 6-chlorobenzothiazolyl-2-thiosemicarbazide with aldehydes
or ketones.
THERAPEUTIC EVALUATION
Thiosemicarbazones exhibit a wide variety of biological activities which










Antimicrobial act ivi ty of thiosemicarbazone derivatives have been
reported.190,191 Siatra T. et al.192 have synthesised some new thiosemicarbazones
from 3-acetyl indole and repor ted its effect on DNA synthesis and cell
proliferation. 5-chloro salicyaldehydic thiosemicarbazone derivatives have been





































N-substituted thiosemicarbazones showing antitumor activity have been
reported194. Wang D. et al.195 patented thiosemicarbazones useful as sodium
channel blockers. Krezel I.196 has prepared thiosemicarbazones (I) from 1,3-
cyclic diamino and reported as anticancer agent. Fedorova O. et al.197
synthesised some thiosemicarbazones (II) having potent in vitro tuberculostatic
activity.
Some 3-aminopyrimidine 2-carboxaldehyde thiosemicarbazone derivatives
are reported as novel prodrug forms of ribonucleotide reductase inhibitors 3-
AP and 3-AMP by Li Jun et al.198
Some new thiosemicarbazone derivatives have been studied for their
anticancer activity.199 Teoh-Siang et al.200 have synthesised thiophene 2-
carboxaldehyde thiosemicarbazones and evaluated their toxicity and fungiocity.
Dulanyan and co-workers201 have synthesised 4-substituted thiosemicarbazones
and reported its antitumor activity. Thiosemicarbazone derivatives as potent
antiviral agents have been investigated.202
Moreover,  J in  Shuhui  and co-workers203 have prepared
th iosemicarbazones  and repor ted them for  ant i funga l  ac t iv i ty.
Thiosemicarbazones (I I I )  showing signif icant antimicrobial  act ivi ty are
described.204 Nilgun K.205 have synthesised some thiosemicarbazones (IV)




















Due to the physiological and biological activities of thiosemicarbazones, it
was contemplated to synthesise some new thiosemicarbazones with a hope that
these compounds may have better pharmacological activities.




















SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-[5 ' - (m,p-
D I C H L O R O P H E N Y L ) - 2 ' - F U R Y L ] - 1 - A R Y L - 2 - P R O P E N E - 1 -
THIOSEMICARBAZONES
With a view to getting better therapeutic activity and considering the
association of various biological activities with thiosemicarbazones, we have
synthes i sed 3- [5 ' - (m,p-d ich loropheny l ) -2 ' - fu ry l ] -1-ary l -2-propene-1-
thiosemicarbazones of  type (VI)  by the react ion of  1-ary l -3-[5 ' - (m,p-
dichlorophenyl)-2'-furyl]-2-propene-1-ones with thiosemicarbazide shown as
under.
The constitution of the synthesised products have been characterised using
elemental analyses, IR and 1H nuclear magnetic resonance spectroscopy and
mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.




















IR SPECTRAL STUDY OF 3-[5'-(m,p-DICHLOROPHNYL)-2'-FURYL]-1-(p-ANISYL)-
2-PROPENE-1-THIOSEMICARBAZONE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2970 2975-2950 444
-CH3 C-H def. (sym.) 2893 2880-2860 "
C-H def. (asym.) 1467 1470-1435 "
C-H def. (sym.) 1388 1390-1370 "
Aromatic C-H str. 3060 3080-3030 445
C=C str. 1515 1520-1480 "
C-H i.p.def. 1055 1070-1000 "
C-H o.o.p. def. 827 835-810 "
Furyl moiety C-O-C str. (sym.) 1253 1275-1200 444
C-O-C str. (asym.) 1022 1075-1020 "
C-Cl str. 752 800-750 "
Thosemi N-H str. 3382 3400-3200 "
-carbazone C= N str. 1606 1630-1580 "










PMR SPECTRAL STUDY OF 3-[5'(m,p-DICHLOROPHENYL)-2'-FURYL]-1-(p-TOLYL)-
2-PROPENE-1-THIOSEMICARBAZONE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons in Hz
1 2.46 3H singlet -CH3 -
2 6.24 1H doublet Vin-H J=16.0
3 6.41 1H doublet furyl-H J=3.6
4 6.68 1H doublet furyl-H J=3.6
5 7.06 1H doublet Vin-H J=16.0
6 7.14 2H doublet Ar-Hd,d' Jed=8.0
7 7.38 2H doublet Ar-He,e' Jde=7.9
8 7.45 1H doublet Ar-Ha Jab=8.6
9 7.50 1H double doublet Ar-Hb Jba=8.7
Jbc=2.1
10 7.78 1H doublet Ar-Hc Jcb=2.0



















































































































m/z = 430 (m+ peak)
m/z = 354
(base peak)











m/z = 371 m/z = 136 m/z = 118
89
EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC  EVALUATION OF 3-[5'-(m,p-
D I C H L O R O P H E N Y L ) - 2 ' - F U R Y L ] - 1 - A R Y L - 2 - P R O P E N E - 1 -
THIOSEMICARBAZONES
(A) Preparation of 1-Aryl-3-[5'-(m,p-dichlorophenyl)-2'-furyl]-2-propene-
1-ones
Part - I, Section - I (B)
(B) Preparation of 3-[5'-(m,p-Dichlorophenyl)-2'-furyl]-1-(p-tolyl)-2-
propene-1-thiosemicarbazone
A mixture of 1-(p-tolyl)-3-[5'-(m,p-dichlorophenyl)-2'-furyl]-2-propene-1-
one (3.57g, 0.01M) and thiosemicarbazide (0.91g, 0.01M) in ethanol (20 ml)
containing catalytic amount of acetic acid and refluxed for 8-10 hrs on water
bath. The reaction mixture was then cooled and diluted with cold water. The
separated solid was collected, washed, dried and crystallised from DMF. Yield
66%, m.p. 198oC. (C21H17Cl2N3OS; required : C, 58.61; H, 3.98; N, 9.76%;
found : C, 58.42; H, 3.77; N, 9.50%).
Similarly other substituted thiosemicarbazones were prepared. The physical
constants are recorded in Table No. 6.
(C) Therapeutic evaluation of 3-[5'-(m,p-Dichlorophenyl)-2'-furyl]-1-
aryl-2-propene-1-thiosemicarbazones
Antimicrobial testing was carried out as described in Part - I, Section - I
























6a C6H5- C20H15Cl2N3OS 416 175 0.70 70 10.09 9.86
6b 3-NH2-C6H4- C20H16Cl2N4OS 431 160 0.68 65 12.99 12.71
6c 4-NH2-C6H4- C20H16Cl2N4OS 431 170 0.74 68 12.99 12.78
6d 4-Br-C6H4- C20H14BrCl2N3OS 495 198 0.81 63 8.49 8.25
6e 4-Cl-C6H4- C20H14Cl3N3OS 450.5 225 0.55 65 9.32 9.05
6f 4-F-C6H4- C20H14Cl2FN3OS 434 200 0.56 69 9.68 9.35
6g 2-OH-C6H4- C20H15Cl2N3O2S 432 190 0.81 68 9.72 9.50
6h 4-OCH3-C6H4- C21H17Cl2N3O2S 446 152 0.66 70 9.41 9.14
6i 4-CH3-C6H4- C21H17Cl2N3OS 430 198 0.68 66 9.76 9.50
6j 3-NO2-C6H4- C20H14Cl2N4O3S 461 212 0.71 64 12.14 11.92
6k 4-NO2-C6H4- C20H14Cl2N4O3S 461 184 0.58 66 12.14 11.88
6l α-C4H3S- C18H13Cl2N3OS2 422 228 0.65 61 9.95 9.68































B. mega 12 14 17 17 13 16 13 16 19 17 14 15 22 24 23 25 0
S. aureus 15 11 12 15 20 14 18 19 17 16 13 12 20 22 19 24 0
E. coli 16 14 11 12 18 14 16 13 15 17 13 13 19 18 20 22 0
P. vulgaris 14 17 16 16 15 13 15 17 11 14 12 14 17 20 21 23 0
A.niger 18 15 17 20 14 18 16 20 21 17 14 14 0 0 0 0 26












GRAPHICAL CHART NO. 6 :  ANTIMICROBIAL ACTIVITY OF 3-[5’-(m, p-DICHLOROPHENYL)-2’-FURYL]-1-ARYL-2-





Cyclohexenone is the parent of a series of compounds that is important in
agricultural and medicinal chemistry. Cyclohexenones are derivatives of
cyclohexane with carbonyl group at 1-position and double bond at 2-position
(I). Cyclohexenones can be conveniently synthesised by the treatment of α,β-
unsaturated carbonyl compounds with ethylacetoacetate in basic media.
In recent years cyclohexenone derivatives have gained lots of interest
because of its prominent pharmaceutical properties.
SYNTHETIC ASPECT
Different methods for the synthesis of cyclohexenone derivatives have been
described in literature.206-212
1. N. Nanjundaswami et al.213 have prepared 6,7-dimethoxy-1-aryl-4-oxo-
2-naphthoate derivatives (III) by the reaction of dimethoxyphenyl aryl



















The addition reaction between ethylacetoacetate and α,β-unsaturated
ketone give cyclohexenone via. Michael addition. This reaction has been carried
out in basic  media by using sodium ethoxide or anhy. K2CO3 in acetone. During
the reaction nucleophillic addition of carbanion take place to the C=C of the
acceptor.  The α,β -unsatura ted compound i s  known as  acceptor  and
ethylacetoacetate is known as donor.
THERAPEUTIC EVALUATION
Cyclohexenones and its derivatives are widely used in pharmaceutical
indus t r y.  Cons iderab le  in te res t  has  been shown in  the  chemis t r y  o f
cyclohexenones due to their wide spectrum of therapeutic activities which can













































Cyclohexenone derivatives which possess plant growth regulatory activity
have been reported.224,225 Nagao et al.226 have reported antiarrhythmic
cyclohexenones. Collins and co-workers227 have documented cyclohexenone
derivatives which possess estrogenic activity. Tvanov et al.228 have reported
antimicrobial activity of some cyclohexenone derivatives. V. K. Ahluwalia and
co-workers229 have assessed cyclohexenone derivatives for anti HIV-I, gastric
secretion inhibitors and pesticidal activity. Cyclohexenone derivatives have been
reported to be active as allergy inhibitors, platelet aggregation inhibitors and
fibrinogen antagonist.230
Rheinheimer J. et al.231 have synthesised 5-(dioxabicyclohept-6-yl)
cyclohexenone oxime ethers as herbicides and plant growth regulators. Harimaya
and co-workers232 have synthesised new cyclohexenone derivatives possessing
progesteron receptor binding inhibitory activity. The herbicidal activity of
cyclohexenone derivatives (IV) has been investigated.233
Antimicrobial activity of cyclohexenone derivatives has been studied by
Salama and Atsh ikh234.  Takehi ro and co-workers235 have repor ted
cyclohexenones possessing neutropeptide γ-receptor antagonist activity. Kimura












activity of penienone and they exhibit the remarkable inhibitory activity against
the growth of lettuce seedlings. Broughton H. et al.237 have demonstrated
cyclohexenones as GABA α5 receptor ligands for enhancing cognition properties.
Hermann S. et al.238 have reported cyclohexenones as herbicides.
Anticonvulsant activity of some cyclohexenone derivatives (V) have been
reported by Natalie D. et al.239 Bastiaan and co-workers240 have synthesised
novel cyclohexenone derivatives (VI) which are useful in the treatment of
perkinson's disease. Cyclohexenones (VII) as anticancer and antiinflammatory
agents have been investigated.241
Moreover, H. H. Parekh and co-workers242 have synthesised 6-carbethoxy-
5-(4'-cinnamoyloxyphenyl)-3-aryl-2-cyclohexenones and all the products have
been evaluated for their antimicrobial activity. Zhang C. et al.243 have prepared
tricyclic heterocycles, containing furan and cyclohexenone nucleus for treating
hyper-proliferative disorders.
With a view to getting better therapeutic agent, it was contemplated to
synthesise cyclohexenones bearing furan nucleus to enhance the overall activity
of resulting compounds, which have been described as under.
























SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-ARYL-5-[5'-(m,p-
DICHLOROPHENYL)-2'-FURYL]-6-CARBETHOXY-2-CYCLOHEXENONES
The growing potent literature of recent years demonstrates that the
cyclohexenone derivatives are used as better therapeutic agents. These findings
prompted us to synthesise a series of 3-aryl-5-[5'-(m,p-dichlorophenyl)-2'-furyl]-
6-carbethoxy-2-cyclohexenones of type (VII). The synthesis was carried out by
the condensation of chalcones of type (I) with ethylacetoacetate in acetone.
The constitution of the synthesised products have been characterised using
elemental analyses, IR and 1H nuclear magnetic resonance spectroscopy and
mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.


















IR SPECTRAL STUDY OF 3-(p-TOLYL)-5-[5'-(m,p-DICHLOROPHENYL)-2'-FURYL]-
6-CARBETHOXY-2-CYCLOHEXENONE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2974 2975-2950 444
-CH3 C-H def. (sym.) 2869 2880-2860 "
C-H def. (asym.) 1465 1470-1435 "
C-H def. (sym.) 1371 1390-1370 "
Aromatic C-H str. 3051 3080-3030 445
C=C str. 1535 1520-1480 "
C-H i.p.def. 1028 1070-1000 "
C-H o.o.p. def. 819 835-810 "
Furyl moiety C-O-C str. (sym.) 1244 1275-1200 444
C-O-C str. (asym.) 1062 1075-1020 "
C-Cl str. 790 800-750 "
Cyclohe- C= O str. of ester 1733 1750-1725 "









PMR SPECTRAL STUDY OF 3-(p-ANISYL)-5-[5'(m,p-DICHLOROPHENYL)- 2'-FURYL]-
6-CARBETHOXY-2-CYCLOHEXENONE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons in Hz
1 1.13 3H triplet -CH3-CH2 -
2 2.14 1H doublet -CHf -
3 2.42 1H doublet -CHg -
4 3.23 1H doublet -CHi -
5 3.75 3H singlet -OCH3 -
6 4.01 1H multiplet -CHh -
7 4.14 2H quartet -CH3-CH2 -
8 5.66 1H singlet -CHj -
9 6.33 1H doublet furyl-H J=3.3
10 6.92 2H doublet Ar-He,e' Jed=8.7
11 7.04 1H doublet furyl-H J=3.3
12 7.45 2H doublet Ar-Hd,d' Jde=8.4
13 7.62 1H double doublet Ar-Hb Jba=8.4
Jbc=1.8
14. 7.68 1H doublet Ar-Ha Jab=8.4


















7a C6H5- 1747 1708
7b 3-NH2-C6H4- 1736 1702
7c 4-NH2-C6H4- 1740 1706
7d 4-Br-C6H4- 1735 1700
7e 4-Cl-C6H4- 1746 1712
7f 4-F-C6H4- 1745 1706
7g 2-OH-C6H4- 1735 1698
7h 4-OCH3-C6H4- 1740 1705
7i 4-CH3-C6H4- 1733 1706
7j 3-NO2-C6H4- 1742 1712
7k 4-NO2-C6H4- 1745 1710
7l α-C4H3S- 1736 1700
Sr.
 No. R
Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)


















































































m/z = 485 (m+ peak)
(base peak)

















SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-ARYL-5-[5'-(m,p-
DICHLOROPHENYL)-2'-FURYL]-6-CARBETHOXY-2-CYCLOHEXENONES
(A) Preparation of 1-Aryl-3-[5'-(m,p-dichlorophenyl)-2'-furyl]-2-propene-
1-ones
Part - I, Section - I (B)
(B) Preparation of 3-(p-Anisyl)-5-[5'-(m,p-dichlorophenyl)-2'-furyl]-6-
carbethoxy-2-cyclohexenone
A mixture of 1-(p-anisyl)-3-[5'-(m,p-dichlorophenyl)-2'-furyl]-2-propene-1-
one (3.73g, 0.01M),  ethylacetoacetate (1.3 ml, 0.01 M) and K2CO3 (1.38 g,
0.01 M) was taken into dry acetone (30-40 ml) and then the mixture was stirred
at room temperature till the acetone is evaporated off. The contents were then
poured into crushed ice and neutrallised with HCl. The product separated was
filtered and crystallised from ethanol. Yield 75%, m.p. 122oC. (C26H22Cl2O5
required: C, 64.34; H, 4.57%; found: C, 64.10; H, 4.37%).
Similarly other substituted cyclohexenones were prepared. The physical
constants are recorded in Table No. 7.
(C) Therapeutic evaluation of 3-Aryl-5-[5'-(m,p-dichlorophenyl)-2'-
furyl]-6-carbethoxy-2-cyclohexenones
Antimicrobial testing was carried out as described in Part-I, Section -
























7a C6H5- C25H20Cl2O4 455 178 0.71 67
7b 3-NH2-C6H4- C25H21Cl2NO4 470 190 0.78 70 2.98 2.70
7c 4-NH2-C6H4- C25H21Cl2NO4 470 172 0.68 66 2.98 2.78
7d 4-Br-C6H4- C25H19BrCl2O4 534 220 0.72 63
7e 4-Cl-C6H4- C25H19Cl3O4 489.5 223 0.60 65
7f 4-F-C6H4- C25H19Cl2FO4 473 112 0.66 73
7g 2-OH-C6H4- C25H20Cl2O5 471 150 0.81 60
7h 4-OCH3-C6H4- C26H22Cl2O5 485 122 0.50 75
7i 4-CH3-C6H4- C26H22Cl2O4 469 178 0.66 67
7j 3-NO2-C6H4- C25H19Cl2NO6 500 140 0.82 64 2.80 2.55
7k 4-NO2-C6H4- C25H19Cl2NO6 500 180 0.71 68 2.80 2.58
7l α-C4H3S- C23H18Cl2O4S 461 120 0.68 60
































B. mega 18 20 14 21 18 16 13 15 21 20 14 12 22 24 23 25 0
S. aureus 12 15 19 20 13 11 15 16 17 12 14 13 20 22 19 24 0
E. coli 18 13 14 13 17 20 11 12 14 15 14 13 19 18 20 22 0
P. vulgaris 13 18 13 14 12 14 16 16 13 12 17 14 17 20 21 23 0
A.niger 18 17 18 20 21 17 18 14 15 16 14 14 0 0 0 0 26












GRAPHICAL CHART NO. 7 :  ANTIMICROBIAL ACTIVITY OF 3-ARYL-5-[5’-(m, p-DICHLOROPHENYL)-2’-FURYL]-6-





Heterocyclic compounds bearing 1,2-diazole ring system i.e. pyrazole ring
system, attached to benzene ring system are known as benzopyrazole or indazole
(I). Indazole was first described by Buchner in 1869.
SYNTHETIC ASPECT
Several methods have been reported in the literature244-249 for the
preparation of indazoles.
1. Cyclocondensation of activated acetylenes with hydrazine afforded indazole
derivatives.250
2. B. V. Badami et al.251 have synthesised indazoles from chalcone derivatives




























3. A facile synthesis of substituted indazoles from 2-acyl mesylates and
hydrazines has been described by Caron S. et al252.
THERAPEUTIC EVALUATION
It is revealed from the literature survey that indazole derivatives are better
therapeutic agents and they have been found possessing various biological











Some indazoles (II) synthesised by Duzinska-Usarewicz et al.264 have been
found to possess antiinflammatory activity. Effland R. et al.265 Synthesised 3-














Butera J. A. et al.266 prepared some indazole derivatives which showed
antihypertensive, muscle relaxant and potassium activator activity. Several co-
workers have patented indazole derivatives useful as hypolipidemic agent267,
5-HT3 antagonists268, enzyme inhibitor269 etc. Some indazole derivatives as
novel antiasthametic agents have been investigated.270 Ooe T. et al.271
synthesised indazoles which have been found to possess varied biological
activities such as hematinics, immunostimulants and antitumor agents. The
remarkable cytotoxic activity of indazoles have been reported.272
Lavielle G. et al.273 prepared [(pyrolidinyl) methyl]-indazoles and
suggested them for the treatment of migrains. Marfat Anthony274 has patented
indazole derivatives useful as phosphodiesterase and tumor necrosis factor
production inhibitors. Indazoles derivatives have been evaluated as α-2-
adrenoreceptor agonists .275 Antivira l  act iv i ty of  indazoles have been
reported.276 Badran M. et al.277 synthesised some novel indazole derivatives
fused with triazines and triazoles for exploring their antiinflammatory activity.
Newshaw R. and co-workers278 prepared 4-amino ethoxy indazoles and
reported them as dopamine D2 agonists. Kania R. et al.
279 have synthesised
indazole derivatives as protein kinase inhibitors. Indazole derivatives useful as
inhibitors of cell proliferation have been synthesised.280 The remarkable









Z = (un)-substituted piperazino,
piperidino, etc.
(IV)
Balakrishna and co-workers282 have synthesised indazole derivatives and
evaluated them as antiinflammatory and analgesic activity. Malmstroem J. et
al.283 have prepared indazoles (V) as inhibitors of Jun N-terminal kinases (JNK).
Aminoindazoles (VI) useful in the treatment of central & peripheral nervous
system diseases have been synthesised.284
In the light of these valid opservations, it was thought worth while to
synthesise a new series of indazoles has been described in the following section.




















SYNTHESIS AND THERAPEUTIC EVALUATION OF 6-ARYL-4-[5'-(m,p-
DICHLOROPHENYL)-2'-FURYL]-3-OXO-3,3a,4,5-TETRAHYDRO-2H-
INDAZOLES
Indazole derivatives have attained much interest owing to their interesting
biological activities such as anticancer, antiinflammatory, anticonvulsant etc.
With a view to getting better therapeutic agents, a series of 6-aryl-4-[5'-(m,p-
dichlorophenyl)-2'-furyl]-3-oxo-3,3a,4,5-tetrahydro-2H-indazoles of type (VIII)
has been synthesised. The synthesis was carried out by the condensation of
cyclohexenones of type (VII) with hydrazine hydrate.
The constitution of the synthesised products have been characterised using
elemental analyses, IR and 1H nuclear magnetic resonance spectroscopy and
mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towared Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.



















IR SPECTRAL STUDY OF 6-(p-ANISYL)-4-[5'-(m,p-DICHLOROPHENYL)-2'-FURYL]-
3-OXO-3,3a,4,5-TETRAHYDRO-2H-INDAZOLE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2956 2975-2950 444
-CH3 C-H str. (sym.) 2837 2880-2860 "
C-H def. (asym.) 1450 1470-1435 "
Aromatic C-H str. 3045 3080-3030 445
C=C str. 1504 1520-1480 "
C-H i.p.def. 1020 1070-1000 "
C-H o.o.p. def. 835 835-810 "
Furyl moiety C-O-C str. (sym.) 1247 1275-1200 444
C-O-C str. (asym.) 1055 1075-1020 "
C-Cl str. 773 800-750 "
Indazole N-H str. 3288 3400-3200 446
C=O str. 1672 1680-1640 "
N-H def. 1616 1650-1580 "











PMR SPECTRAL STUDY OF 6-(p-ANISYL)-4-[5'(m,p-DICHLOROPHENYL)-2'-FURYL]-
3-OXO-3,3a,4,5-TETRAHYDRO-2H-INDAZOLE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons in Hz
1 2.63 1H doublet -CHf -
2 3.00 1H doublet -CHg -
3 3.57 1H doublet -CHi -
4 3.73 3H singlet -OCH3 -
5 4.16 1H multiplet -CHh -
6 5.22 1H singlet -CHj -
7 6.22 1H doublet furyl-H J=3.0
8 6.87 2H doublet Ar-He,e' Jed=8.7
9 6.98 1H doublet furyl-H J=3.0
10 7.47 2H doublet Ar-Hd,d' Jde=8.7
11 7.58 1H double doublet Ar-Hb Jba=8.4
Jbc=1.5
12 7.62 1H doublet Ar-Ha Jab=8.4
































Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
















































































































SYNTHESIS AND THERAPEUTIC  EVALUATION OF 6-ARYL-4-[5'-(m,p-
DICHLOROPHENYL)-2'-FURYL]-3-OXO-3,3a,4,5-TETRAHYDRO-2H-
INDAZOLES
(A) Preparation of 1-Aryl-3-[5'-(m,p-dichlorophenyl)-2'-furyl]-2-propene-
1-ones
Part - I, Section -  I (B)
(B) Preparation of 3-Aryl-5-[5'-(m,p-dichlorophenyl)-2'-furyl]-6-
carbethoxy-2-cyclohexenones
Part - V, Section - I (B)
(C) Preparation of 6-(p-Anisyl)-4-[5'-(m,p-dichlorophenyl)-2'-furyl]-3-
oxo-3,3a,4,5-tetrahydro-2H-indazole
A mixture of 3-(p-anisyl)-5-[5'-(m,p-dichlorophenyl)-2'-furyl]-6-carbethoxy-
2-cyclohexenone (4.85g, 0.01M) and hydrazine hydrate (1.0g, 0.02M) in
methanol was refluxed for 5 hrs. The mixture was poured into crushed ice and
neutrallised with HCl. The product separated was filtered and crystallised from
DMF.  Yield 70%, m.p. 206oC. (C24H18Cl2N2O3; required : C, 63.59; H, 4.00;
N, 6.18%; found : C, 63.41; H, 3.75; N, 5.92%).
Similarly other substituted indazoles were prepared. The physical constants
are recorded in Talbe No. 8.
(D) Therapeutic evaluation of 6-Aryl-4-[5'-(m,p-dichlorophenyl)-2'-
furyl]-3-oxo-3,3a,4,5-tetrahydro-2H-indazoles
Antimicrobial testing was carried out as described in Part - I, Section -
























8a C6H5- C23H16Cl2N2O2 423 260 0.81 74 6.62 6.42
8b 3-NH2-C6H4- C23H17Cl2N3O2 438 282 0.65 68 9.59 9.36
8c 4-NH2-C6H4- C23H17Cl2N3O2 438 210 0.64 63 9.59 9.29
8d 4-Br-C6H4- C23H15BrCl2N2O2 502 180 0.52 75 5.58 5.25
8e 4-Cl-C6H4- C23H15Cl3N2O2 457.5 244 0.55 65 6.12 5.86
8f 4-F-C6H4- C23H15Cl2FN2O2 441 254 0.83 66 6.35 6.08
8g 2-OH-C6H4- C23H16Cl2N2O3 439 194 0.81 62 6.38 6.10
8h 4-OCH3-C6H4- C24H18Cl2N2O3 453 206 0.55 70 6.18 5.92
8i 4-CH3-C6H4- C24H18Cl2N2O2 437 268 0.65 60 6.41 6.14
8j 3-NO2-C6H4- C23H15Cl2N3O4 468 172 0.78 64 8.97 8.70
8k 4-NO2-C6H4- C23H15Cl2N3O4 468 248 0.72 65 8.97 8.74
8l α-C4H3S- C21H14Cl2N2O2S 429 230 0.58 66 6.53 6.26
































B. mega 13 18 19 19 18 16 18 21 11 14 15 14 22 24 23 25 0
S. aureus 13 12 14 15 11 17 19 18 14 17 15 14 20 22 19 24 0
E. coli 15 11 16 18 17 14 19 18 17 14 14 12 19 18 20 22 0
P. vulgaris 12 16 11 13 12 16 20 13 15 15 14 13 17 20 21 23 0
A.niger 13 16 14 19 18 21 17 16 20 18 14 15 0 0 0 0 26












GRAPHICAL CHART NO. 8 :  ANTIMICROBIAL ACTIVITY OF 6-ARYL-4-[5’-(m, p-DICHLOROPHENYL)-2’-FURYL]-3-






The emerging role of barbitones in pharmaceutical chemistry as well as in
biochemistry stimulated tremendous interest in the synthesis of barbitones of
therapeutic interest. Most important is the effect of barbiturates on the central
nervous system. Barbituric acid derivatives constitute an important class of
compounds possessing diverse type of biological properties including hypnotic,
sedative, anticonvulsant, cardiovascular etc.
Derivatives of barbituric acid are perhaps the most widely used pyrimidines
in medicine. Veronal (I) and Luminol (II) possess hypnotic activities, while
pentothiol (III) is used as an anaesthetic.
SYNTHETIC ASPECT
Different methods for the synthesis of barbitones have been described in
literature.285-289









































2. Cao-Yun et al291 have prepared barbituric acid derivatives by the reaction
of different aldehydes with barbituric acid in basic media.
3. P. K. Roy et al292 have synthesised barbituric acid derivatives by the
reaction of urea derivatives with malonic acid.
THERAPEUTIC EVALUATION
At present great interest is being taken in barbituric acid derivatives because
of its biological activity and their relation with nucleic acids, viz uracil, thymine
and cytosine.
Some barbiturates showing cardiovascular,293,294 antiinflammatory295
and pesticidal296 activities have been repor ted. D. Peters et al297 have
synthesised some uracil derivatives and screened for antiviral activity. Raymond
et al298 synthesised some barbiturates (IV) which showed anticancer activity.
Several co-workers have synthesised barbitone derivatives and reported
their antagonist,299 antitumor,300 anticonvulsant301 and metalloproteinase
inhibitor302 activities. Abdel-Hamide and co-workers303 have prepared

































have demonstrated barbitone derivatives as porphyrin melamine calixarene
receptor. Wolf-Gang et al305 have reported 5-(3-benzylthiazolidine-2-ylidene)-
1,3-dimethyl hexahydro pyrimidine-2,4,6-trione having agricultural activity.
Some barbituric acid derivatives used as herbicides and insecticides have been
demonstrated.306
Omar M. T.307 has synthesised barbitone derivativse showing antimicrobial
activity. Sakai et al308 have synthesised some new barbitones which were
assessed for bone and cartilage disease. Grams and Zimmermann309 have
prepared barbitones as metalloprotease inhibitors. Some barbitone derivatives
have been studied for their antitumor activity.310
Moreover, isotylidene barbiturates (VI) showing antibacterial activity have
been synthesised.311 Geppert D. and co-workers312 have prepared new
pyrimidine-2,4,6-triones (VII) as metalloproteinase inhibitors.
Keeping in view the important biological activities possessed by barbituric
acid derivatives, we have tried to synthesise some new barbitones having better
biological activities.

























SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-ARYL-3-[5'-(m,p-
DICHLOROPHENYL)-2'-FURYL]-2-PROPENYLIDENE BARBITURIC
ACID
Barbituric acid derivatives are claimed to have a wide spectrum of biological
activities. Furan containing heterocyclic moiety possess diversified biological
properties. Considering all the above facts, it was thought that if barbituric acid
group could be introduced to furan moiety, the resulting compounds might have
some significant biological properties. For this purpose, some new barbituric
acid derivatives of type (IX) were prepared by the condensation of chalcones of
type (I) with barbituric acid in glacial acetic acid.
The constitution of the synthesised products have been characterised using
elemental analyses, IR and 1H nuclear magnetic resonance spectroscopy and
mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towared Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.






















IR SPECTRAL STUDY OF 1-(p-ANISYL)-3-[5'-(m,p-DICHLOROPHENYL)-2'-FURYL]-
2-PROPENYLIDENE BARBITURIC ACID
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2952 2975-2950 444
-CH3 C-H def. (asym.) 1440 1470-1435 "
C-H def. (sym.) 1406 1390-1370 "
Aromatic C-H str. 3055 3080-3030 445
C=C str. 1504 1520-1480 "
C-H i.p.def. 1056 1070-1000 "
C-H o.o.p. def. 819 835-810 "
Furyl moiety C-O-C str. (sym.) 1257 1275-1200 444
C-O-C str. (asym.) 1056 1075-1020 "
(overlaped)
C-Cl str. 786 800-750 "
Barbitone N-H str. 3396 3450-3250 "
C=O str. 1712 1750-1700 "
C=C str. 1585 1590-1550 "











PMR SPECTRAL STUDY OF 1-(p-ANISYL)-3-[5'(m,p-DICHLOROPHENYL)-2'-FURYL]-
2-PROPENYLIDENE BARBITURIC ACID
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons in Hz
1 3.90 3H singlet -OCH3 -
2 6.78 1H doublet furyl-H J=3.9
3 6.79 1H doublet furyl-H J=4.0
4 7.00 2H doublet Ar-He,e' Jed=8.8
5 7.49 1H doublet Ar-Ha Jab=8.2
6 7.52 1H doublet Vin-H J=15.0
7 7.57 1H double doublet Ar-Hb Jba=8.1
Jbc=2.1
8 7.59 1H doublet Vin-H J=15.0
9 7.84 1H doublet Ar-Hc Jcb=2.1































Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)







































































































m/z = 203m/z = 131m/z = 265
m/z = 220
m/z = 357
m/z = 395 (base peak)
127
EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-ARYL-3-[5'-(m,p-
DICHLOROPHENYL)-2'-FURYL]-2-PROPENYLIDENE BARBITURIC
ACIDS
(A) Preparation of 1-Aryl-3-[5'-(m,p-dichlorophenyl)-2'-furyl]-2-propene-
1-ones
Part - I, Section -  I (B)
(B) Preparation of 1-(p-Anisyl)-3-[5'-(m,p-dichlorophenyl)-2'-furyl]-2-
propenylidene barbituric acid
A mixture of 1-(p-anisyl)-3-[5'-(m,p-dichlorophenyl)-2'-furyl]-2-propene-1-
one (3.73g, 0.01 M) and barbituric acid (1.28g, 0.01M) in glacial acetic acid
was refluxed for 8 hrs on oil bath. The contents were poured into ice and product
was isolated, crystallised from DMF. Yield 71%, m.p. 152oC. (C24H16Cl2N2O5;
required: C, 59.64; H, 3.34; N, 5.80%; found: C, 59.35; H, 3.12; N, 5.58%).
Similarly other substituted barbitones were prepared. The physical constants
are recorded in Table No. 9.
(C) Therapeutic evaluation of 1-Aryl-3-[5'-(m,p-dichlorophenyl)-2'-
furyl]-2-propenylidene barbituric acids
Antimicrobial testing was carried out as described in Part-I, Section-
























9a C6H5- C23H14Cl2N2O4 453 165 0.65 63 6.18 5.92
9b 3-NH2-C6H4- C23H15Cl2N3O4 468 210 0.55 65 8.97 8.70
9c 4-NH2-C6H4- C23H15Cl2N3O4 468 175 0.81 68 8.97 8.77
9d 4-Br-C6H4- C23H13BrCl2N2O4 532 190 0.88 66 5.26 5.00
9e 4-Cl-C6H4- C23H13Cl3N2O4 487.5 138 0.71 68 5.74 5.48
9f 4-F-C6H4- C23H13Cl2FN2O4 471 185 0.63 73 5.94 5.72
9g 2-OH-C6H4- C23H14Cl2N2O5 469 230 0.52 69 5.97 5.75
9h 4-OCH3-C6H4- C24H16Cl2N2O5 483 152 0.78 71 5.80 5.58
9i 4-CH3-C6H4- C24H16Cl2N2O4 467 204 0.71 64 5.99 5.78
9j 3-NO2-C6H4- C23H13Cl2N3O6 498 124 0.84 65 8.43 8.15
9k 4-NO2-C6H4- C23H13Cl2N3O6 498 172 0.54 67 8.43 8.22
9l α-C4H3S- C21H12Cl2N2O4S 459 144 0.53 61 6.10 5.86
































B. mega 15 16 19 17 17 20 14 19 11 17 21 14 22 24 23 25 0
S. aureus 15 14 14 15 11 12 15 13 16 17 14 17 20 22 19 24 0
E. coli 19 13 15 14 15 17 15 16 13 11 13 16 19 18 20 22 0
P. vulgaris 14 11 13 13 12 14 13 16 14 15 14 13 17 20 21 23 0
A.niger 14 14 21 15 13 18 20 17 16 17 18 14 0 0 0 0 26


















The five membered heterocyclic ring system 5-oxo-imidazoline (I) have
two nitrogen atoms in the 1- and 3-positions and a carbonyl group at 5-position.
The discovery of the 2-substituted-5-imidazolines dates back to the year
1888, when A. W. Hoffmann313 for the first time discovered 5-oxo-imidazoline
by heating N1-diacetyl ethylene diamine in a stream of dry hydrogen chloride
and moreover the same compound was prepared by A. Ladenburg314 by the
fusion of two equivalents of sodium acetate with one equivalent of ethylene
diamine dihydrochloride.
SYNTHETIC ASPECT
Various methods have been reported for the synthesis of imidazolinones in
literature315. Aminolysis of oxazolone with amines led to the formation of
imidazolinones which has been reported in literature316.
























2. Allimony et al.318 have synthesised new imidazolinone derivatives by
conventional method.
3. Feng-Jun-Cai et al.319 have synthesised 5-imidazolinone derivatives by
microwave irradiation.
MECHANISM
Azlactone reacts with variety of compounds such as water, alcohols, amines
and hydrogen halides. Amides of α-acylaminoacrylic acids obtained from the
condensat ion of  az lactone and pr imary amine can be conver ted into
imidazolinone derivatives as shown in equation (III).
The ring closure can be effected under a variety of conditions. Substituted
anilides have been converted into imidazolinone derivatives by the action of
phosphorous oxychloride.
THERAPEUTIC EVALUATION
Naphazoline hydrochloride, xylometazoline hydrochloride etc. are various
imidazolinone derivatives which have been used as adrenergic stimulants and
to lazo l ine  and phento lamine as  adrenerg ic  b lock ing agents .  Var ious




























1. Potent CNS depressant320










Bascou and co-workers331 have prepared some new imidazolinones and
reported their agrochemical activity. Kolhe Vishnu et al.332 have reported anti
AIDS, antibacterial and fungicidal activity of 5-oxo-imidazolines. Herbicidal
activity of imidazolinone derivatives have been reported by U. Akyoshi et al.333
Ding M. et al.334 and Pilkington B. et al.335 have reported a new series of
biologically active analogues of 5-oxo-imidazolines. Imidazolinone derivatives
which possess antifungal activity have been reported.336 Some new 5-oxo-
imidazolines as antimicrobial agents have been investigated.337  L. Joseph Patel
and co-workers338 have prepared substituted imidazolinones which inhibited
the abnormal cell growth in human body. B. Kalluraya et al.339 (IV) have










CONTRIBUTION FROM OUR LABORATORY
A.  R.  Par ikh  e t  a l .  have synthes i sed imidazo l inones  bear ing
chloramphenicol,340 aminobenzylamino341 and phthalazine342 moiety at one
position which were evaluated for their antimicrobial activity. H. H. Parekh and
co-workers have assessed imidazolinones containing isoniazid343, s-triazine344
and benzimidazole345 moiety which were demonstrated as potent antimicrobial
agents.
General structure for above references is as under.
H. H. Parekh and co-workers346  have reported imidazolinone derivatives
as antimicrobial agents. Khyati Parikh and co-workers347 have synthesised
imidazolinone derivatives and described antimicrobial activity. H. H. Parekh et
al.348 have prepared imidazolinones and all products have been evaluated for
































Moreover, Battistina et al.349 have demonstrated some novel imidazolines
to possess insecticidal activity. Imidazoline derivatives showing anti HIV activity
have been repor ted.350 Abde l  Rahman e t  a l .351  have synthes i sed
imidazolinones and evaluated for their ability to bind to DNA. Prasanna and
co-workers352 have reported imidazolinone derivatives as potent anticancer
agent. Biological activity of imidazolinone derivatives have been reported.353
The development of efficient and selective synthesis of imidazolinones has
at t racted increasing at tent ion because they of ten br ing about unique
pharmacodynamic activities. In search of biologically potent imidazolinone
derivatives, it was considered worthwhile to synthesise imidazolinones which
have been described as under.





SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-ARYL-2-PHENYL-
4 - [ 5 ' - ( m , p -D I C H LO R O P H E N Y L ) - 2 ' -F U R Y L I D E N E ] - 5 - OXO -
IMIDAZOLINES
Various imidazolinones have resulted in many potential drugs and are
known to possess a broad biological spectrum. Looking to the interesting
properties of imidazolinones, it was considered worthwhile to synthesise a series
of 5-oxo-imidazolines of type (X) which were prepared by the condensation of
4-oxo-2-phenyl-5-[5'-(m,p-dichlorophenyl)-2'-furylidene] oxazole with different
arylamines in dry pyridine.
The constitution of the synthesised products have been characterised using
elemental analyses, IR and 1H nuclear magnetic resonance spectroscopy and
mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of synthesised compounds were compared with standard
drugs.
































Type (X) R = Aryl
137
138
IR SPECTRAL STUDY OF 1-(o-TOLYL)-2-PHENYL-4-[5'-(m,p-DICHLOROPHENYL)-
2'-FURYLIDENE]-5-OXO-IMIDAZOLINE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2962 2975-2950 444
-CH3 C-H str. (sym.) 2846 2880-2860 "
C-H def. (asym.) 1456 1470-1435 "
C-H def. (sym.) 1367 1390-1370 "
Aromatic C-H str. 3030 3080-3030 445
C=C str. 1517 1520-1480 "
C-H i.p.def. 1024 1070-1000 "
C-H o.o.p. def. 827 835-810 "
Furyl moiety C-O-C str. (sym.) 1265 1275-1200 444
C-O-C str. (asym.) 1024 1075-1020 "
(overlaped)
C-Cl str. 759 800-750 "
Imidazoli- C=O str. 1722 1760-1655 448
none C=N str. 1596 1640-1500 "








PMR SPECTRAL STUDY OF 1-(p-CARBETHOXYPHENYL)-2-PHENYL-4-[5'(m,p-
DICHLOROPHENYL)-2'-FURYLIDENE]-5-OXO-IMIDAZOLINE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons in Hz
1 1.39 3H triplet -COOCH2CH3 -
2 4.35 2H quartret -COOCH2CH3 -
3 6.54 1H doublet furyl-H J=3.6
4 6.61 1H doublet furyl-H J=3.5
5 6.93 1H double doublet Ar-Hb -
6 7.15 1H doublet Ar-Ha Jab=8.5
7 7.30 1H doublet Ar-Hc Jcb=1.5
8 7.52-7.68 5H multiplet Ar-Hf,g,h,i,j -
9 7.92 2H doublet Ar-He,e' Jed=8.4
10 8.02 2H doublet Ar-Hd,d' Jde=7.3




































Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)


























































































SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-ARYL-2-PHENYL-
4 - [ 5 ' - ( m , p -D I C H LO R O P H E N Y L ) - 2 ' -F U R Y L I D E N E ] - 5 - OXO -
IMIDAZOLINES
(A) Preparation of 5-(m,p-Dichlorophenyl)-2-furaldehyde
Part - I, Section - I (A).
(B) Preparation of 4-Oxo-2-phenyl-5-[5'-(m,p-dichlorophenyl)-2'-
furylidene] oxazole
A mixture of 5-(m,p-dichlorophenyl)-2-furaldehyde (6.02 g, 0.025 M),
benzoyl glycine (4.47 g, 0.025 M), acetic anhydride (7.6 ml, 0.075 M) and sodium
acetate (2.0 g) was heated on a waterbath for 4 hrs. Resulting mass was poured
into water filtered and crystallised from methanol. Yield 70%, m.p. 210oC.
(C) Preparation of 1-(p-Carbethoxyphenyl)-2-phenyl-4-[5'-(m,p-
dichlorophenyl)-2'-furylidene]-5-oxo-imidazolines
A mixture of 4-oxo-2-phenyl-5-[5'-(m,p-dichlorophenyl)-2'-furylidene]
oxazole (3.84 g, 0.01 M) and benzocaine (1.65 g, 0.01 M) in dry pyridine was
refluxed for 6 hrs. in oil bath. Resulting mass was poured into crushed ice and
neutralised with HCl, filtered and the product was crystallised from DMF. Yield
66%, m.p. 174oC. (C29H20Cl2N2O4; required: C, 65.55; H, 3.79; N, 5.27%;
found: C, 65.32; H, 3.60; N, 5.00%).
Similarly other substituted imidazolinones were prepared. The physical
constants are recorded in Table No. 10.
(D) Therapeutic evaluation of 1-Aryl-2-phenyl-4-[5'-(m,p-dichloro
phenyl)-2'-furylidene]-5-oxo-imidazolines
Antimicrobial testing was carried out as described in Part - I, Section - I






























10a C6H5- C26H16Cl2N2O2 459 136 0.55 68 6.10 5.84
10b 4-COOC2H5-C6H4- C29H20Cl2N2O4 531 174 0.65 66 5.27 5.00
10c 3-Cl-C6H4- C26H15Cl3N2O2 493.5 200 0.68 70 5.67 5.48
10d 4-Cl-C6H4- C26H15Cl3N2O2 493.5 143 0.79 62 5.67 5.38
10e 3-Cl,4-F-C6H3- C26H14Cl3FN2O2 511.5 148 0.78 76 5.47 5.20
10f 2,6(Cl)2-C6H3- C26H14Cl4N2O2 528 212 0.50 66 5.30 5.05
10g 2,4(CH3)2-C6H3- C28H20Cl2N2O2 487 156 0.52 63 5.75 5.52
10h 4-F-C6H4- C26H15Cl2N2O2 477 280 0.81 70 5.87 5.68
10i 2-OCH3-C6H4- C27H18Cl2N2O3 489 265 0.65 72 5.72 5.46
10j 4-OCH3-C6H4- C27H18Cl2N2O3 489 241 0.68 69 5.72 5.40
10k 2-CH3-C6H4- C27H18Cl2N2O2 473 208 0.55 66 5.92 5.71
10l 3-CH3-C6H4- C27H18Cl2N2O2 473 198 0.58 58 5.92 5.62
10m 4-CH3-C6H4- C27H18Cl2N2O2 473 201 0.72 66 5.92 5.68
10n 3-NO2-C6H4- C26H15Cl2N3O4 504 166 0.50 62 8.33 8.08
10o 4-NO2-C6H4- C26H15Cl2N3O4 504 184 0.71 64 8.33 8.12

























B. mega 18 20 16 17 16 14 16 15 17 19 18 18 14 13 12 22 24 23 25 0
S. aureus 15 17 14 18 13 12 13 15 14 16 17 12 15 14 14 20 22 19 24 0
E. coli 18 16 14 13 14 12 13 12 13 14 15 17 14 17 13 19 18 20 22 0
P. vulgaris 17 15 18 13 19 15 12 13 13 15 14 15 17 14 12 17 20 21 23 0
A.niger 13 18 14 13 17 17 20 17 18 19 15 14 13 15 16 0 0 0 0 26




















4-Thiazolidinones are derivatives of thiazolidine with a carbonyl group at
4-position (I). The cyclic structure was assigned after the recognition of mercapto
acetic acid as the primary product of hydrolysis of 3-phenyl-2-phenylamino-4-
thiazolidinone.354
A well known antibiotic, actithiazic acid (II), isolated from a species of
streptomyces  shows specific in vitro activity against M. tuberculosis, but it is
inactive in vivo probably due to antagonisation by biotin, bears the 4-
thiazolidinone skeleton355. The chemistry of 4-thiazolidinone was reviewed in
depth by F. Brown356 in 1962 and by G. Newkome357 in 1977.
SYNTHETIC ASPECTS
Synthesis of 4-thiazolidinones has been reported either by cyclisation of
acyclic compounds or by interconversion among appropriately substituted
thiazolidinone derivatives.




































2. Mogilaiah et al.359 have synthesised 2-aryl-3-(2-trif luromethyl-1,8-
naphthyridine-3-carbonylamino)-4-thiazolidinones.
3. Synthesis of 4-thiazolidinones has been reported by the microwave
irradiation360,361
MECHANISM
The cyclocondensation proceeds by the attack of the mercaptoacetic acid
upon the C=N group. The HSCH2COOH adding to the carbon atom followed
by the cyclisation.
Sometimes, the uncyclised product in these reaction  has been isolated362.
Phosphorous pentoxide in dioxan was used for subsequent cyclisation of certain
uncyclised products.363
The nucleophillic attack of thioglycolic anion on carbon of azomethine
having posi t ive  character  and ni t rogen having negat ive character  i s
evidenced364. Simultaneously, the removal of water take place, is rate
determining step and helps in cyclisation.
THERAPEUTIC EVALUATION
The thiazolidinone derivatives substituted at 2- and 3-position are
































Tamura et al.380 have reported antimicrobial activity of 4-thiazolidinone
derivatives. B. Lohary et al.381 have synthesised and reported hypolipidemic
activity of 4-thiazolidinone derivatives. Bhawana et al.382 have assessed some
new 4-thiazolidinones as antiinflammatory agents. Antifungal and antibacterial
activity of thiazolidinones has been reported.383 O. A. Fathalla384 have
synthesised some new 4-thiazolidinones as anticancer and antibacterial agent.
Mohie A. and co-workers385 investigated some new 4-thiazolidinones as
anticancer agent. Antiinflammatory and analgesic activity of 4-thiazolidinones
has been investigated.386
CONTRIBUTION FROM OUR LABORATORY
Parikh et al. have synthesised variety of 4-thiazolidinones bearing diphenyl
sulphone387, subst i tuted aryl388,389, arsani l ic acid390, 2-aryl-1,3,4-
thiadiazole391, γ-picolinylamino,392 s-triazine393, benzoylamino acetamido394,
sulphonamido benzoylamino395, phthalazine-1-yl-amino396, aryl substituted
hydroxyaryl, β-β-dichloroethylaminophenyl and 8-hydroxyquinolinyl moieties
of 4-thiazolidinone ring system (V) have been reported as potent antimicrobial
agents.
Thiazolidinones... 148
H. H. Parekh and co-workers have synthesised 4-thiazolidinones bearing
s - t r iaz ine ,397 acr id ine-9-y l398,  thymoloxyace tamido399,  6-hydroxy
pyrimidine400, dapson401 moieties of 4-thiazolidinone ring system (V), which
is represented as under and evaluated them for antimicrobial activity.
General structure for above references is as under.
Moreover, H. H. Parekh and co-workers402 have synthesised new bis-4-
thiazolidinones and studied their biological activity. A. R. Parikh and co-
workers403 have assessed thiazolidinone derivatives bearing 7-methoxyquinoline










































Siddique and co-workers404 have synthesised novel thiazolidinones and
evaluated for the ant i thyroid act iv i ty.  Mayer et  a l .405 have prepared
thiazolidinones and studied their herbicidal activity. Archana and Srivastava406
have synthesised new 4-thiazolidinones (VI) as potent anticonvulsant agent. S.
K. Srivastava et al.407 have formulated some new 4-thiazolidinones (VII) as
antibacterial, antifungal, analgesic and diuretic agents.
Thiazolidinones useful in the treatment of inflammation have been
synthesised.408 Govindarajan R. et al.409 have described thiazolidinone
derivatives of pyrazinoic acid and reported their antibacterial, antifungal and
antitubercular activity. Thiazolidinones for the inhibition of phosphatases and
the treatment of cancer have been reported.410
Considerable evidence has been accumulated to demonstrate the wide
applications of thiazolidinone derivatives and also furan nucleus have drawn
the attention of chemists due to diversified biological activities associated with
it. In view of these findings, it appeared of interest to synthesise, newer
thiazolidinone derivatives with better potency.
SECTION - 1 : SYNTHESIS AND THERAPEUTIC EVALUATION OF



























SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-ARYLIMINO-3-
A RY L - 5 - [ 5 ' - ( m , p -D I C H LO R O P H E N Y L ) - 2 ' -F U R Y L I D E N E ] - 4 -
THIAZOLIDINONES
With a view to getting better therapeutic agents and considering the
associat ion of various biological act ivi t ies of thiazol idinone and furan
heterocycles, the preparation of arylidenes of type (XI) have been undertaken
by the condensation of 2-arylimino-3-aryl-5H-4-thiazolidinones with 5-(m,p-
dichlorophenyl)-2-furaldehyde in glacial acetic acid.
The constitution of the synthesised products have been characterised using
elemental analyses, IR and 1H nuclear magnetic resonance spectroscopy and
mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of synthesised compounds were compared with standard
drugs.


















































Type (XI) R = Aryl
152
153
IR SPECTRAL STUDY OF 2-ARYLIMINO-3-(m-TOLYL)-5-[5'-(m,p-DICHLOROPHENYL)-
2'-FURYLIDENE]-4-THIAZOLIDINONE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2948 2975-2950 444
-CH3 C-H def. (asym.) 1454 1470-1435 "
C-H def. (sym.) 1404 1390-1370 "
Aromatic C-H str. 3043 3080-3030 445
C=C str. 1490 1520-1480 "
C-H i.p.def. 1033 1070-1000 "
C-H o.o.p. def. 817 835-810 "
Furyl moiety C-O-C str. (sym.) 1207 1275-1200 444
C-O-C str. (asym.) 1051 1075-1020 "
C-Cl str. 790 800-750 "
Thiazo- C=O str. 1710 1760-1655 449
lidinone S-C=N str. 1629 1640-1605 "
C–N str. 1136 1220-1020 "
C-S-C str. 688 700-600 "
Arylidene =CH i.p. 1357 1420-1290 "











PMR SPECTRAL STUDY OF 2-(p-TOLYLIMINO)-3-(P-TOLYL)-5-[5'(m,p-DICHLORO
PHENYL)-2'-FURYLIDENE]-4-THIAZOLIDINONE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons in Hz
1 2.37 3H singlet -CH3 -
2 2.41 3H singlet -CH3 -
3 6.76 1H doublet furyl-H J=3.7
4 6.78 1H doublet furyl-H J=3.7
5 6.92 2H doublet Ar-Hf,f' Jed=8.3
6 7.18 2H doublet Ar-He,e' Jgf=8.1
7 7.32-7.39 6H multiplet Ar-Hd,d';Ar-Hg,g'; -
Ar-Ha;Ar-Hb
8 7.55 1H singlet -CHx -



































Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)














































































































SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-ARYLIMINO-3-
A RY L - 5 - [ 5 ' - ( m , p -D I C H LO R O P H E N Y L ) - 2 ' -F U R Y L I D E N E ] - 4 -
THIAZOLIDINONES
(A) Preparation of 5-(m,p-Dichlorophenyl)-2-furaldehyde
Part - I, Section - I (A).
(B) Preparation of N1,N3-Bisaryl thiourea411
In a round bottom flask, a mixture of arylamine (0.2 mol), carbon disulphide
(7 ml, 0.1 mol) and absolute alcohol (20 ml) was heated on waterbath for 5-6
hrs. On completion of reaction, the excess of carbon disulphide and alcohol
was removed by distillation. The product was treated with dilute hydrochloric
acid to remove excess of amine present and crude product was isolated,
crystallised in rectified spirit.
(C) Preparation of 2-Arylimino-3-aryl-5H-4-thiazolidinones412
A solution of N1,N3-Bisaryl thiourea (0.01 mol) and chloroacetic acid (0.94
g, 0.01 mol) in glacial acetic acid (15 ml) was refluxed with fused sodium acetate
(1.25 g, 0.015 mol) for 5 hrs. The reaction product was poured in water; kept
overnight, crude product was isolated, crystallised from methanol.
(D) Preparation of 2-(p-Tolylimino)-3-(p-tolyl)-5-[5'-(m,p-dichloro
phenyl)-2'-furylidene)-4-thiazolidinone
A mixture of 2-(p-tolylimino)-3-(p-tolyl)-5H-4-thiazolidinone (2.96 g, 0.01
mol), 5-(m,p-dichlorophenyl)-2-furaldehyde (2.41 g, 0.01 mol) and fused sodium
acetate (1.25 g, 0.015 mol) was refluxed in glacial acetic acid (15 ml) for 4-5
hrs, cooled and poured into water. The solid thus obtained was filtered, washed,
dried and crystallised from DMF. Yield 72%, m.p. 182oC. (C28H20Cl2N2O2S;
required : C, 64.74; H, 3.88; N, 5.39%; found: C, 64.50; H, 3.71; N, 5.15%).
Similarly other substituted arylidenes were prepared. The physical constants
are recorded in Table No. 11.
(E) Therapeut ic  evaluat ion of  2-Ar yl imino-3-ar y l -5- [5 ' - (m,p-
dichlorophenyl)-2'-furylidene]-4-thiazolidinones
Antimicrobial testing was carried out as described in Part - I, Section - I (C).























11a C6H5- C26H16Cl2N2O2S 491 225 0.78 74 5.70 5.45
11b 4-Cl-C6H4- C26H14Cl4N2O2S 560 205 0.72 65 5.00 4.80
11c 3,4-(Cl)2-C6H3- C26H12Cl6N2O2S 629 190 0.48 72 4.45 4.19
11d 4-F-C6H4- C26H14Cl2F2N2O2S 527 240 0.84 68 5.31 5.04
11e 2-OCH3-C6H4- C28H20Cl2N2O4S 551 280 0.82 60 5.08 4.78
11f 4-OCH3-C6H4- C28H20Cl2N2O4S 551 180 0.51 62 5.08 4.88
11g 2-CH3-C6H4- C28H20Cl2N2O2S 519 252 0.78 69 5.39 5.20
11h 3-CH3-C6H4- C28H20Cl2N2O2S 519 198 0.72 71 5.39 5.09
11i 4-CH3-C6H4- C28H20Cl2N2O2S 519 182 0.55 72 5.39 5.15
11j 2-NO2-C6H4- C26H14Cl2N4O6S 581 152 0.81 70 9.64 9.35
11k 3-NO2-C6H4- C26H14Cl2N4O6S 581 200 0.67 63 9.64 9.44
11l 4-NO2-C6H4- C16H14Cl2N4O6S 581 228 0.68 66 9.64 9.40
































B. mega 22 20 14 13 19 20 18 22 17 12 16 15 22 24 23 25 0
S. aureus 20 19 14 13 21 18 21 12 15 16 14 19 20 22 19 24 0
E. coli 17 16 14 13 17 16 18 19 14 12 15 16 19 18 20 22 0
P. vulgaris 19 14 14 15 13 16 19 17 16 14 13 12 17 20 21 23 0
A.niger 20 14 15 16 22 20 19 21 17 16 14 18 0 0 0 0 26


















Nitriles are reported to possess various therapeutic activities, but due to
their high toxicity, they have low therapeutic importance. The term "Nitrile"
was first introduced by Febung413 in 1844. The first synthesis of nitrile has
been reported by Wohler and Liebig414 in 1832 and Pelouze415 in 1834. They
are very much useful as intermediates for various products such as acrylonitrile
for plastics, synthetic rubber and fibers, phthalonitrile for dye stuff.
SYNTHETIC ASPECT
Various methods of preparation of nitriles have been reviewed by D. T.
Mowry416. Few recent methods are as  mentioned below.
1. From halides using NaCN; Al2O3.
417
2. From alkyl halides using KCN, tetraalkylammonium salt and water in
trace.418
3. Dehydrating amides using POCl3
419
4. The pyrolysis of Schiff's base420
MECHANISM
























Reaction between CN and aldehyde is type of nucleophilic substitution
reaction. From the above reaction, it can be seen that a nucleophile (CN) attacks
on the carbonyl carbon of aldehyde and yield cyanohydrin, which reacts with
amine to form nitrile derivatives.
THERAPEUTIC EVALUATION









Cordenolide nitrile showed moderate biological activity in rats.429 Nitriles
with fused pyridine ring were reported as ulcer inhibitor.430 M. C. Dougal et
al.431 have synthesised nitriles and studied their pharmacological activities.
Nitriles (I) showing fungicidal activity have been reported.432 Parlo S. et al.433















R = Alkyl, alkenyl, cycloalkyl
R' = Substituted alkyl, aryl, haloalkenyl
A. R. Parikh et al.434 have synthesised α-arylamino-α-2-chloro-7-
methoxyquinoline-3-yl acetonitriles and reported their antimicrobial  activity.
Volmajer J. et al.435 synthesised some new nitriles and reported them as
anticonvulsant agent. Shibata Y. and co-workers436 have synthesised nitrile
derivatives associated with insecticidal activity. Nosyrava et al.437 have prepared
novel nitriles which have been shown to possess muscle relaxant activity.
Yogihara and co-workers438 have reported nitriles which possess antimicrobial
and antiinflammatory activity.
Iwasa T. et al.439 have studied thiazolylcinnamonitrile derivatives as
pesticides. H. H. Parekh and co-workers440 have synthesised nitriles (III) bearing
quinoline moiety and reported their antimicrobial activity. Nitriles (IV) as potent
antifungal agents have been investigated.441
Moreover, Bhatnagar and co-workers442 have evaluated nitrile derivatives
as cathepsin K inhibitors. Murakami H. et al.443 have synthesised some new
nitrile derivatives as pesticides and marin antifouling agents.
With a view to getting better therapeutic agents, we have synthesised some
new nitrile derivatives of type (X) by the reaction of 5-(m,p-dichlorophenyl)-2-
furaldehyde with different aromatic amines as described in section (I).

















SYNTHESIS AND THERAPEUTIC EVALUATION OF α-ARYLAMINO-[5'-
(m,p-DICHLOROPHENYL)-2'-FURYL]-ACETONITRILES
Nitrile derivatives are of considerable interest due to many bioactivities. In
view of these valid observation, it was contemplated to synthesise some new
nitriles of type (XII) possessing higher therapeutic activity. Nitriles of type (XII)
have been synthesised by the action of 5-(m,p-dichlorophenyl)-2-furaldehyde
with different aromatic amines by using potassium cyanide in presence of acetic
acid at 0 to 5oC.
The constitution of the synthesised products have been characterised using
elemental analyses, IR and 1H nuclear magnetic resonance spectroscopy and
mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of synthesised compounds were compared with standard
drugs.















IR SPECTRAL STUDY OF α-o-ANISYLAMINO-[5'-(m,p-DICHLOROPHENYL)-2'-FURYL]-
ACETONITRILE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2945 2975-2950 444
-CH3 C-H str. (sym.) 2875 2880-2860 "
C-H def. (asym.) 1461 1470-1435 "
Aromatic C-H str. 3066 3080-3030 445
C=C str. 1602 1520-1480 "
C-H i.p.def. 1070 1070-1000 "
C-H o.o.p. def. 831 835-810 "
Furyl moiety C-O-C str. (sym.) 1226 1275-1200 444
C-O-C str. (asym.) 1028 1075-1020 "
C-Cl str. 792 800-750 "
Nitrile N-H str. (sym.) 3319 3200-3350 "








PMR SPECTRAL STUDY OF α-p-TOLYLAMINO-[5'(m,p-DICHLOROPHENYL)-2'-FURYL]-
ACETONITRILE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons in Hz
1 2.28 3H singlet -CH3 -
2 5.51 1H singlet -CHx -
3 6.66 1H doublet furyl-H J=3.8
4 6.67 1H doublet furyl-H J=3.9
5 6.74 2H doublet Ar-Hd,d' Jed=8.3
6 7.10 2H doublet Ar-He,e' Jde=8.3
7 7.44 1H doublet Ar-Ha Jab=8.3
8 7.48 1H double doublet Ar-Hb Jba=8.6
Jbc=2.0






























Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)



























































































SYNTHESIS AND THERAPEUTIC EVALUATION OF α-ARYLAMINO-[5'-
(m,p-DICHLOROPHENYL)-2'-FURYL]-ACETONITRILES
(A) Preparation of 5-(m,p-Dichlorophenyl)-2-furaldehyde
Part - I, Section - I (A)
(B) Preparation of α-p-Tolylamino-[5'-(m,p-dichlorophenyl)-2'-furyl]-
acetonitrile
5-(m,p-dichlorophenyl)-2-furaldehyde (2.41g, 0.01M) dissolved in ethanol
(10 ml) was added to potassium cyanide (0.64g, 0.01M) dissolved in water (5
ml) followed by glacial acetic acid (5 ml). The contents were then stirred for 5
minutes to form aldehydecyanohydrin at 0oC. 4-Methyl aniline (1.07g, 0.01M)
dissolved in ethanol was added to the reaction mixture, contents were kept for
24 hrs at room temperature and poured into ice. The solid product was
crystallised from ethanol. Yield 68%, m.p. 142oC. (C19H14Cl2N2O; required:
C, 63.88; H, 3.95; N, 7.84%; found: C, 63.72; H, 3.78; N, 7.60%).
Similarly other substituted nitriles were prepared. The physical constants
are recorded in Table No. 12.
(C) Therapeutic evaluation of α-Arylamino-[5'-(m,p-dichlorophenyl)-2'-
furyl]-acetonitriles
Antimicrobial testing was carried out as described in Part-I, Section-I(C). The





























12a C6H5- C18H12Cl2N2O 343 192 0.75 75 8.16 7.87
12b 4-Cl-C6H4- C18H11Cl3N2O 377.5 112 0.73 65 7.42 7.08
12c 3-Cl,4-F-C6H3- C18H10Cl3FN2O 395.5 198 0.81 85 7.08 6.86
12d 2,6(Cl)2-C6H3- C18H10Cl4N2O 412 134 0.55 70 6.80 6.58
12e 2,5(OCH3)2-C6H3- C20H16Cl2N2O3 403 106 0.85 72 6.95 6.67
12f 2,4(CH3)2-C6H3- C20H16Cl2N2O 371 210 0.42 66 7.55 7.28
12g 2-F-C6H4- C18H11Cl2FN2O 361 228 0.52 68 7.76 7.45
12h 4-F-C6H4- C18H11Cl2FN2O 361 168 0.62 75 7.76 7.54
12i 2-OCH3-C6H4- C19H14Cl2N2O2 373 118 0.80 70 7.51 7.28
12j 4-OCH3-C6H4- C19H14Cl2N2O2 373 152 0.64 65 7.51 7.22
12k 2-CH3-C6H4- C19H14Cl2N2O 357 122 0.82 60 7.84 7.58
12l 3-CH3-C6H4- C19H14Cl2N2O 357 190 0.72 74 7.84 7.64
12m 4-CH3-C6H4- C19H14Cl2N2O 357 142 0.55 68 7.84 7.60
12n 3-NO2-C6H4- C18H11Cl2N3O3 388 218 0.64 62 10.82 10.62
12o 4-NO2-C6H4- C18H11Cl2N3O3 388 156 0.52 59 10.82 10.52

























B. mega 21 14 15 18 17 14 13 12 16 18 20 19 22 14 15 22 24 23 25 0
S. aureus 20 19 14 14 13 17 18 12 15 16 14 21 13 16 14 20 22 19 24 0
E. coli 19 14 13 17 16 15 12 14 15 12 17 18 17 14 12 19 18 20 22 0
P. vulgaris 17 14 16 14 12 14 16 12 13 15 18 16 19 13 14 17 20 21 23 0
A.niger 21 20 14 15 13 16 17 15 14 16 22 20 16 17 14 0 0 0 0 26














GRAPHICAL CHART NO. 12 :  ANTIMICROBIAL ACTIVITY OF α-ARYLAMINO-[5’-(m, p-DICHLOROPHENYL)-2’-FURYL]-
        ACETONITRILES
REFERENCES
1. Tains Steven P., Herrinton Paul M., Dixon Lisa A.;
Tetrahedron Lett., 26(44), 5347-50 (1985); Chem. Abstr., 105, 133733z (1986).
2. Bakshaev Yurij V.;
U.S.S.R. SU, 1, 834, 888 (Cl. C07D405/12) (1993); Chem. Abstr., 123, 198808u (1995).
3. Herndon James W., Wang Haixia;
J. Org. Chem., 63(14), 4564-65 (1998); Chem. Abstr., 129, 136041d (1998).
4. V. D. Dyachenko, V. P. Litvinov;
Russ. J. Org. Chem., 34(5), 696-698 (1998); Chem. Abstr., 130, 223189x (1999).
5. Hanna Issam;
Tetrahedron Lett., 400(3), 2521-24 (1999); Chem. Abstr., 130, 296566c (1999).
6. S. L. Belagali, K. Harish Kumar, Poojara Boja, M. Himaja;
Indian J. Chem., 37(B), 370-375 (1998).
7. H. Surya Prakash and S. Jothilinagam;
J. Org. Chem., 68, 5392-94 (2003).
8. Lanyi Gyorgy, Nagy Lajos, Denes Valeria, Somfai Eva, Radvany Erzsebet;
PCT Int. Appl. WO 86, 03, 202 (Cl. C07D307/79) (1986); Chem. Abstr., 105, 190900a
(1986).
9. Rao P., Reddy K., Vishnu V., Ashok D.;
Indian J. Heterocycl. Chem., 8(1), 51-54 (1998); Chem. Abstr., 130, 81436z (1991).
10. Brouwer, Walter Gerhard;
Can. Pat. Appl. CA 2, 163, 175 (Cl. C07D 307/68) (1996); Chem. Abstr., 125, 22155g
(1996).
11. Kinoshita Katsutoshi, Matsunaga Hirofumi, Odaka Kenji, Kawahara Nobuyuki;
Jpn. Kokai Tokkyo Koho JP, 08, 176, 132 (Cl. C07D 307/14) (1996); Chem. Abstr.,
125, 221555m (1996).
12. Edihara Koichi, Hashimota Hideaki, Ozawa Shuji, Kaiho Tatsuo;
Jpn. Kokai Tokkyo Koho JP 09, 110,848 (Cl. C07D 307/14) (1995); Chem. Abstr.,
127, 34111t (1997).
13. JagMohan and Vineet Kumar;
Indian J. Chem., 36(B), 414-417 (1997).
14. Iwasawa Yoshikazu, Aoyama Tetsuya, Kawakami Kumiko, Arai Sachie;
PCT Int. Appl. WO 97, 29,074 (Cl. C07C233/01) (1997); Chem. Abstr., 127, 176418x
(1997).
15. Swelam S. A., (National Research Centre, Cairo, Egypt);
Indian J. Heterocycl. Chem., 8(2), 147-150 (1998); Chem. Abstr., 130, 237524q (1998).
16. Guillon J., Alsaidi A., Dallemagne P., Rault S.;
Pharm. Pharmacol. Commun., 4(5), 231-235 (1998); Chem. Abstr., 129, 122520x
(1998).
173
17. Matsumura Katsuhiro, Maki Toshinide, Shisai Kimihiro, Itakuro Yoichi;
Jpn. Kokai Tokkyo Koho JP 11, 199, 579 (Cl. C07D 309/40) (1999); Chem. Abstr.,
131, 102197k (1999).
18. Miyazaki Masahiro, Ueno Ryonei, Iuki Yosinori, Tamaru Masatoshi;
Jpn. Kokai Tokkyo Koho JP 11, 140, 083 (Cl. C07D 405/04); Chem. Abstr., 131, 44839h
(1999).
19. Kelleher Jodith A., Maples Kirk R., Zhang Yong Kang;
PCT Int. Appl. WO 99, 36, 415 (Cl. C07D 307/64) (1999); Chem. Abstr., 131, 102186f
(1999).
20. Gadaginamath Guru S., Kavali Rajesh R.;
Indian J. Heterocycl. Chem., 8(3), 217 (1999); Chem. Abstr., 131, 87843x (1999).
21. Posner Gary H., Parker Michael H., Northrop John, Elias Jeffery S.;
J. Med. Chem., 42(2), 300-304 (1999); Chem. Abstr., 130, 1339466c (1999).
22. Kindon Nicholas, Megnani Premji, Thom Stephen;
PCT Int. Appl. WO 99, 26, 944 (Cl. C07D 403/04) (1999); Chem. Abstr., 131, 19017f
(1999).
23. Sanchez Juan Jose Marugan, Marder Victor J., Uprichard David C.;
PCT Int. Appl. WO 02 88,188 (Cl. C07D 409/12) (2002); Chem. Abstr., 137, 352888t
(2002).
24. Staon Garypaul, Gao Hong, Gildersleeve;
PCT Int. Appl. WO 02 88, 135 (Cl. C07D 493/04) (2002); Chem. Abstr., 137, 353038c
(2002).
25. Oomura Osamu, Shindo Makoto;
Jpn. Kokai Tokkyo Koho JP 11, 35,567 (Cl. C07D 307/52); Chem. Abstr., 130, 209595v
(1995).
26. Hulin Bernard;
U. S. US 5, 306, 726 (Cl. 514-375; C07D 263/56) (1994); Chem. Abstr., 123, 143628e
(1995).
27. Nishimura Yasunobu, Kagawa Mitsuhiro, Ishii Akihisa, Morino Yuzuru, Kikuchi Yoshuki;
Jpn. Kokai Tokkyo Koho JP 07, 10,863 (Cl. C07D 307/38) (1995); Chem. Abstr., 123,
143627d (1995).
28. O'Malley Gerard, Hedtmann Udo;
Eur. Pat. Appl. EP 6, 37, 586 (Cl. C07D 405/04) (1995); Chem. Abstr., 123, 169515r
(1995).
29. Boykin David M., Dukstra Christin C., Tidwell Richard R., Hall James E., Wilson W.
David;
PCT Int. Appl. WO 96, 15, 126 (Cl. C07D 405/14) (1996); Chem. Abstr., 125, 11460e
(1996).
174
30. Smith S., Blackwell G. J., Demaine D. A., Garland L. G.,  Hodson H. F., Hyde R. M.;
Eur. J. Med. Chem., 31(5), 347-358 (1996); Chem. Abstr., 125, 195315m (1996).
31. Matsuno Hirozumi, Nakaya Michihiko, Shiraishi Shiro;
Jpn. Kokai Tokkyo Koho JP 08, 231, 524 (Cl. C07D 307/14) (1996); Chem. Abstr.,
125, 300813x (1996).
32. Toyoo Nakayama, Seizo Taira, Hiroyuki Kawamura, Shibuya Masaoki;
U. S. US 5, 532, 267 (Cl. 514-467; A 61 K 31/335) (1996); Chem. Abstr., 125, 142529c
(1996).
33. Black Cameron, Erich Grimm, Serge Leger, Prashit Petpiboon;
PCT Int. Appl. WO 96, 19, 469 (Cl. C07D 307/58 (1996); Chem. Abstr., 125, 142530w
(1996).
34. Bryant Henry U., Dodge Jeffrey A.;
U.S. US 5, 523, 309 (Cl. 514-320; C07D 307/81) (1996); Chem. Abstr., 125, 142536c
(1996).
35. Uhlman Henry Bryant, Kennan Joseph, Jone Charles David;
PCT Int. Appl. WO 96, 09, 040 (Cl. A 61 K31/34); Chem. Abstr., 125, 86481s (1996).
36. Matsuo Masaaki, Okumura Kazuo, Shigenaga Shinji, Nishimura Hiroaki;
PCT Int. Appl. WO 97, 27, 190 (Cl. C07D 417/04) (1997); Chem. Abstr., 127, 205572a
(1997).
37. Kamijo Tetsukiyo, Yamaguchi Toshiaki, Yanagi Takashi, Tsuchiya Ikuo, Takeuchi Hideki;
Jpn. Kokai Tokkyo Koho JP 09, 124, 630 (Cl. C07D 307/20) (1995); Chem. Abstr.,
127, 341116y (1997).
38. Fancelli Daniele, Caccia Carla, Severino Dino, Vaghi Fabrizio, Varashi Mario;
PCT Int. Appl. WO 96, 33, 186 (Cl. C07D 307/79) (1996); Chem. Abstr., 126, 18795t
(1997).
39. Akamatsu Hidekaz V.;
Jpn. Kokai Tokkyo Koho JP 09, 255, 675 (Cl. C07D 307/68) (1997); Chem. Abstr.,
127, 307296f (1997).
40. Elliott John Duncan;
PCT Int. Appl. WO 97, 28, 159 (Cl. C07D 409/2) (1997); Chem. Abstr., 127, 205467v
(1997).
41. Miyoshi Shiro, Ogawa Kohei;
PCT Int. Appl. WO 97, 25,311 (Cl. C07C311/37) (1997); Chem. Abstr., 127, 149154b
(1997).
42. Ridgeway James Madison, Janusz John Michael;
PCT Int. Appl. WO 97, 28, 145 (Cl. C07D 307/79) (1997); Chem. Abstr., 127, 205468w
(1997).
43. Mohan Jag, Kumar Vineet;
Indian J. Chem., Sect B.; Org. Chem. Incl. Med. Chem., 36B(5), 414-417 (1997);
Chem. Abstr., 127, 161802u (1997).
175
44. Yadav Ashok K., Agrawal Hemlata, Singh Arpita, Prakash Lalit;
Indian J. Heterocycl. Chem., 6(3), 237-38 (1997); Chem. Abstr., 127, 17901h (1997).
45. Hirai Keiiehi, Koyama Junko;
Jpn. Kokai Tokkyo Koho JP 09, 235,280 (Cl. C07D 307/92) (1997); Chem. Abstr.,
127, 278132s (1997).
46. Ehlhart William J., Ray James E., Toth John E.;
U.S. US 5, 827, 879 (Cl. 514-469; A61K 31/34) (1998); Chem. Abstr., 129, 316135w
(1998).
47. Kifagawa Tokujiro, Tgutsui Chinatsu;
Chem. Pharm. Bull., 46(8), 1308-10 (1998); Chem. Abstr., 127,  260288d (1998).
48. Vivian Cody, Nikolai Galitsky, Joseph R. Luft, Walter Pangborn, Raymond L. B.;
Anticancer Drug Design, 13, 307 (1998).
49. Battistino Lucia, Rassur Gloria, Pinna Luigi, Zanardi Franca, Casiraghi Giovanni;
Tetrahedron; Asymmetry, 10(4), 765-773  (1999).
50. Sasaki Tsutomu, Matsudo Takanoa, Saito Mori Kenj;
Jpn. Kokai Tokkyo Koho JP 11, 140, 072 (1999); Chem. Abstr., 131, 44728w (1999).
51. Baker Robert K, Bao Jianming, Kayser Frank, Maio  Shouwa  Parsons,  William H,
Rupprecht Katnleen;
PCT Int. Appl. WO 99, 20, 267 (Cl. A 61 K 31/34); Chem. Abstr., 130,  311953x
(1992).
52. Mederski  Werner W. K. R., Osswald Mathius, Dorseh Dieter, Christadler Maria;
Bio. Org. Med. Chem. Lett. 9(4), 619 (1999); Chem. Abstr., 130,  325070u (1999).
53. Y. Cheng Chen, Robert Larsen, Tan Lushi;
PCT Int. Appl. WO 99, 15, 513 (Cl. C07 D3 07/02); Chem. Abstr., 130, 252235w
(1999).
54. Helene Perrier, Yongxin Han, Bayly Christopher;
PCT Int. Appl. WO 99, 18, 095 (Cl. C07D 07/42) (1999); Chem. Abstr., 130, 281981k
(1999).
55. Nguyen Quang Dat, Dinh Thi Thanh  Hai, Dang Thi Kim Hue;
Tap Chi Duoc Hoc 1, 10-12 (1999); Chem. Abstr., 131, 87774a  (1999).
56. Dijcks Frederieous Antonium, Grove Simmon, James Anthony, Carlyle  Ian Craig;
PCT Int. Appl. WO 99, 18, 941 (Cl. A 61 K 3100); Chem. Abstr., 130, 311785u (1999).
57. Cheng Soan, Gold Stein, David Michael, Martin Tereja, Alejandra  Trejo, Sjogren Eric;
PCT Int. Appl. WO 99, 20, 624 (Cl. C 07 D 471/04); Chem. Abstr., 130, 325138x
(1999).
58. Wang Zhaoyin, Leger Serge, Grimm Erich;
PCT Int. Appl. WO 99, 23, 087 (Cl. C 07 D 307/58); Chem. Abstr., 130,  338014d
(1999).
176
59. Collot Valerie, Dallemagne  Patrick,  Bovy Philippe R., Rault  Sylvain;
Tetrahedron 55(22), 6917-6922 (1999); Chem. Abstr., 131, 116185s (1999).
60. Ohno Norio, Nakano Masakazu, Endon Jun-ichi, Miura Masataka Aizawa;
PCT Int. Appl. WO 99, 05, 595 (Cl. C 07 C 237/20); Chem. Abstr., 130, 153567t
(1999).
61. El-Nabawia, El-Said Goda;
Alexandria J. Pharm. Sci., 13(2), 145-148 (1999); Chem. Abstr., 132,  151650g (2000).
62. Chang Chien-Ping, Lin Bung-Ping;
Chinese Pharma. Journal (Taipei,  Taiwan) 53(5), 239-256 (2001); Chem. Abstr., 137,
352927e (2002).
63. Sui Zhihua, Macielag Mark, Lanter James  C.;
PCT Int. Appl. WO 02 48,112 (Cl. C07D  215/22) (2002); Chem. Abstr., 137, 47129m
(2002).
64. Srinivas  C., Rao C. Papa;
Indian J. Heterocycl. Chem., 11(3), 249-250 (2002); Chem. Abstr., 137, 47137n (2002).
65. Buckleu George M., Cooper Nicola, Davenport Richard J., Dyke Hazel J., Galleway
Fiona P., Gewers Lewis, Haughan Sabin Verity, Sharpe Andrew;
Bioorganic & Med. Chem. Lett., 12(3), 509-512 (2002); Chem. Abstr., 137, 78877h
(2002).
66. Hennequin Laurent Francois, Gibson Keith Hopkinson, Foote Kevin Michael;
PCT Int. Appl. WO 03, 48, 159 (Cl. C 07 D  405/12) (2003); Chem. Abstr.,  139,
36451a (2003).
67. Ravindra V. C., Barsu G. Khadse, Anil S. Bobde, Rajesh H. Bahekar;
Eur. J. Med. Chem., 38, 89-100 (2003).
68. Chang Chia-Lin, Wu Chin-Sheng, Kuo Sheng-Chu, Wang Jih-Pyang, Jih-Pyang, Teng
Che-Ming;
Chinese Pharma. Journal (Taipei, Taiwan) 54(2), 127-140 (2002); Chem. Abstr., 138,
238038m (2003).
69. Cudahy Michele M., Shnute Mark E., Tanis Steven P., Perrault William R., Herrinton
Paul M., Nair Sajiv K.;
PCT Int. Appl. WO 03 59,911 (Cl. C07D 491/04) (2003); Chem. Abstr., 139, 117411q
(2003).
70. Tulshian Deen, Silverman Lisa S., Matasi Julius J., Kiselgot Eugenia Y., Caldwell John P.;
PCT Int. Appl. WO 03, 32, 996 (Cl. A 61 K 31/505) (2003); Chem. Abstr., 138,  338161q
(2003).
71. Deborch H. Slee, Abhijit S. Bhat, Truc N. Nguyen, Mary Kish, Katy Landeen, Michael J.
Newman;
J. Med. Chem., 26, 532 (2003).
177
72. M. A. El. Hashah, M. El-Kady, M. A. Saiyed, A. A. Elsawy;
Egypt. J. Chem., 27(6), 715-21 (1985) (Eng.); Chem. Abstr., 105, 20868u (1986).
73. R. A. Kabli, A. M. Kaddah, A. M. Khalil, A. A. Khalaf;
Indian J. Chem., 25(B), (2), 152-6 (1986); Chem. Abstr. 106, 11975b (1987).
74. M. Hassaneen Hamdi, A. Ead Hamad, A. H. Mousa Hiyam;
Sulfur Lett. 8(5), 27582 (1989); Chem. Abstr., 111, 5761l (1989).
75. S.S. Nayal and G.P. Singh;
Asian J. Chem., 11 (1), 207-212 (1999); Chem. Abstr., 130, 153602a (1999).
76. A. K. Reda, A. A. Khalaf, M. T. Zimaltu, A. M. Khalil, A. M. Kaddah and H. A. Al-Rifuie;
J. Indian Chem. Soc., 68, 47-51 (1991).
77. K. Zalgislaw, and A. Seffan ;
Acta. Pol. Pharm., 36(6), 645 (1979); Chem. Abstr., 93, 204525e (1980).
78. Z. Brozozowsk, E. Pomarnacka;
Acta. Pol. Pharm., 37(4), 1378, 80 (1980); Chem. Abstr., 25, 8080f (1981).
79. K. Wellinga, H. H. Eussen Jacobus;
Eur. Pat. Ep. 269 141 (C1. C07D 231/06) (1988); Chem. Abstr., 110,  8204e (1989).
80. P. Desaea; A. Nunrich; M. Carderny and G. Devaux;
Eur. J. Med. Chem., 25, 285 (1990).
81. B. Roman;
Pharmazie, 45, 214 (1990).
82. D. Bhaskar Reddy, T. Seshama, B. Seehaina and M.V. Ramma Reddy;
Indian J. Chem., 30(B), 46, (1991).
83. D. B. Reddy, T. Senshuma, B. Seenhaina and M.V. Ramana Reddy;
Indian J. Chem., 30(B), 46, (1991).
84. Delay Francois (Fermenich S. A.) Patent Schrift (Swifz);
Chem. Abstr., 117, 90276f (1992).
85. W. I. Ronald, A. Adriano;
U.S. US, 5, 297, 821 (1997); Chem. Abstr., 126, 181346f (1997).
86. Reddy Y. S. R., Mani T. Sosamma, Sharma G. V. S. Rama, Suresh B.;
Indian J. Chem. Sci., 61(1), 25-28 (Eng.) (1999); Chem. Abstr., 131, 44765f (1999).
87. Ferro M. P., Wachter M. P.;
U. S. US 5, 843, 958 (1999); Chem. Abstr., 130, 25067f (1999).
88. Nayal S.S. and Singh C.P.;
Asian J. Chem., 11 (1), 207-212 (1999); Chem. Abstr., 130, 153602a (1999).
89. N. Richard, M. Megan et al.;
J. Med. Chem., 36(1), 134-139 (1993); Chem. Abstra.,  118, 191847u (1993).
90. M. Koos, M. Repas, B. Steiner, D. Mynarnick;
Chem. Pap., 44(1), 105-10 (1990); Chem. Abstr., 113, 78232y (1990).
91. T. Atif, E. Fatema, A. M. Abdela;
Chim Pharm. J. 47(1), 37-45 (1995); Chem. Abstr., 123, 228016d (1995).
178
92. R. H. Udupi, A. R. Bhat;
Indian J. Hete. Chem., 8(2), 143-146 (1998).
93. G. N. Mishirika, N. Assad, F. M. Fawzy;
Pharmazie 53(8), 543-547 (1998); Chem. Abstr., 129, 26038o (1998).
94. T. M. Stavenson, D. W. Piotrowski, M. A. H. Fahmy, R. L. Lowe, K. L. Monaco;
American Chemical Society, 217, MAR Part - I, 29 AGRO (1999).
95. T. Katsuhori, A. Hiroyuki, K. Masumij;
PCT Int. Appl. WO 98, 56, 760; Chem. Abstr., 130, 66492w (1999).
96. M. K. Shivnanda, P. M. Akberali, B. Holla, Shivarama, M. Shenoy, Shalini;
Indian J. Chem. Sec. 13 Org. Chem. Incl. Med. Chem., 39B(6), 440-447 (Eng.); Chem.
Abstr., 134, 86195n (2000).
97. K. P. Roda, R. N. Vansdadia and H. H. Parekh;
J. Inst. Chem., 64, 74 (1988).
98. Jatin Upadhyay, Utpal Dave and Hansa Parekh;
Chem. Abstr., 116, 128768n (1992).
99. H. J. Vikani, K. D. Ladva and Hansa Parekh;
J. of Sciences Islamic Repbucli of Iran 4, 3 (1993).
100. P. Patel, S. Karegaokar, M. Shah & H. Parekh;
IL Pharmaco 51(1), 59-63 (1996).
101. Oza Haresh, Joshi Dharti, Parekh Hansa;
J. Inst. Chem. (India) (1998); Chem. Abstr., 130, 13968z (1999).
102. Akhil H. Bhatt, H. H. Parekh, Khyati Parikh & A. R. Parikh;
Indian J. Chem., 40B, 57-61 (2001).
103. Fatema Bharmal, Devendra Kaneriya and Hansa Parekh;
Indian J. Heterocyclic Chem., 12, 21-24 (2002).
104. E. Palska, M. Aytemin, I. T. Uzboy, D. Erol;
Europian Journal of Medicinal Chemistry, 36(6), 539-543 (Eng), 2001; Chem. Abstr.,
136, 18374v (2002).
105. Eggenweiler Michael, Eiermann Volker, and Schelling Pierre;
Chem. Abstr., 137, 125171k (2002).
106. Shalabh Sharma, Virendra Shrivastava, Ashok Kumar;
Eur. J. Med. Chem., 37, 689-697 (2002).
107. Mourer Fritz, Fuchs Rainer, Erdelen Christoph and Turberg Andreas;
PCT Int. Appl. WO 03 58, 887 (2002); Chem. Abstr., 139, 117441z (2003).
108. K. Mogilaiah and G. Raman Sudhakar;
Indian J. Chem., 42B, 636-40 (2003).
109. A. L. Barry;
The antimicrobial susceptibility tests, Principle and practices edited by Illus Lea and
Febiger; (Philadelphia, pel U.S.A.) 180; Bio. Abstr., 64, 25183 (1970).
179
110. Ibrahim, Ahmed, Mohamad Kamal;
J. Indian Chemical Soc., 66, 393-397 (1989).
111. Jairo Quirogy, Alvarado Mario;
J. Heterocycl. Chem., 1998.
112. Dayochenko U. P.;
Russ. J. Org. Chem., 34(4), 554-556 (1998); Chem. Abstr., 130, 223222c (1999).
113. Okazoe Takashi;
PCT Int. Appl. WO 00 06, 547; Chem. Abstr., 132, 321784y (2000).
114. Kanded Ez-El-Din M.;
Chin. Pharm. J. (1999); Chem. Abstr., 132, 321784z (2000).
115. Samour A., Y. Akhnookh and H. Jahine;
(Pac. Sci. Ain Sharm Uni. Cairy UAK) J. Chem. 1970 13(4), 421-37 (Eng.); Chem.
Abstr., 77, 10134g (1972).
116. V. Scott and E. Joseph;
Jap. Pat., 2, 803, 592 (1979); Chem. Abstr., 92, 4721b (1980).
117. V. Scott and E. Joseph;
Jap. Pat., 7, 998, 338 (1979); Chem. Abstr., 92, 8242f (1980).
118. W. Von Behenburg, J. Engel, J. Heese and K. Thiele;
Ger. Offen., D. E., 3, 337, 593 (ClC 07D 213/72) 1984; Chem. Abstr., 101, 130595n
(1984)
119. M. R. Pavia, C. P. Taylor, F. M. Hershenon and S. J. Lobbestael;
J. Med. Chem., 30, 1210 (1987).
120. Omar M. T., Fatima, Hamad, Gl-Deem, Shehab;
J. Pharm. Sci. 37(1-6); 233-240 (1996); Chem. Abstr., 126, 251105c (1997).
121. Dyachenku V. D., Krivokolysko S. G.,  Nesterov V. N.; Litvinov;
Chem. Heterocycl. compd.,33(12), 1430-1437 (1998).; Chem. Abstr., 129, 230617t
(1998).
122. Nebel, Kurt, Brunner, H-Geary, S. Rolf;
PCT Int. Appl. WO 98, 21, 199; Chem. Abstr., 129, 27898t (1998).
123. Abdallah Nevine A., Zamimagdi E. A.;
Acta Pharm (Zagreb) 1999; Chem. Abstr., 132, 137287n (2000).
124. Al-Omran, Fatima, Elassar, Abdel, El-Khair, Abdel-A.;
PCT Int. Appl. WO 04, 29, 679 (Cl. C07D 408/09); Chem. Abstr., 136, 309834q (2002).
125. S. S. Verma, P. Taneja, L. Prakash, A. L. Mittal;
J. Ind. Chem. Soc. 65, 798 (1988).
126. Y. Sasaki, J. Takuro, M. Ooishi, M. Sekine and S. Imaki;
Jpn. Kokai Tokkyo Koho J.P., 06, 315, 390 (1994); Chem. Abstr., 122, 131184y (1995).
127. Ijmde Teu, Kusunoki, Masayuki Takuro, Maechara Shinya, Kutsuma Seiikhi;
Jpn. Kokai Tokkyo Koho JP 09, 95,489 (1997); Chem. Abstr., 127, 17699y (1997).
180
128. Hussans M., Emam H. A., El-maghruby A. A.;
J. Serb. Chem. Soc., 62(7), 541-549 (1997); Chem. Abstr., 127, 638p 19069v (1997).
129. Guru S. Gadaginamath, Ashok S. Shya digeri and Rajesh R. Kavali;
Indian J. Chem., 37B, 1137c (1998).
130. Manna Fedele, Chimenti Franco, Bolasco Adriana, Bizzari Bruna, Filippeli Walter, Filppelli,
Amelia, Gangliardi, Luigi;
Eur. J. Med. Chem., 34(3), 245-254 (1999); Chem. Abstr., 130, 352178s (1999).
131. Hammama Abou, Elfatoon G., El-Hafeza N. A., M. Wandall, Z. Naturforsch B.;
Chem. Sci., 2000.
132. Ranjan C. Khunt, N. J. Datta, F. M. Bharmal, G. P. Mankad and A. R. Parikh;
Indian J. Chem., 10, 97 (2000).
133. Akhil Bhatt, H. H. Parekh,  K. Parikh and A. R. Parikh;
Indian J. Chem., 40B, 57 (2001).
134. Pyachenko U.D., Roman S.V.;
Visnik Kharkivs Kogo. Natsional nogo. Uni 495-59-64 (Russ) Chem. Abstr., 136(21),
325448x (2002).
135. El-Taweel F. M., Sofan M.A.;
Egyption J. Med. Chem., 36(2), 539-534 (2002); Chem. Abstr., 137, 63154w (2002).
136. A. V. Dobaria, J. R. Patel, H. H. Parekh;
J. Indian Chem. Soc, 79, 772-773, (2002).
137. Lowinger Timothy B., Murata Toshiki, Umeda Masaomi Sakakibare;
PCT Int. Appl. WO 02 24, 679 (Cl. C07D 401/04); Chem. Abstr., 136, 279345m (2002).
138. Haruda Hiroki, Moritano Ayako, Takuwa Tomofumi, Hirano Yuruke;
Jpn Kokai Tokkyo Koho JP 03, 183, 254 (2003); Chem. Abstr., 139, 69158p (2003).
139. Mona M. Kamel, Manal M. Hussein;
Indian J. Chem., 42(B), 2136-2141, (2003).
140. Villhauer Edwin B., Brinkman John A., Naderi Goli B., Burkey Bryan F., Hugher Thomas E.;
J. Med. Chem., 46(13), 2774-2789 (2003).
141. Tominago Yoshinori & Matsuoka Kohra Akira;
Heterocycles 26(3), 613-16 (1987); Chem. Abstr., 107, 236648w (1987).
142. M. Seada, M. Abdel-Megid & I. M. El-Deen;
Indian J. Heterocycl. Chem., 3, 81-86 (1993).
143. Mehta P. A., Naik H. B.;
Asian J. Chem. 10(4), 1017-18 (1998); Chem. Abstr, 129, 330703m (1998).
144. Barnett Charles J., Wilson Thomas M.;
U.S. US 5 969, 136 (Cl. 544-279, C07D 487/04); Chem. Abstr., 131, 286530t (1999).
145. Rasaki Abayomi Osisanya & James Olabisi Oluwadiya;
J. Heterocyclic Chem., 26, 947 (1989).
181
146. Y. L. N. Murthy & G. Jagmohan;
Indian J. Heterocyclic Chem., 8, 277-80 (1999).
147. Abd El-Gail, E. Amr.;
Indian J. Heterocyclic Chem, 10, 49-58 (1999).
148. V. Karbanow, L. P. Prikarchikova, V. Boldirev, I.A. Nasyr et al.;
Chem. Abstr., 94, 15741 (1981).
149. Tanaka Masaaki, Murakami Yukitoshi;
Jpn. Kokai Tokkyo Koho JP 662, 123, 177 (Cl. C07 D 239/30); Chem. Abstr., 107,
236727w (1987).
150. Kovalenko A.L., Krutika V.I., Zolotukhina M.M. and Alekseava L.E.;
Zh. Obsch. Khim, 62(6), 1363-66 (1992); Chem. Abstr., 118, 101909r (1993).
151. A. S. K. Anjaneyulu, G. Sudha Rani, U. V. Mallavadhani and Y.L.N. Murthy;
Indian J. Heterocyclic Chem., 4, 277-80 (1995).
152. Zimmermann Jureg;
U.S. 5, 521, 184 (Cl. 514-252; C07 D239/92); Chem. Abstr., 125, 114681c (1996).
153. Obatokio, Fujii, Katsu, Toshi, Narita;
Jpn. Tokkyo Koha JP 08, 269, 021 (1995); Chem. Abstr., 126, 74864b (1997).
154. Boschelli Diane Harris, Dobrusin Ellen Mura, Doherty Annette Marian;
PCT Int. Appl. WO 98 33,  798; Chem. Abstr,m 129, 3700a (1998).
155. Bothara K. G., Kadam S. S., Sai Shivram V.;
Indian Drugs 35(6) (1998); Chem. Abstr., 129, 245107a (1998).
156. Walter, Herald;
PCT Int. Appl. WO 99 14, 202 (Cl. C07 D239/00) (1999); GB Appl. 97/19, 411 (1997);
Chem. Abstr., 131, 252368k (1999).
157. Kitano Yasunori, Kawahara Eiji, Takayanagi Hisao, Suzuki Takeshi, Ohya Atsushi, Hara
Hiroto;
Jpn. Kokai Tokkyo Koha JP 11, 80, 131 (Cl. C07 D239/74) (1999); Appl. 97/251, 348;
Chem. Abstr., 131, 267450e (1999).
158. Poss Michael A, Purandare Ashok V., Mattson Ronald J., Sam Li-Quiang;
PCT Int. Appl. WO 01 85, 701 (Cl. C07D 239/00); Chem. Abstr., 135, 357949g (2001).
159. Gangjee Aleen, Zhu Yuanming, Queener Sherry F.;
J. Med. Chem. 41(23), 4533-4541 (1996); Chem. Abstr., 130, 13966x (1998).
160. Pan Senliang, Bukrinsky Michael, Haffar Omar K.;
U.S. US 5, 808, 068 (C07D 239/24) (1998); Appl. 912, 076 (1997); Chem. Abstr., 129,
245162q (1998).
161. Ugarkar Bheemarao G., Erion Mark D., Gomez Galeno Jorge E.;
U.S. US 5, 795, 977 (Cl. 536-27; CO7 H19/16) (1998); US Appl., 473 (1995); Chem.
Abstr., 129, 175920j (1998).
182
162. Pandeya S. N., Sriram D. Nath G., De Clercq E.;
Farmaco, 54(9), 624-58 (1999).
163. Breault, Gloria, Anne, James, Stewart Russell;
PCT Int. Appl. WO 00 53, 595 (Cl. CO7D403/04); Chem. Abstr., 133, 238016z (2000).
164. Uckun, Fatin. M, Lin, Xing-Ping, Narla, Rama K.;
PCT Int. Appl. WO 00 56, 720 (Cl. C07D 239/94); Chem. Abstr., 133, 266866v (2000).
165. Chamanlal J. Shishoo, Vikas S. Shirsath, Ishwarsinh S. Rathod, Vikas D. Vande;
Eur. J. Med. Chem., 35, 351-358 (2000).
166. Hewawasam Piyasena, Dodd Dharmpal, Weaver Charles, Dextraze Pierre;
PCT Int. Appl. WO 02 66, 036 (Cl. A61K31/505) (2002); Chem. Abstr., 137, 185498g
(2002).
167. Bargiotti Alberto, Ermoli Antonella, Menichincheri Maria, Vanotti Ermes;
PCT Int. Appl. WO 02 90, 357 (Cl. CO7D 473/18) (2002); Chem. Abstr., 137, 352825v
(2002).
168. Jden and Juan;
PCT Int. Appl. WO 02 64, 096 (Cl. A61K), (2002); Chem. Abstr., 137, 185498g (2002).
169. Tsutsumi, Hideo, Yonishi, Satoshi;
PCT Int Appl. WO 03 57,689 (Cl. C07D 403/04) (2002); Chem. Abstr., 139, 117434z
(2003).
170. Pierre C. Wyss, Paul Gerber, Peter G. Hartman, Christian Hubschwerlen, Martin Stahl;
J. Med. Chem., 46(12), 2304-2311 (2003).
171. Patricia Fernandez-Ferri, Amalia Ubeda, Isabel Guillen, Jamal Lasri, Mohamed Akssira;
Eur. J. Med. Chem., 38, 289-296 (2003).
172. Yadav Bodke & S. S. Sangapure;
J. Indian Chem. Soc., 80, 187-189 (2003).
173. Aleem Gangjee, Jianming Yu, Roy Kisliuk, Willian Haile, Giulia Sobrero;
J. Med. Chem., 46(4), 591-597 (2003).
174. Huang Taishang, Xiaman Daxye Xyebao;
Ziran Kexueban, 33(G), 827-31 (1994); Chem. Abstr., 123, 9277m (1995).
175. Ershor A. U., Gribanov A. V., Gindin V. A.;
Russ. J. Org. Chem., 33(10), 1490-93 (1997); Chem. Abstr., 129, 202913t (1998).
176. Hunter Duncan H., Mc Roberts Chantelle, Vittal Jugadese J.;
Can. J. Chem., 76(5), 522-24 (1998).
177. Cusas J. S., Castellano E. E., Gracia Tasende M. S., Sanchez A. et al.;
Polyhedrom, 17 (13-14), 2249-56 (1998); Chem. Abstr., 129, 155679n (1998).
178. Tomchin A. B.;
Russ. J. Org. Chem.,  33(4), 567-68 (1997); Chem. Abstr., 128, 192597f (1998).
183
179. Perumal Yogeeswari, Dharmarajan Sriram, Logantha Ramamoorthy, Sathiyanesan
Sathishkumar, James Stables ;
Eur. J. Med. Chem., 37, 231-236 (2002).
180. E. T. Dickson, J. P. Scovill, D. L. Kayman, A. S. Dobek, E. C. Trumoht;
Antimicrobial agents, Chemother., 18, 27 (1980).
181. Rao K, Srinivasa Rastogi K., Sridhar D. R., Jain M. C.;
Indian J. Chem., 26B, 596-98 (1987); Chem. Abstr., 108, 150395v (1998).
182. Kalyancuoglu M, Rollas S., Yegenoglu Y. et al.;
Pharmazie, 47(10), 796-97 (1992).
183. Cesur Nersin, Cesur Zafar and Guersoy Aysel;
Arch-Pharm., 35(9), 623-24 (1992); Chem. Abstr., 118, 6327j (1993).
184. Missbach Martin;
PCT Int. Appl. Wo 14, 686 (Cl. C07D27/06) (1995); Chem. Abstr., 123, 169641d (1995).
185. Zhong Mehg, Liu Luosheng, Wen Xiao Xia, Ling Pei Xhe;
Huaxi Yaocue Zazhi, 12(2), 85-86 (1997); Chem. Abstr., 127, 65635w (1997).
186. J. F. Bartoseivch, T. S. Griffin, C. J. Manson, J. P. Scovill;
J. Med. Chem., 22, 855 (1997).
187. Kanvechi B., Johnson C. B., Cellik C and Yuksek H.;
Acta Pol. Pharm., 54(4), 307-12 (1997); Chem. Abstr., 128, 396 (1998).
188. E. Silva Maria Joselice, Alves Antonio Jose, D O Nasimento Silene C.;
Farmaco, 53 (3), 241-43 (1998); Chem. Abstr., 129, 109012p (1998).
189. Hu Wei-Xiao Sun Nan, Yong Zhong Yu;
Gaodeng Xuexiao Huaxue Xuebao 22(12), 2014-17 (2001); Chem. Abstr., 136,
294802b (2002).
190. Kalyan Couglu N., Rollas S., Yegenogly Y.;
Pharmazie, 47(10), 796-97 (1992).
191. A. M. Abdel-Halim, Fekria S. Sayed, R. M. Abdel-Aziz, H. S. El-Dein;
Indian J. Heterocyclic Chem., 3, 201-204 (1994).
192. Siatra T., Tsotinis A., Sambari C., Thomou H.;
Eur. J. Med. Chem., 30(2), 107-14 (1995); Chem. Abstr., 123, 11798u (1995).
193. Quianawin Zhao, Wan Xinba, Liu Cuiyibang, Wang Defeng;
Chem. Abstr., 129, 336521a (1998).
194. E. Silva Maria Joselice, Alves Antonio Jose, Silence C.;
Farmaco, 53(3), 241-243 (1998); Chem. Abstr., 129, 109012p (1998).
195. Wang Deteng, Wan Xinbo, Liu Cuiyibang, Zhao Quianquin;
Huxai Yaoque Zohi 13(2), 75-76 (1998); Chem, Abstr., 129, 336521a (1998).
196. Krezel Izabella;
Acta Pol. Pharma. 55(2), 125-28 (1998).
184
197. Fedorova O. V., Mordovskoi G.G., Rusinov G. L.;
Khim-farm Zh. 32(2), 11-12 (1998); Chem. Abstr., 129, 81555s (1998).
198. Li Jun, Niu Chuhan-Sheng, Li Xiuyan, Doyle Terrence V.;
U. S. US 5, 767, 134 (Cl. 514-533 A 61k 31/34), (1998); Chem. Abstr., 129, 677109g
(1998).
199. Magalhaes Nereide, Stela Santos, Alves Antonio Jose, Alencar et al.;
Rev. Cienc, Farm. 19(1), 49-66 (1998); Chem. Abstr., 130, 223025t (1999).
200. Teoh-Siang Guan, Ang Show-Hing, Ongchiwi;
J. Orgmet. Chem. 580(1), 17-21 (1999); Chem. Abstr., 131, 73727a (1999).
201. Dulanyan E. R., Ovsepyan T. R., Stepanyan G. M., Avsenyan F. G.;
Khim. Farm. Zh. 32(7), 14-15 (1998); Chem. Abstr., 130, 24828e (1999).
202. Alves Antonio Jose, Ramos Selma Veronica, E. Silva Maria Joselice;
Rev. Farm. Bioquim Uni. Sao Paulo, 34(2), 77-83 (1998); Chem. Abstr., 131, 116046x
(1999).
203. Jin Shuhui, Chen Li, Zhang Zhenye, Liang Xiaomei;
Nongyaoxue Xuebao 1(3), 88-90 (1999); Chem. Abstr., 135, 92383j (2001).
204. Rajasekaran A. and Murugesan S.;
J. Indian Chem. Soc. 79(6), 544-45 (2002); Chem. Abstr., 137, 369945g (2002).
205. Nilgun Karali;
Eur. J. Med. Chem., 37, 909-18 (2002).
206. Miura Tooru, Wada Masaru, Furuya Masayuki, Nagato Teruyuki;
Jpn. Kokai Tokkyo Koho JP, 01, 160, 932 (1990); Chem. Abstr., 112, 35332t (1990).
207. Matsuoka Rikitaro, Watanabe Kiyoshi;
Jpn. Kokai Tokkyo Koho JP, 04, 316, 556 (1993); Chem. Abstr., 118, 14749b (1993).
208. Esteban Gemma, Lopez-Sanchez Mighei A., Martinez Maria Engenia, Plumert Joaquin;
Tetrahedron, 1998; Chem. Abstr., 128, 114765v (1998).
209. Carieno M. Carmen, Perez Gonzalez, Manual Ribagorda Maria, Houk K. N.;
J. Org. Chem., 1998; Chem. Abstr., 129, 54166j (1998).
210. E. M. Hammouda M., Sadek E. G., Khalij A. M.;
Indian J. Heterocycl. Chem.,1998; Chem. Abstr., 130, 81476n (1999).
211. Palacious Francisco, Herran Esther, Rubiales Gloria;
J. Org. Chem., 64(17), 1999; Chem. Abstr., 131, 243104u (1999).
212. Taber Douglass F., Kanai Kazuo, Jiang Qiro, Bui Gina;
J. Am. Chem. Soc., 2000; Chem. Abstr., 133, 178965x (2000).
213. N. Nanjundaswami, K. M. Lokanatha Rai, S. Shashikanth;
Indian J. Chem., 40B, 274-277 (2001).
214. Felix, Raymound A.;
U. S. US 4, 336, 062 (Cl. 71-98, A01 N31/00) (1982); Chem. Abstr., 97, 144458f
(1982).
185
215. Melvin Lawrence S. Jr., Johnson Michael R.;
U.S. US 4, 379, 783 (Cl. 424-184, A61K31/695); Chem. Abstr., 99, 22684x (1983).
216. Nagarjan K., Shenoy S. J.;
Indian J. Chem., Sec. B, 1987; Chem. Abstr., 108, 150224p (1988).
217. Scott Keneth R., Nicholson Jesse M., Edatiogho Ivan O.;
PCT Int. Appl. WO 93, 17, 678; Chem. Abstr., 120, 233914u (1994).
218. Assy M. G., Hataba A.A.;
J. Indian Chem. Soc., 1997; Chem. Abstr., 127, 5060v (1997).
219. Shimazaki Toshiyuki, Yamashita Hiroyashi;
Jpn. Kokai Tokkyo Koho JP, 09, 118, 653; Chem. Abstr., 127, 3410j (1997).
220. Albaugh Pamela, Liu Gang, Hutchison Alan;
U.S. US 5, 723, 462 (1998); Chem. Abstr., 128, 204804m (1998).
221. Alcaraz Lilian, Taylor Richard J. K.;
Chem. Commun. 1998; Chem. Abstr., 129, 95339m (1998).
222. Copar Auton, Salmajer Tomaji, Anzik Borut, Kuzman Tadeya, Mesar Tomaj, Koczan
Dariko;
Eur. Pat. Appl. Ep. 854, 143; Chem. Abstr., 129, 148908e (1998).
223. Jacobsen Poul, Trappendahl Sevend, Bury Paul Stanley, Kanstrup Anders, Christiansen
Lise Brown;
PCT Int. Appl. WO, 98, 18,777; Chem. Abstr., 128, 321562s (1998).
224. Dzhalilov T.N., Isaeva F.G., Gasanov T.A., Budagyants A.;
U.S.S.R.815, 007 (Cl. C07 C 103/19) (1981); Chem. Abstr., 95, 80282t (1981).
225. Keil Michael, Schirmer Ulrich, Kolassa Dieter, Rademacher Wilhelm, Jung Johan;
Ger. Offen. DE 3, 604, 871 (Cl. C07 C 49/753); Chem. Abstr., 108, 37277v (1988).
226. Nagao Keishrio, Suzuki Akio, Nakagawa Masazumi;
Jpn. Kokai Tokkyo Koho JP, 62, 89, 660 (1988); Chem. Abstr., 108, 94379d (1988).
227. Collis David J., Cullen John D., Stone Graant M.;
Aust. J. Chem., 1998; Chem. Abstr., 110, 94655g (1989).
228. Tvanov E. L., Konupl P., Konup L. A., Stepanov D. E., Groshcha K. V.;
Khim. Farm. Zh., 1993; Chem. Abstr., 121, 35462w (1994).
229. V. K Ahluwalia, Pooja Sharma, Bindu Goyal;
I. J. Chem., 36B, 519, 1997.
230. Alkekseeva L. M., Krinchevskii E. S., Anisimova O. S., Parshin V. A., Ashina V. V.,
Granik V. G.;
Khim. Farm. Zh., 1997; Chem. Abstr., 128, 244027s (1998).
231. Rheinheimer Joachim, Maywald Volker, Kardorff Ume, Westphalen Karl-Otto, Misslitz Ulf;
PCT Int Appl. WO 98, 30, 565 (Cl. C07D493/04) (1998); Chem. Abstr., 129, 122655v
(1998).
186
232. Harimaya Kenzo, Magome Emiko, Tabato Yuji, Sasaki Toru;
Eur. Pat. Appl.  EP 820, 995 (Cl. C07D307/92) (1998); Chem. Abstr., 128, 154254j
(1998).
233. Engle Stepfan, Baumann Ernst, Von Deyn, Wolf  Gang, Hill Regina Luice;
Chem. Abstr., 130, 450c (1999).
234. Salama M. A., Atshikh M. A.;
Egypt J. Pharm. Sci. 1997; Chem. Abstr., 130, 81478q (1999).
235. Takehiro Fukami, Fukuroda Takahiro, Kamatani Akiolhara;
PCT Int. Appl. WO 99, 15,516; Chem. Abstr., 130, 237476a (1999).
236. Kimura Yasuo, Mizuno Takashi, Kawano Tsuyoshi, Shimada Alsami;
Z. Naturforsch. B. Chem. Sci., 1999; Chem. Abstr., 132, 35551b (2000).
237. Broughton Howard Barff, Bryant Helen Jane, Chambers Mark Stuart, Curtis Neil Roy;
PCT Int. Appl. WO. 99, 62, 899; Chem. Abstr., 132, 12259y (2000).
238. Hermann Stefan, Hoischen Dorothee, Kather Kristian, Mueller Klaus, Schallner Otto,
Pontzen Rolf;
Ger. Offen. DE 10,  136,449 (Cl. C07D 231/20) (2002); Chem. Abstr., 137,  353015t
(2002).
239. Natalie D. Eddington, Donna S. Cox, Ralph  R. Roberts, Raymond J. Butcher, Iven O.
Edafiogho, James P. Stables, Neville Cooke;
Eur. J. Med. Chem., 37, 635-648 (2002).
240. Bastiaan J. Venhuis, Durk Dijkstra, David J. Wustrow, Leonard J. Meltzer, Hakeen V.
Wikstrom
J. Med. Chem., 46(4), 584-90 (2003).
241. Honda Tadashi, Favaloro Frank G., Gribble Gordon W., Sporn Michael B., Suh Nanjoo
PCT Int.  Appl. WO 03,  59,339  (Cl.  A61K31/215) (2003); Chem. Abstr., 139, 133695r
(2003).
242. Vasavada Jaladhi A., Parekh H. H.;
J. Ind. Chem. Soc., 80(1), 55-56  (2003).
243. Zhang Chengzhi, Burke Michael, Chen Zhi, Dumas Tacques, Fan Dongping, Ladouceur
Gaetan;
PCT Int. Appl. WO 03, 72, 566 (Cl. C07D 307/92) (2003); Chem. Abstr., 139,  22166z
(2003).
244. Watabe Yoshihisa, Kondo Teruyuki and Akazome Motohiro;
Jpn. Kokai Tokkyo Koho JP, 04, 282, 372 (Cl. CO7D 231/56) (1992); Appl. 91/43, 583
(1991).
245. Welch Willard M., Hanau Catherine E. and Whalen William M.;
Synthesis, 10, 937-39 (1992); Chem. Abstr., 118, 6910y (1993).
246. Kim Byung Chul, Kim Jin Li and Jhang Y. Urngdang;
Bull. Korean Chem. Soc., 15(2), 97-98 (1994); Chem. Abstr., 121, 9269u (1994).
187
247. Strakovsk A., Strakova I. and Ptrova M.;
Latv. Kim. Z., (5-6), 96-100 (1995).
248. Qui Chaumin, Wang Xiaoyuan;
Beijing Shifan Daxue Xuebao, Ziran Kexueban, 32(4), 524-28 (1996); Chem. Abstr.,
127, 81393w (1997).
249. Lyubchankya Valeriy M., Alekseeva Lyudmila M., Granik Vladimir G.;
Tetrahedron, 53(44), 15005-10 (1997); Chem. Abstr., 128, 22855w (1998).
250. Vasilevsky Sergey F., Prikhoa'Ko Tat'yana A.;
Mendeleev Commun., (3), 98-99 (1996); Chem. Abstr., 125, 114539n (1996).
251. Bharti V. Badami, Chandrashekar K. Hoshami;
Indian J. Heterocyclic Chem., 7, 24 (1998).
252. Caron Stephane, Vazquez Enrique;
Synthesis, (4), 588-92 (1998); Chem. Abstr., 131, 5226m (1999).
253. Kariyone Kazuo, Yogi Hideo;
Jpn, Kokai Tokkyo Koho JP, 80, 31, 050 (Cl. CO7D 231/56) (1978); Chem. Abstr., 93,
186340j (1980).
254. Fujimura Yasuo, Ikeda Yugo, Matsunaga Fujimura et al;
Yakugaku Zasshi, 106(11), 995-1001 (1986); Chem. Abstr., 107, 198158b (1987).
255. H. M. Mokhtar and H. M. Faidallah;
Pharmazie, 42, 481 (1987).
256. H. D. Showalter, M. M. Angelo, E. M. Berman;
J. Med. Chem., (3), 1527 (1988).
257. D. W. Fry and T. A. Besserer;
Mol. Pharmacol., 33, 84 (1988).
258. Roman;
Pharmazie, 45, 214 (1990).
259. Koeing Bernhard, Leser Ultrike, Mertenes Alfred;
Ger. Offen DE, 4, 311, 782 (Cl. CO7D 231/56) (1994); Chem. Abstr., 121, 300888t
(1994).
260. Sasaki Toshiro, Nakatani Juko, Hiranuma Toyoichi, Kashima Hiroko et al;
Jpn. Kokai Tokkyo Koho JP, 07, 33, 744 (Cl. CO7D 231/56) (1995); Appl., 93, 204 612
(1993); Chem., Abstr., 123, 55870x (1995).
261. Heistracher Elisabeth, Rueb Lothar, Hamprecht Gerhard;
PCT Int. Appl. WO 96, 06, 830 (Cl. CO7D 231/56) (1996); Chem. Abstr., 125, 86636w
(1996).
262. Kyomura Nobuo, Okaishuko Ikeda Yoshiya, Suzuki Shigeru et al.
Eur. Pat Appl. EP. 726, 266 (Cl. CO7D 401/12) (1996); JP Appl. 95/21, 383 (1995);
Chem Abstr., 125, 195645u (1996).
188
263. Alkhader Mohmed A and Mohmed Gamal B.;
Quator Uni. Sci. J., 14, 114-22 (1994); Chem. Abstr., 127, 81369t (1997).
264. Duzinska-Usarewicz J., Wrzecino U., Frankiewicz A., Linkowska E.;
Pharmazie, 43(9), 611-13 (1989); Chem Abstr., 110, 154217c (1989).
265. Effland Richard Charles, Klein Joseph Thomas, Martin Lawrence Leo;
Eur. Pat. Appl. EP 509, 402 (Cl. CO7D 401/12) (1992); US Appl. 688, 964 (1991).
266. Butera John A. and Anthane Schuyler A.;
U.S. US, 5, 179, 118 (Cl. 514-405; A61K31/415) (1993); Chem. Abstr., 118, 213068v
(1993).
267. Conoly Peter J. and Wachter Micheal P.;
U.S. US, 5, 387, 639 (Cl. CO7D 231/54) (1995); US Appl. 742, 788 (1991); Chem
Abstr., 122, 265369w (1995).
268. Kato Shiro, Morie Tosha, Yoshida Naoyuki;
Jpn. Kokai Tokkyo Koho Jp. 06, 135, 960 (Cl. CO7D 403/12) (1994); Chem Abstr.,
121, 205338e (1995).
269. Bigham Eric, Reinhard John  Fredric J.;
PCT Int. Appl. WO 94, 14, 780 (Cl. CO7D 239/48) (1994); Chem Abstr., 122, 160666n
(1995).
270. Yamaguchi Masahisa, Maruyama Noriyaki, Kamei Kenshi et al;
Chem. Pharm. Bull., 43(2), 332-34 (1995); Chem Abstr., 123, 9419j (1995).
271. Ooe Taknori, Kobayashi Haruhito, Ikezawa Ryuhei, Kudome Masao;
Jpn. Kokai Tokkyo Koho JP, 07, 02, 786 (Cl. CO7D 231/56) (1995); JP Appl. 93/81,
438 (1993); Chem. Abstr., 122, 239697g (1995).
272. Aran Vincente J., Flores Maria, Munor Pilar;
Liebigs Ann., 5, 817-24 (1995); Chem. Abstr., 123, 285914u (1995).
273. Lavielle Gilbert, Muller Oliver, Millan Mark, Audinot Valerie;
Eur. Pat. Appl. EP 747, 379 (1996), FR Appl. 95/6, 663 (1995); Chem. Abstr., 126,
89534j (1997).
274. Marft Anthony;
PCT Int. Appl. WO 97, 42, 174 (1997); Chem. Abstr., 128, 13274d (1998).
275. Cups Thomas Lee, Bogdan Sophie Eva, Henry et al.;
PCT Int. Appl. WO 96, 28, 609 (1996); Chem. Abstr., 129,  41131u  (1998).
276. De Lucca Gerorge V., Liang Jing, Kim VIt-Bacheler Lee T.;
J. Med. Chem., 41(13), 2411-23 (1998).
277. Badran Mogha M., Ismail Mohmad A., Youssef Khairia;
J. Pharm. Sci., 13(1), 73-79 (1999); Chem. Abstr., 131, 18990f (1999).
278. Newshw Richard Eric and Verwijis Anthonie Johan;
U.S. US, 5, 872, 144 (Cl. 514-403; A61K31/415) (1999); Chem. Abstr., 130, 182463m
(1999).
189
279. Kania Robert Steven, Bender Steven Lee, Borchardt Allen J.,  Braganze John F.;
PCT Int. Appl. WO 01, 02, 369 (Cl. CO7D 23/00) (2001); Chem. Abstr.,  134, 100864p
(2001).
280. Lee Jin Ho, Hong, Chang Yong, Park Jac Sik, Shin Dong Kyu;
PCT Int. Appl. WO 01, 85, 726 (Cl. CO7D 417/14); Chem. Abstr., 135, 357922t (2001).
281. Stack Gary Paul and Tran Megan;
PCT Int. Appl. WO 02, 88, 133 (Cl. CO7D 491/04) (2001); Chem. Abstr., 137, 353042z
(2002).
282. Balakrishna Kalluraya and M. Abdul Rahiman;
Indian J. Chem., 42B, 1141-1148 (2003).
283. Malmstroem Jonas, Swahn Britt-Marie;
PCT Int. Appl. WO 03 68, 754 (Cl. CO7D 231/56) (2003); Chem. Abstr., 139, 197477d
(2003).
284. Dutruc Rosset Gilles, Lesuisse Dominique, Rooney Thomas;
Fr. Demande, FR 2, 836, 915 (Cl. CO7D 231/56) (2003); Chem. Abstr., 139, 246027t
(2003).
285. A. R. Grey and J. B. Dickey;
Org. Syn. Coll. 2, 60 (1943).
286. C. B. Reese and S. R. James;
Tetrahedron Letters, 2915 (1975).
287. Gill G. Bryon, Hidris Muhammad S.;
Tetrahedron, 49, 219-34 (1993); Chem. Abstr., 118, 191669n (1993).
288. Gursu Esin, Vlusoy Nuray;
Acta. Pharma. 38(4), 107-9 (1996); Chem. Abstr., 126, 59802m (1997).
289. Ogus Funda, Dogan Llknur;
Spectrosc, Lett., 31(2), 469-82 (1998); Chem. Abstr., 129, 16097e (1998).
290. M. R. Mahmoud, Awatef E. F. Ebrahim, M. S. Abd El-Halim, A. M. Radwan;
Indian J. Heterocyclic Chem., 4, 131-36 (1994).
291. Cao-Yun Weu, Chai Xian Dong, Jiang Yue-Shan et al.;
Gaodeng Xuexiao Huaxue Xuebao, 16(2), 225-29 (1995); Chem. Abstr., 123, 33021u
(1995).
292. P. K. Roy Chowdhury, S. Mehrotra, S. Srivastava, P. K. Srivastava;
Indian J. Heterocyclic Chem., 12, 221-24 (2003).
293. Y. K. Gupta, K. P. Bhargava, K. Shanker, J. C. Agarwal;
Indian J. Chem.,  20B, 714 (1981).
294. J. C. Agarwal, Y. K. Gupta, P. Kumar, C. Nath, K. P. Bhargava and K. Shanker;
Indian J. Chem., 22B, 955 (1981).
295. Y. Furukawa;
European Patent Appl. EP 88, 413 (1983); Chem. Abstr., 100, 22688u (1983).
190
296. Z. H. Khalil, A. I. M. Koroiem and R. M. Abu-El-Hameed;
J. Chem. Technol, Biotechnol., 36, 473 (1986).
297. D. Peters, A. B. Hornfield and S. Gromowitz;
J. Heterocyclic Chem., 27, 2165 (1990).
298. Raymond P., Diane L., Dan-Chang Wei, Wang;
J. Heterocyclic Chem., 30, 1399 (1993).
299. R. F. Burns;
J. Heterocyclic Chem., 33, 1025 (1996).
300. A. G. Manukyan, R. G. Malik, B. T. Guri b-dzhanyan;
Khim-Pharm., Zh., 19, 685 (1995); Chem. Abstr., 104, 207622s (1996);
301. Wyzlic I. M., Tjarks W., Soloway A. H., Perkins D. J., Burgos M.;
Inorg. Chem., 35(16), 4541-47 (1996); Chem. Abstr., 125, 168582a (1996).
302. Bosies Elmar, Eswein Angelika, Grams Frank, Krellohans Willi;
Ger. Offen. DE 19, 548, 624 (Cl. C07D 401/04) (1997); Chem. Abstr., 127, 121746x
(1997).
303. Abdel-Hamide S. G., El-Hakim A. E., El-Helby A. A.;
Al-Azhar J. Pharm. Sci., 17, 35-40 (1996); Chem. Abstr., 126, 225269q (1997).
304. Shivanyuk A. N., Rudkevich D. M., Reinhoudt D. N.;
Tetrahedron Letters, 37(52), 9341-44 (1996); Chem. Abstr., 126, 144028h (1996).
305. Wolf-Gang, Hanefeld and Helge Hurms;
Indian J. Heterocyclic Chem., 34, 509 (1997).
306. Andre Roland, Dollinger Markus and Erdelen Christopher;
Ger. Offen DE 19, 715, 017 (Cl. C07D 401/12) (1998); Chem. Abstr., 129, 302655d
(1998).
307. Omar M. T.;
Egypt J. Pharma. Sci. 38, 281-89 (1997); Chem. Abstr., 131, 257514k (1999).
308. Sakai, Kunikazu, Satoh, Yusuke;
PCT Int. Appl. WO 99, 50, 252 (Cl. C07D 239/62) (1999); Chem. Abstr., 131, 243286a
(1999).
309. Grams Frank, Zimmermann Gerd;
PCT Int. Appl. WO 98, 58,915 (Cl. C07D 239/00) (1999); Chem. Abstr., 130, 95559d
(1999).
310. Oliva Ambrogio, De Cillis Gianpiero, Grams Frank, Livi Valeria, Menta Ernesto;
PCT Int. Appl. WO 98, 58, 925 (Cl. C07D 401/12) (1999); Chem. Abstr., 130, 95560x
(1999).
311. R. J. Pardasani, S. K. Jain, S. K. Yadav, I. Sharma;
Indian J. Heterocyclic Chem., 12, 179-80 (2002).
312. Geppert Dagmar, Grams Frank, Krell Hans-Willi, Leinert Herbert, Menta Ernesto;
PCT Int. Appl. WO 02, 79, 170 (Cl. C07D 239/62) (2002); Chem. Abstr., 137, 294967e
(2002).
191
313. A. W. Hoffmann;
Ber., 21, 2332 (1880).
314. A. Ladenburg;
Ibid., 27, 2952 (1894).
315. Zednikova Gabriela, Nalepa Karela;
Acta Univ. Palacki Olumuc., Fac. Rerum Nat. Chem., 1998; Chem. Abstr., 131, 116188v
(1999).
316. C. Granachar and G. Gulbas;
Helv. Chem. Acta. 10, 818-26 (1927); Chem. Abstr., 22, 781 (1928).
317. A. Saxena, N. C. Desai, Kesha K. Awasthi;
Indian J. Chem., 40(B), 201 (2001).
318. Allimony H. A., Sadd H. A. and F. A. A. el-Mariah;
Indian J. Chem., 38(B), 445 (1999).
319. Feng Jun-Cai, Meng Qing-Hua, Liu Yang, Dai-Li;
Org. Prep. Proceed Int., (1997); Chem. Abstr., 128, 61455k (1998).
320. R. Agarwal, C. Chaudhary and V. S. Misra;
Indian J. Chem., 22(B), 308 (1983); Chem. Abstr., 99, 88128o (1983).
321. P. Kumar, C. Nath and K. Shanker;
Pharmazie, 40H, 267 (1985).
322. C. R. Sharma and D. R. Shridhar;
Indian Pat. IN 154-314 (1984); Chem. Abstr., 105, 13373f (1986).
323. Archana Jyoti Srivastava, Sanjay Swaroop, V. K. Saxena and P. Srivastava;
Indian J. Pharma. Soc., 51(6), 23 (1989).
324. Hussieny Hamed Moharram, R. Samiya El-Amin and Ahmed El-Dawany;
J. Serb. Chem. Soc., 54(7), 335-42 (1989); Chem. Abstr., 114, 101822x (1991).
325. S. M. Sethna and R. C. Shah;
J. Indian Chem. Soc., 13, 1459 (1993).
326. Vaccaro Wayne D., Walin Ronald L., Saloman Daniel M.;
PCT Int. Appl. WO 99, 24, 421 (Cl. C07D 401/06) (1998); Chem. Abstr., 131, 338115n
(1998).
327. Kawasaki Kazuyuki Kobayashi Haruhito, Ehara Syuji Sato Hideaki;
PCT Int. Appl WO 98 32, 740 (Cl. C07D 233/60) (1998); Chem. Abstr., 114, 148945h
(1998).
328. Chang Linda I.;
PCT Int. Appl. WO 22, 208 (1998); Chem. Abstr., 129, 41134x (1998).
329. Kiec-Kononowicz Kataryna, Szymanska E., Motyl M, Holzer W., Bialecka A., Kasprowicz A.;
Pharmazie, 53(10), 680-684 (1998); Chem. Abstr., 130, 3606f (1999).
330. Altenburger J. M., Gilbert L.;
Chem. Abstr., 131, 76653y (1999).
192
331. Bascou J. P., Lacrox G., Perez J. O. and Schmitz C.;
PCT Int. Appl. WO 94, 01, 410, 20 Jan. (1994); Chem. Abstr., 121, 83334c (1994).
332. Kolhe Vishnu, Dhingra Vinod;
Indian J. Heterocycl. Chem., 4(1), 69-70 (1994); Chem. Abstr., 122, 105757t (1995).
333. Ueda Akyoshi, Myazawa Yasuyuki et. al.;
Jpn. Kokai Tokkyo Koho JP. 7, 206, 829 (1995); Chem. Abstr., 123, 283031r (1995).
334. Ding Ming WO, Tu Hai-Yang Liu Zhao-Jie, Zhuang Nong-Bo.;
Gaodeng Xuexiau Huaxue Xuebao, 19(6), 895-898 (1998); Chem.  Abstr.,  129,
122615h (1998).
335. Pilkington Brian Leslie, Russell Sally Elizabeth, Whittle Alan John, Mound William
Roderick;
Brit. UK Pat. Appl. GB., 2, 329, 180 (Cl. C07D 233/80) (1999); Chem. Abstr., 129,
58826r (1999).
336. Earmshow Christopher Geoffrey, Hough T. L., Mitchell D. R.;
PCT Int. Appl., WO 51, 673 (1998); Chem. Abstr., 130, 13990a (1999).
337. Biplab De and G. V. S. Ram Sarma;
Indian J. Heterocyclic Chem., 9, 185 (2000).
338. Lyssikotos Joseph Patel, Yang Bingwei Vera;
Eur. Pat. Appl. WO 1006, 113; Chem. Abstr., 133, 30729b (2000).
339. B. Kalluraya, A. M. Isloor, M. Rao and D. P. Shetty;
Indian J. Heterocyclic Chem., 11, 155-158 (2001).
340. P. S. Upadhyay, S. N. Joshi, A. J. Baxi and A. R. Parikh;
J. Indian Chem. Soc., 68, 364 (1991); Chem. Abstr., 116, 1062211y (1991).
341. V. C. Soni and A. R. Parikh;
Indian J. Pharm. Sci., 53, 185 (1991); Chem. Abstr., 116, 15165g (1992).
342. P. S. Upadhyay, H. D. Joshi, A. J. Baxi and A. R. Parikh;
Indian J. Hetero. Chem., 1, 71 (1991); Chem. Abstr., 117, 48407z (1992).
343. P. S. Upadhyay, A C. Pandya and H. H. Parekh;
J. Indian Chem. Soc., 68, 296-98 (1991).
344. N. Joshi, A. Bapodara and H. H. Parekh;
Indian J. Chem., 33(B), 662 (1994).
345. Dharti G. Joshi, Haresh B. Oza and H. H. Parekh;
Heterocyclic Communications, 3(2), 169 (1997).
346. P. S. Patel, S. Koregaokar, Hansa Parekh;
I. Journal of Heterocycl. Commun., (1997).
347. Khyati Parikh, Paresh Oza and A. R. Parikh;
J. Inst. Chem., 71(3), 83-87 (1999); Chem., Abstr., 133, 308291r (2000).
348. S. B. Hirpara, K. A. Parikh, B. C. Merja and H. H. Parekh;
Indian J. Chem., 42B, 1172-1175 (2003).
193
349. Battistina Asproni, Anedeo Pau, Mauro Bitti;
J. Medicinal Chem., 45, p-4655 (2002).
350. Declerca Arthur, Herdeciln Piet;
PCT Int. Appl. WO 02 68, 395 (Cl. C07D 235/84) (2002); Chem. Abstr., 137, 201308c
(2002).
351. Abdel-Rahman A. H., Khalil A.M., Keshk E. M.;
Bollettino Chemico Farmaceutico, 140(6), 387-396 (2001); Chem. Abstr., 137, 352951h
(2002).
352. Prasanna A. Datar, P. Y. Shirodkar and K. R. Panikkar;
Indian J. Chem., 42(B), 690-694 (2003).
353. Chafiq Hamdouchi, Concha Sanchez, Joseph Gruber, Miriamdel Prado;
J. Medicinal Chem., 46, 4333-4341 (2003).
354. C. Libermann and A. Lange;
Ann., 207, 121 (1881).
355. W. E. Grandy, A. C. Whiterman, E. C. Rizok, E. J. Rolzok, H. E. Hanes and J. C. Sylverster;
Antibiotics and Chemotherapy, 2, 399 (1952).
356. F. C. Brown;
Chem. Revs., 61, 463 (1962).
357. G. R. Newkome and A. Nayak;
Advances of Heterocyclic Chemistry, 25, 83 (1977).
358. R. A. Mane and V. S. Ingle;
Indian J. Chem., 40B, 124-128 (2001).
359. Mogilaiah K., R. Babu Rao and K. Narendra Reddy;
Indian J. Chem., 38B, 818-822 (1999).
360. Abdel Rahman, R. M. Seada, Fawzy M.;
el-Bez I. Boll. Chim. Farm., 133(6), 374-80 (1994).
361. Abdullah Mohammed asiri;
Molecules, 6, M213 (2001).
362. J. S. Webb, R. W. Broschand, W. E. Meyer and J. E. Lancster;
J. American Chem., Soc., 84, 3185-7 (1962); Chem. Abstr., 57, 13745c (1962).
363. S. M. Bukely et al.;
Proc. Soc. Expt. Bio. Med., 78, 299 (1951); Chem. Abstr., 46, 1640h (1952).
364. G. Fench and P. Monforte;
American Chem. Abstr., 53, 8121 (1959).
365. Ogawa, Kazuo, Yamawaki, Ichiro and Matsushita Yoichi;
Jpn. Kokai Tokyo Koho JP 01, 090, 189 (1989); Chem. Abstr., 111, 180338l (1980).
366. Kawaski Takao et al.;
Eur. Pat. Appl. Ep. 50, 002 (1982); Chem. Abstr., 97, 92267w (1982).
194
367. Ten Haken, Pieter Vebb, Shirley Beatric;
Eur. Pat. Appl. Ep. 91, 148 (1982); Chem. Abstr., 110, 139089n (1984).
368. Merck and Co. Inc.;
Japan Kokai Tokkyo Koho Jpn. 59, 148, 719 (1984); Chem. Abstr., 102, 62216h (1985).
369. J. P. Singh, A. K. Saxena, J. N. Sinha, K. Shanker;
Eur. J. Med. Chem. Chim-Therap., 20(30), 283-6 (1986); Chem. Abstr., 104, 168410y
(1986).
370. S. Grasso, A. Chimirri, P. Monforte, G. Fenech, M. Zappalar, A. M. Monforte;
Farmaco Ed. Sci. 43(10), 851-6 (1988); Chem. Abstr., 110, 50734c (1989).
371. Cetenk Wiaczeslaw Antin, Connor David Thomas, Sorenson R.J.;
Eur. Pat. Appl. Ep. 343643, 29 Nov. (1989); Chem. Abstr., 112, 235298y (1990).
372. M. A. Moustfa, S. M. Bayomi, A. A. El-man and M.M. Kerdwy;
Sci. Pharma., 57(2), 125-30 (1989); Chem. Abstr., 112, 98444b (1990).
373. R. P. Rao;
Curr. Sci., 35, 541 (1996).
374. R. S. Lodhi and S. D. Shrivastava;
Indian J. Chem., 36B, 997 (1997).
375. G. S. Gadaginamath, A. S. Shyadligeri and R. R. Kavali;
Indian J. Chem., 38B, 156-159 (1999).
376. Goel Bhawna, Tyagi Rita, Bansal Ekta, Sinha N.J.;
Eur. J. Med. Chem., 34(3), 256-259 (1999). Chem. Abstr., 131(7), 87859g (1999).
377. El-Subbagh, Hussein I.;
Soudi Pharm. J., 7(1-2), 14-21 (1999); Chem. Abstr., 131, 212875h (1999).
378. Liu Jun, Hu Xian Hing,  Xu Han Sheng;
Chim. Chem. Lett., 10(3), 199-200 (1999); Chem. Abstr., 131, 199659y (1999).
379. Diurno, M. Vittnsia et. al.;
Farmaco., 54(9), 579-583 (1999); Chem. Abstr., 132, 35644j (2000).
380. Tamura, Kazuhiko, Suzuki Yoshiyuki, Akima Michitak;
PCT Int. Appl. WO 96, 19, 210 (1996); Chem. Abstr., 125, 142718p (1996).
381. B. B. Lohary, V. Bhushan, A. Sekar Reddy and R. Rajagopalan;
Indian J. Chem., 38B, 403 (1999).
382. Bhawana Goel, Ram Tilak, Tyagi Rini et al.;
Eur. J. Med. Chem., 34(3), 205-209 (1999); Chem. Abstr., 131, 8785q (1999).
383. Eldin Sanaam;
Z. Noturforsch; B. Chem Sci, 54(12), 1589 (1999); Chem. Abstr., 132(22), 2390740k
(2000).
384. O. A. Fathalla;
Indian J. Chem., 40B, 37-42 (2001).
195
385. Mohie A. Sharat, G. Hamman, Naglaa A Abd El-Hofez;
Indian J. Chem., 40B, 213-216 (2001).
386. Vigorita M. G., Ottana R., Monforte F., Maccari R., Traovato A.;
Bio. Org. Med. Chem. Lett., 11(21), 2791-4 (2001).
387. G. C. Kamdar, D. J. Bhatt and A. R. Parikh;
J. Inst. Chem., 52(1), 18-20 (1980); Chem. Abstr., 93, 12413g (1980).
388. K. J. Mehta, A. C. Chawda and A. R. Parikh;
J. Indian Chem. Soc., 56(2), 173-4 (1979); Chem. Abstr., 92, 5866s (1980).
389. G. C. Kamdar, D. J. Bhatt and A. R. Parikh;
Ada. Cienc. Indica (ger) Chem., 8(3), 134-6 (1982); Chem. Abstr., 98, 125955v (1983).
390. G. C. Kamdar, D. J. Bhatt and A. R. Parikh;
Ada. Ciencia Indica, 90(2), 65 (1983); Chem. Abstr., 101, 151971x (1984).
391. S. B. Kaliaya and A. R. Parikh;
J. Inst. Chem., 57, 161 (1985); Chem. Abstr., 104, 109527u (1986).
392. R. R. Shah, R. D. Mehta and A. R. Parikh;
J. Indian Chem. Soc., 62, 255 (1985); Chem. Abstr., 105, 78865s (1986).
393. A. C. Chawda, G. C. Kamdar and A. R. Parikh;
J. Indian Chem. Soc., 64, 298 (1987); Chem. Abstr., 108, 131655p (1988).
394. P. M. Parashrya and A.R . Parikh;
J. Inst. Chem., 63, 63 (1991); Chem. Abstr., 115, 256053s (1991).
395. V. L. Pachhamia and A. R. Parikh;
Acta Ciencia Indica, 17c(1), 67 (1991); Chem. Abstr., 117, 26399w (1992).
396. S. B. Bhawsar, R. G. Shah and A. R. Parikh;
J. Inst. Chem., 64, 62 (1992).
397. C. L. Patel and H. H. Parekh;
J. Indian Chem. Soc., 65, 574 (1988).
398. C. L. Patel and H. Parekh;
J. Indian Chem. Soc., 65, 282 (1988).
399. K. P. Roda, R. N. Vansdadia and H. Parekh;
J. Inst. Chem. Soc., 64, 109 (1988).
400. K. Ladva, U. Dave and H. Parekh;
J. Indian Chem. Soc., 68, 370-71 (1991).
401. V. Dave, K. Ladva and H. Parekh;
J. Inst. Chem., 64, 74 (1992).
402. Nailesh Joshi, Pankaj Patel and H. H. Parekh;
Indian J. Chem., Aug. (1996).
403. R. C. Khunt, Neela Datta, Fatema Bharmal and A. R. Parikh;
J. Indian Chem. Soc., 78, 47 (2001).
404. Siddique Mond, Ifreesw Mohd., Doshi A. G.;
Asian J. Chem., 14(1), 181-184 (2002).
196
405. Mayer, Guido, Misslitz, Vlf;
PCT Int. Pat. Appl. WO 02, 48, 140 (Cl. C07D 413/D6); Chem. Abstr., 137, 33290v
(2002).
406. Archana V. K. and Srivastava A. K.;
Eur. J. Med. Chem., 37, 873-882 (2002).
407. S. K. Srivastava, Soumya Srivastava, S. D. Srivastava;
Indian J. Chem., 41B, 1937-1945 (2002); Chem. Abstr., 138, 153485e (2003).
408. Fujiwara Norio and Antoku Fujio;
PCT Int. Appl. WO 03 57, 693 (2003); Chem. Abstr., 139, 117415u (2003).
409. Govindarajan R., Jameela H. J., Bhatt A. R.;
Indian J. Hetero. Chem., 12(3), 229-232 (2002); Chem. Abstr., 139, 149604w (2003).
410. Pfahl Magnus, Al-Shamma Hussien A.; Fanjul Andrea N., Pleynet David P. M., et al.;
PCT Int. Appl. WO 03 50, 098 (Cl. C07D277/38) (2003); Chem. Abstr., 139, 36523a
(2003).
411. Vogel's Text book of practical organic chemistry. 5th Addition, method no. 6.97, page
No. 964.
412. M. Saeda, M. Abdel-Megid, I. M. El-Deen;
Indian J. Heterocycl. Chem., 3, 81-86 (1993).
413. Febung Anon;
Ber., 18, 1814 (1844).
414. Wahler F and Liebig;
J. Ann. 3, 249, 267 (1832).
415. Pelouze;
J. Ann. 10, 249 (1834).
416. D. T. Mowry;
Chem. Rev., 2, 189 (1948).
417. Hsiu Shih Mei, Ting Lin Kwang;
Hua Hsueh, 42(4), 125-31 (1984); Chem. Abstr., 103, 141038a (1985).
418. Bram G., Loupy A., Pedouassaut M.;
Bull. Soc. Chim. Fr., 1, 124-8 (1986); Chem. Abstr., 105, 190460g (1986).
419. Takabe Akinisa;
Jpn. Kokai Tokkyo Koho JP, 62, 289, 552 (Cl. CO7C121/16) (1987); Chem. Abstr.,
109, 54333y (1988).
420. Shepherd R. G.;
U.S. 7, 27149 (1988); Chem. Abstr., 111, 97104h (1989).
421. Uhlendrof Jaochim, Gabbar Haimed, Graf Eric, Doppe feld, Illestephanie;
Ger. Offen. D.E. 3, 024, 836 (1982); Chem. Abstr., 96, 142481p (1982).
422. Stezhko T. V., Granik V. G., Glushokov R. G., Roshehina L. F., Polezhaeva A. I.,
Mashkovskii M. O.;
Kim Farm Zh. 18(3), 296-7 (1984); Chem. Abstr., 101, 90704p (1984).
197
423. Uhlendorf Jochim, Leyck Sigurd, Nattermann A.;
Chem. Abstr., 100, 68161s (1984).
424. Bremanis G., Kolvins I., Acena I, Lukevics E., Veveris M., Kauss V., Trapentsiser P.,
Lierins E.;
Chem. Abstr., 103, 5967f (1985).
425. Dave M. P., Patel J. M., Thaker K. A.;
J. Inst. Chem. India 56(4), 169-70 (1984); Chem. Abstr., 102, 131660n (1985).
426. Tanaka Masato, Sakakura Toshi Yasu;
Jpn. Kokai Tokkyo Koho JP, 60, 184, 056 (Cl. CO7C121/34) (1985); Chem. Abstr.,
104, 88317h (1986).
427. Sato Hiroshi;
Hirose Kenchi Chem. Abstr., 108, 556-70 (1988).
428. Lai Hoi Kiong, Relyea Douglas, Irving Davis, Robert Allan;
U.S. US 5, 945, 436 (Cl. 514-357; A61K31/44) (1999); Chem. Abstr., 131, 170273g
(1999).
429. Makarenich I. F., Mokrouz M. V., Topchif L., Kovalev I. P., Sokolova V. E., Gubin Yu. I.,
Bublik N. P., Polyalov V. A.;
Khim. Prir. Soedin (5), 608-12 (1983), (Russ.); Chem. Abstr., 100, 156894p (1984).
430. Shepherd R. G.;
U. S. 7, 37449 (1997); Chem. Abstr., 114, 97406h (1998).
431. M. C. Dougal, Carol Lakshikantham, Mohan Krishna A. K.;
Chem. Abstr., 128(23), 28275j (1999).
432. Lai Hoi Kiong, Davis Robert Allan, Relyea Douglas Irving;
Chem. Abstr., 131(13), 170273q (1999).
433. Parlo Sanna, Antonio Carta, Mohamma E., Rahbar Nikooka;
Eur. J. Med. Chem., 35, 535-43 (2000).
434. Ranjan C. Khunt, Neela Datta, A. R. Parikh;
J. Inst. Chem., 72, 119 (2000).
435. Volmajer Juliya, Toplak Renata, Mujeen Le Marechal;
Fak. Za. Strojnistro Univ. 26, 138 (2001); Chem. Abstr., 134, 207662y (2001).
436. Shibata Yasushi, Yagihara Tomio, Kashahari Isumu;
Chem. Abstr., 134(25), 353299q (2001).
437. Nosyrava V. V., Andriyankova L. V.;
PCT Int. Appl. WO 08, 49, 148 (Cl. C07D 47/22), (2002); Chem. Abstr., 136(14),
216684q (2002).
438. Yogihara, Tomio, Kuchi, Tetsushi;
PCT Int. Appl. WO 02, 64, 554 (Cl. C07D 327/44) (2002); Chem. Abstr., 137(12),
169325t (2002).
198
439. Iwasa Takao, Hotano Renpei, Yagihara Tomio, Takebayashi Michinori;
PCT Int. Appl. WO 02, 88, 099 (Cl. C07D 277/30) (2002); Chem. Abstr., 137, 353012q
(2002).
440. F. M. Bharmal, D. J. Kaneria, H. H. Parekh;
Indian J. Hetero. Chem., 12, 279-80 (2003).
441. Collin Xavier, Sauleau Armelle, Coulon Joel;
Bioorganic & Med. Chem. Lett., 13(15), 2601-05(2003); Chem. Abstr., 139, 245956h
(2003).
442. Bhatnagar Neerja, Benard Didier, Gourvest Jean Francois, Mauger Jacques;
Fr. Demande FR 2, 835, 835 (Cl. C07D 237/04) (2003); Chem. Abstr., 139, 180074x
(2003).
443. Murakami Hiroshi, Masuzawa Yoshihide, Tokii Shinji, Ito Toshinori;
Jpn. Kokai Tokkyo Koho JP 2, 06,281 (Cl. C07D 231/12) (2003); Chem. Abstr., 139,
117421t (2003).
444. V. M. Parikh;
"Absorption spectroscopy of organic molecule". Addition wesley pub. Co. London, 243-
256 (1978).
445. A. R. Kartizky and R. Alan Jones;
J. Chem. Soc., 2942 (1960).
446. F. V. Loffe;
Khim. Gelerokeiki Soedin., 6, 1089 (1968);
Chem. Abstr., 70, 72338 (1986).
447. V. G. Thakare and K. N. Vadodkar;
Indian J. Chem., 25B, 610-12 (1986).
448. F. C. Brown;
Chemical Review "4-thiazolidinones", 465-511 (1961).
449. "Strukturaufklarang organischer Verbindungen" Mit Spektroskopischen methoden zweith,
uberarbeitete and erganzte Auflage (Springe-Verlag, Berlin Heildelberg, New Yourk-
1981).
199
LIST OF
NEW COMPOUNDS
R R R
C6H5-
3-NH2-C6H4-
4-NH2-C6H4-
4-Br-C6H4-
4-Cl-C6H4-
4-F-C6H4-
2-OH-C6H4-
4-OCH3-C6H4-
4-CH3-C6H4-
3-NO2-C6H4-
4-NO2-C6H4-
C6H5-
3-NH2-C6H4-
4-NH2-C6H4-
4-Br-C6H4-
4-Cl-C6H4-
4-F-C6H4-
2-OH-C6H4-
4-OCH3-C6H4-
4-CH3-C6H4-
3-NO2-C6H4-
4-NO2-C6H4-
α-C4H3S-
C6H5-
3-NH2-C6H4-
4-NH2-C6H4-
4-Br-C6H4-
4-Cl-C6H4-
4-F-C6H4-
2-OH-C6H4-
4-OCH3-C6H4-
4-CH3-C6H4-
3-NO2-C6H4-
4-NO2-C6H4-
α-C4H3S-
O
R
O
Cl
Cl
O
Cl
Cl
NN
O
CH3
R
O
Cl
Cl
NN
R
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R R R
C6H5-
3-NH2-C6H4-
4-NH2-C6H4-
4-Br-C6H4-
4-Cl-C6H4-
4-F-C6H4-
2-OH-C6H4-
4-OCH3-C6H4-
4-CH3-C6H4-
3-NO2-C6H4-
4-NO2-C6H4-
α-C4H3S-
C6H5-
3-NH2-C6H4-
4-NH2-C6H4-
4-Br-C6H4-
4-Cl-C6H4-
4-F-C6H4-
2-OH-C6H4-
4-OCH3-C6H4-
4-CH3-C6H4-
3-NO2-C6H4-
4-NO2-C6H4-
α-C4H3S-
C6H5-
3-NH2-C6H4-
4-NH2-C6H4-
4-Br-C6H4-
4-Cl-C6H4-
4-F-C6H4-
2-OH-C6H4-
4-OCH3-C6H4-
4-CH3-C6H4-
3-NO2-C6H4-
4-NO2-C6H4-
α-C4H3S-
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Cl
Cl
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Cl
Cl
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R R R
C6H5-
3-NH2-C6H4-
4-NH2-C6H4-
4-Br-C6H4-
4-Cl-C6H4-
4-F-C6H4-
2-OH-C6H4-
4-OCH3-C6H4-
4-CH3-C6H4-
3-NO2-C6H4-
4-NO2-C6H4-
α-C4H3S-
C6H5-
3-NH2-C6H4-
4-NH2-C6H4-
4-Br-C6H4-
4-Cl-C6H4-
4-F-C6H4-
2-OH-C6H4-
4-OCH3-C6H4-
4-CH3-C6H4-
3-NO2-C6H4-
4-NO2-C6H4-
α-C4H3S-
C6H5-
3-NH2-C6H4-
4-NH2-C6H4-
4-Br-C6H4-
4-Cl-C6H4-
4-F-C6H4-
2-OH-C6H4-
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4-CH3-C6H4-
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R R R
C6H5-
4-Cl-C6H4-
3,4(Cl)2-C6H3-
4-F-C6H4-
2-OCH3-C6H4-
4-OCH3-C6H4-
2-CH3-C6H4-
3-CH3-C6H4-
4-CH3-C6H4-
2-NO2-C6H4-
3-NO2-C6H4-
4-NO2-C6H4-
C6H5-
4-Cl-C6H4-
3-Cl,4-F-C6H3-
2,6(Cl)2-C6H3-
2,5(OCH3)2-C6H3-
2,4(CH3)2-C6H3-
2-F-C6H4-
4-F-C6H4-
2-OCH3-C6H4-
4-OCH3-C6H4-
2-CH3-C6H4-
3-CH3-C6H4-
4-CH3-C6H4-
3-NO2-C6H4-
4-NO2-C6H4-
C6H5-
4-COOC2H5-C6H4-
3-Cl-C6H4-
4-Cl-C6H4-
3-Cl,4-F-C6H3-
2,6(Cl)2-C6H3-
2,4(CH3)2-C6H3-
4-F-C6H4-
2-OCH3-C6H4-
4-OCH3-C6H4-
2-CH3-C6H4-
3-CH3-C6H4-
4-CH3-C6H4-
3-NO2-C6H4-
4-NO2-C6H4-
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O
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